

Rhinitis 2020: A practice parameter update



Mark S. Dykewicz, MD,^a Dana V. Wallace, MD,^b David J. Amrol, MD,^c Fuad M. Baroody, MD,^d Jonathan A. Bernstein, MD,^e Timothy J. Craig, DO,^f Chitra Dinakar, MD,^g Anne K. Ellis, MD,^h Ira Finegold, MD,ⁱ David B. K. Golden, MD,^j Matthew J. Greenhawt, MD,^k John B. Hagan, MD,^l Caroline C. Horner, MD,^m David A. Khan, MD,ⁿ David M. Lang, MD,^o Desiree E. S. Larenas-Linnemann, MD,^p Jay A. Lieberman, MD,^q Eli O. Meltzer, MD,^{r,s} John J. Oppenheimer, MD,^{t,u} Matthew A. Rank, MD,^v Marcus S. Shaker, MD,^w Jeffrey L. Shaw, MD,^x Gary C. Steven, MD,^y David R. Stukus, MD,^{z,aa} and Julie Wang, MD^{bb}

Chief Editor(s): Mark S. Dykewicz, and Dana V. Wallace

Joint Task Force on Practice Parameters: Chitra Dinakar, Anne K. Ellis, David B. K. Golden, Matthew J. Greenhawt, Caroline C. Horner, David A. Khan, David M. Lang, Jay A. Lieberman, John J. Oppenheimer, Matthew A. Rank, Marcus S. Shaker, David R. Stukus, and Julie Wang

Workgroup Contributors: Mark S. Dykewicz, Dana V. Wallace, David J. Amrol, Fuad M. Baroody, Jonathan A. Bernstein, Timothy J. Craig, Ira Finegold, John B. Hagan, Desiree E. S. Larenas-Linnemann, Eli O. Meltzer, Jeffrey L. Shaw, and Gary C. Steven *St Louis, Mo; Fort Lauderdale, Fla; Columbia, SC; Chicago, Ill; Cincinnati, Cleveland, and Columbus, Ohio; Hershey, Pa; Stanford, and San Diego, Calif; Kingston, Ontario, Canada; New York, NY; Baltimore, Md; Aurora, Colo; Rochester, Minn; Dallas, Tex; Mexico City, Mexico; Memphis, Tenn; New Brunswick, and Morristown, NJ; Scottsdale, Ariz; Lebanon, NH; and Green Bay and Greenfield, Wis*

From ^athe Section of Allergy and Immunology, Division of Infectious Diseases, Allergy and Immunology, Department of Internal Medicine, School of Medicine, Saint Louis University; ^bthe Department of Medicine, Nova Southeastern Allopathic Medical School, Fort Lauderdale; ^cthe Department of Internal Medicine, School of Medicine, University of South Carolina, Columbia; ^dthe Department of Otolaryngology–Head and Neck Surgery, Pritzker School of Medicine, University of Chicago; ^ethe Allergy Section, Division of Immunology, Department of Internal Medicine, College of Medicine, University of Cincinnati; ^fthe Departments of Medicine and Pediatrics, Penn State University, Hershey; ^gthe Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, School of Medicine, Stanford University; ^hthe Division of Allergy and Immunology, Department of Medicine, Queen's University, Kingston; ⁱthe Division of Allergy and Immunology, Department of Medicine, Mount Sinai West, New York; ^jthe Division of Allergy and Clinical Immunology, Department of Medicine, School of Medicine, John Hopkins University, Baltimore; ^kthe Section of Allergy and Immunology, Department of Pediatrics, Children's Hospital Colorado, School of Medicine, University of Colorado, Aurora; ^lthe Division of Allergic Diseases, Mayo Clinic, Rochester; ^mthe Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, School of Medicine, Washington University, St Louis; ⁿthe Division of Allergy and Immunology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas; ^othe Department of Allergy and Clinical Immunology, Respiratory Institute, Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Cleveland; ^pthe Center of Excellence in Asthma and Allergy, Hospital Medica Sur, Mexico City; ^qthe Division of Pulmonary Allergy and Immunology, Department of Pediatrics, The University of Tennessee Health Science Center, Memphis; ^rthe Division of Allergy and Immunology, Department of Pediatrics, School of Medicine, University of California, San Diego; ^sthe Allergy and Asthma Medical Group and Research Center, San Diego; ^tthe Division of Pulmonary & Critical Care Medicine and Allergic & Immunologic Diseases, Department of Internal Medicine, University of Medicine and Dentistry of New Jersey–Rutgers New Jersey Medical School, New Brunswick; and ^uthe Pulmonary and Allergy Associates, Morristown; ^vthe Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic in Arizona, Scottsdale; ^wthe Department of Pediatrics, Dartmouth-Hitchcock Medical Center, Lebanon; ^xthe Prevea Health, Green Bay, Wis; ^ythe Allergy, Asthma and Sinus Center, Greenfield; ^zthe Division of Allergy and Immunology, Nationwide Children's Hospital, Columbus; ^{aa}the Department of Pediatrics, College of Medicine, The Ohio State University, Columbus; and ^{bb}the Division of Allergy

and Immunology, Department of Pediatrics, The Elliot and Roslyn Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York.

Disclosure of potential conflict of interest: The Joint Task Force on Practice Parameters (JTFFP) members' and work group members' conflict of interest disclosure forms can be found at www.allergyparameters.org. Mark S. Dykewicz has served as a committee member for the American Academy of Allergy, Asthma, and Immunology (AAAAI) Rhinitis, Rhino-sinusitis, and Ocular Allergy Interest Section and is also a member of the American College of Asthma, Allergy, and Immunology (ACAAI) Rhinitis/Sinusitis Committee. Dana V. Wallace has received financial support from Mylan, Kaleo, Optinose, ALK-Abelló, Bryan, and Sanofi. David J. Amrol has received financial support from CSL Behring; and is a board member for the Southeastern Allergy, Asthma, and Immunology Society. Fuad M. Baroody is a member of the American Rhinologic Society and a member of the American Academy of Otolaryngology–Head and Neck Surgery. Jonathan A. Bernstein has received financial support from Sanofi Regeneron, AstraZeneca, Merck, Optinose, Takeda, CSL Behring, Biocryst, Pharming, the National Institutes of Health, Taylor Francis, INEOS; is Editor-in-Chief of the *Journal of Asthma*, INEOS medical immunosurveillance director, vice chair, and lectureship chair of the AAAAI Foundation, chairman of AFI, ACAAI Asthma Chair, Scientific Chair, and Young Investigator Award Chair; and serves on the board of directors and scientific committee of Interasma. Timothy J. Craig has received financial support from CSL Behring, Dyax, Takeda, BioCryst, Pharming, Grifols, GlaxoSmithKline, Regeneron, and Novartis/Genentech; is on the medical advisory board for Hereditary Angioedema Association of America; serves of the board of directors for the AAAAI; and is a member of the American Lung Association Mid-Atlantic Board. Chitra Dinakar has received financial support from Propeller Health, ACAAI (stipend for Editorial Board of *AllergyWatch*), and the American Association of Allergists of Indian Origin; serves on the board of directors of the AAAAI and on the medical advisory board of Food Equity Initiative; and is Assistant Editor of *AllergyWatch*. Anne K. Ellis has received financial support from ALK-Abelló, AstraZeneca, Green Cross, Merck, Novartis, Nuvo, Padiapharm, Pfizer, Kaleo, Novartis, Sanofi, and Regeneron; and serves on the board of directors of the Canadian Allergy Society of Allergy and Clinical Immunology. Ira Finegold has no competing relationships, organizational interests, or conflicts to disclose. David B. K. Golden has received financial support from Aquestive, Sandoz, ALK-Abelló, Sandoz, Genentech, Stallergenes-Greer, and UpToDate. Matthew J. Greenhawt has received financial support from Aquestive, Merck, Allergenics, Allergy Therapeutics, Sanofi Genzyme,

This comprehensive practice parameter for allergic rhinitis (AR) and nonallergic rhinitis (NAR) provides updated guidance on diagnosis, assessment, selection of monotherapy and combination pharmacologic options, and allergen immunotherapy for AR. Newer information about local AR is reviewed. Cough is emphasized as a common symptom in both AR and NAR. Food allergy testing is not recommended in the routine evaluation of rhinitis. Intranasal corticosteroids (INCS) remain the preferred monotherapy for persistent AR, but additional studies support the additive benefit of combination treatment with INCS and intranasal antihistamines in both AR and NAR. Either intranasal antihistamines or INCS may be offered as first-line monotherapy for NAR. Montelukast should only be used for AR if there has been an inadequate response or intolerance to alternative therapies. Depot parenteral corticosteroids are not recommended for treatment of AR due to potential risks. While intranasal decongestants generally should be limited to short-term use to prevent rebound congestion, in limited circumstances, patients receiving regimens that include an INCS may be offered, in addition, an intranasal decongestant for up to 4 weeks. Neither acupuncture nor herbal products have adequate studies to support their use for AR. Oral decongestants should be avoided during the first trimester of pregnancy. Recommendations for use of subcutaneous and sublingual tablet allergen immunotherapy in AR are provided. Algorithms based on a combination of evidence and expert opinion are provided to guide in the selection of pharmacologic options for intermittent and persistent AR and NAR. (*J Allergy Clin Immunol* 2020;146:721-67.)

Key words: Allergic rhinitis, nonallergic rhinitis, vasomotor rhinitis, local allergic rhinitis, food allergy antihistamines, corticosteroids, ipratropium, allergen immunotherapy, decongestants

Abbreviations used

AH:	Adenoidal hypertrophy
AIT:	Allergen immunotherapy
AR:	Allergic rhinitis
CBS:	Consensus based statements
CHM:	Chinese herbal medicine
CRS:	Chronic rhinosinusitis
CT:	Computed tomography
DBPC:	Double-blind, placebo controlled
DP:	<i>Dermatophagoides pteronyssinus</i>
FDA:	US Food and Drug Administration
GRADE:	Grading of Recommendations, Assessment, Development and Evaluation
INAH:	Intranasal antihistamines
INCS:	Intranasal corticosteroids
JTFPP:	Joint Task Force on Practice Parameters
LAR:	Local allergic rhinitis
LTRA:	Leukotriene receptor antagonist
NAPT:	Nasal allergen provocation test
NAR:	Nonallergic rhinitis
NARES:	Nonallergic rhinitis with eosinophilia syndrome
NSAID:	Nonsteroidal anti-inflammatory drug
NSD:	Nasal septal deviation
OAS:	Oral allergy syndrome
PAR:	Perennial allergic rhinitis
QOL:	Quality of life
SAR:	Seasonal allergic rhinitis
SCIT:	Subcutaneous allergy immunotherapy
sIgE:	Serum-specific IgE
SLIT:	Sublingual immunotherapy
SLIT-D:	Sublingual immunotherapy administered by liquid drops
SLIT-T:	Sublingual immunotherapy administered via tablets
TRPV1:	Transient receptor potential vanilloid 1
VAS:	Visual analog scale
VMR:	Vasomotor rhinitis
UACS:	Upper airway cough syndrome

Genentech, Aravax, Prota, Before Brands, the Institute for Clinical and Economic Review, ACAAI, DBV Technologies, and Intromune; is supported by the Agency of Healthcare Research and Quality; has served on the advisory board of International Food Protein Induced Enterocolitis Syndrome Association, the Asthma and Allergy Foundation of America, and the National Peanut Board; and is Associate Editor of the *Annals of Allergy, Asthma, and Immunology*. John B. Hagan is member of the Quality, Adherence and Outcomes Committee at the AAAAI; and is chairman of the Rhinitis/Sinusitis/Ocular Committee at the ACAAI. Caroline C. Horner has served as committee chair for the AAAAI Asthma Diagnosis and Treatment Interest Section, Interest Section Coordinating Committee, and In-Training Exam Coordinating Committee. David A. Khan has received financial support from UpToDate and Aimmune; serves on the board of directors of the AAAAI, ACAAI Chair of Literature Review, co-chair of Conjoint Board Review, Texas Allergy, Asthma, and Immunology Society Chair of Meetings Committee; and is Associate Editor of the *Journal of Allergy and Clinical Immunology in Practice*. David M. Lang is on the Editorial Board for *Allergy and Asthma Proceedings*, topic editor for *DynaMed*, Associate Editor for the *Journal of Asthma*; and delegate to the National Quality Forum representing the AAAAI. Desiree E. S. Larenas-Linnemann has received financial support from AstraZeneca, Mylan, GlaxoSmithKline, Sanofi, Novartis, DBV Technologies, SUMA/Circassia, and Thermo Fisher Scientific; is a board member of the Colegio Mexicano de Immunologia Clinica y Alergia, member of Immunotherapy Committee of the AAAAI, chair of Information Technology Interest Group and Task Force of European Academy of Allergy and Clinical Immunology (EAACI), and Chair of International Committee for the Latin portfolio of the ACAAI. Jay A. Lieberman has received financial support from the ACAAI, Aquestive, Aimmune, DBV Technologies, Biotest Pharma, and Regeneron; is Associate Editor of the *Annals of Allergy, Asthma, and Immunology*, vice chair for the ACAAI Food Allergy Committee, and medical director for Food Allergy

Alliance of the MidSouth. Eli O. Meltzer has received support from Boehringer-Ingelheim, GlaxoSmithKline, Glenmark, GossamerBio, Merck, Mylan, Optinose, ALK-Abelló, AstraZeneca, and Regeneron/Sanofi. John J. Oppenheimer has received financial support from DBV Technologies, TEVA, GlaxoSmithKline adjudication/data safety monitoring board, AstraZeneca, Novartis, and Sanofi; is Associate Editor of the *Annals of Allergy, Asthma, and Immunology* and *AllergyWatch*, an American Board of Internal Medicine Council Member and American Board of Allergy and Immunology Liaison to the American Board of Internal Medicine, UpToDate reviewer, American College of Chest Physicians Cough Guideline Committee Member, and WebMD Editor. Matthew A. Rank has received financial support from the ACAAI, National Institutes of Health, and Levin Family Foundation; has served as chair of the AAAAI Health Care Outcomes, Education Delivery and Quality Interest Section; and is research director of the Phoenix Children's Hospital Breathmobile. Marcus S. Shaker has received financial support from the Eastern Allergy Conference; and has a family member who is the chief executive officer of Altrix Medical. Jeffrey L. Shaw is a committee member for the Rhinitis, Sinusitis, and Ocular Committee of ACAAI. Gary C. Steven has received financial support from 3M, AstraZeneca, Attenua, Chiesi, Cipla, Glenmark5, GlaxoSmithKline, Lupin, Menlo, Merck, Novartis, Pearl, Sanofi, TEVA, Stallergenes, NeRRé, Watson, Westward, Aimmune, ALK-Abelló, Regeneron, American Academy of Neurology, Boehringer, and Optinose. David R. Stukus has received financial support from Aimmune, Before Brands, Abbott Nutrition, the American Academy of Pediatrics, and ACAAI; has served as committee chair for AAAAI and ACAAI. Julie Wang has received financial support from ALK-Abelló, Regeneron, DBV Technologies, and Aimmune; is an UpToDate author; serves on the executive committee of the American Academy of Pediatrics Section on Allergy and Immunology; and serves as vice chair of the AAAAI Anaphylaxis, Dermatitis, Drug Allergy Interest Section.

EXECUTIVE SUMMARY

This comprehensive practice parameter for allergic and nonallergic rhinitis provides updated guidance on diagnosis, assessment, selection of monotherapy and combination pharmacotherapy options, and allergen immunotherapy. Food allergy testing and parenteral corticosteroids are not recommended. Key new and updated recommendations are emphasized (Table I).

INTRODUCTION

The diagnosis of rhinitis is suggested by the presence of 1 or more of the following symptoms: nasal congestion, rhinorrhea (anterior and posterior), sneezing, and itching.¹ Rhinitis can be classified by pathogenic mechanisms, as allergic or nonallergic, and differentiated from conditions that have overlapping symptoms of rhinitis.

Rhinitis phenotypes

Although the term rhinitis connotes inflammation, and allergic rhinitis (AR) and some types of nonallergic rhinitis (NAR) are associated with inflammation (eg, nonallergic rhinitis with eosinophilia syndrome [NARES], infectious rhinitis), some forms of NAR such as vasomotor rhinitis (VMR) or atrophic rhinitis may not be associated with inflammation of the nasal mucosa. Rhinitis frequently is accompanied by symptoms involving the eyes, ears, and throat. Conditions that have overlapping symptoms with rhinitis include rhinosinusitis with and without nasal polyps, cerebrospinal fluid rhinorrhea, ciliary dyskinesia syndrome, and structural/mechanical factors, such as congenital anomalies, deviated septum, and pharyngonasal reflux. Recognition of

whether a patient has AR or NAR or another mimicking condition is important because management will differ.

AR affects up to 60 million people in the United States annually, can have a major impact on quality of life (QOL), and poses a substantial economic burden on society. It also is often associated with and can potentially impact asthma, allergic conjunctivitis, rhinosinusitis, and sleep disturbances.

Prevalence

Self-reported rates of AR are 10% to 30% of adults and as many as 40% of children in the United States.² In recent surveys that required a physician-confirmed diagnosis of AR, the prevalence rates were 14% of US adults and 13% of US children.^{3,4} Canadian data support an even higher prevalence of up to 20% of the population having physician-diagnosed AR.⁵ Chronic NAR has been estimated to affect 17% to 52% of adults while up to 34% of patients with rhinitis in the United States may have a combination of AR and NAR, often referred to as “mixed rhinitis.”⁶⁻¹⁰

QOL in rhinitis

Issues of QOL associated with rhinitis include disturbed sleep; daytime somnolence and fatigue; irritability; depression; impairment of physical and social functioning; and attention, learning, and memory deficits. Thirty-five percent to 50% of adults reported that nasal allergies have at least a moderate effect on their daily life.³ Sleep disturbances associated with rhinitis include difficulty falling asleep, staying asleep, and awakening refreshed. Nearly 1 in 4 of adult US respondents report they are unable to sleep or are

Reprints: *Joint Task Force on Practice Parameters Liaison*: Rebecca Brandt (American Academy of Allergy, Asthma, and Immunology, 555 E. Wells Street, Suite 1100, Milwaukee, WI 53202. E-mail: rbrandt@aaaai.org); JTFFP.allergy@gmail.com.

Previously published practice parameters and guidelines of the JTFFP are available at <http://www.allergyparameters.org>, <http://www.AAAAI.org>, and <http://www.ACAAI.org>.

Resolving conflict of interest: The JTFFP is committed to ensuring that all guidelines are based on the best scientific evidence at the time of publication, and that such evidence is free of commercial bias to the greatest extent possible. Before confirming the selection of the work group chairperson and members, the JTFFP discusses and resolves all relevant potential conflicts of interest (COIs) of each work group member. The JTFFP recognizes that experts in a field are likely to have interests that could come into conflict with the development of a completely unbiased and objective guideline. Therefore, a process has been developed to acknowledge potential COIs when making specific recommendations. To preserve the greatest transparency regarding potential COIs, all members of the JTFFP and work group complete a COI form prior to the development of each document and again prior to the guideline submission for publication.

During the review process there are additional measures to avoid bias. At the work group level, all the recommendations and discussion sections are reviewed by all work group members to ensure that content is appropriate and without apparent bias. If any recommendation or section is deemed to have apparent bias, it is appropriately revised, without the section author's involvement, in an attempt to remove potential bias. In addition, the entire document is also reviewed by the JTFFP and any apparent bias is acknowledged and removed at that level. For each and every recommendation, a vote is required by the work group and JTFFP, and any member with any perceived COI is recused from that vote (and so explained in the document). Any dissenting votes that cannot be resolved are described and explained in the document.

In a final stage of review, the practice parameter is sent to invited expert reviewers for review, selected by the AAAAI and the ACAAI. The document is also posted on the AAAAI and ACAAI websites for general membership and the public-at-large to review and offer comment. All reviewers must provide statements of potential COIs. Although the JTFFP has the final responsibility for the content of the documents submitted for publication, each reviewer's comments will be discussed and reviewers will receive written responses to comments when appropriate.

The JTFFP members' and work group members' COI disclosure forms can be found at www.allergyparameters.org.


Disclaimer: The AAAAI and the ACAAI have jointly accepted responsibility for developing “Rhinitis 2020: a practice parameter update.” The medical environment is rapidly changing, and not all recommendations will be appropriate or applicable to all patients and may change over time. Because this document incorporates the efforts of many participants, no single individual, including members serving on the JTFFP, is authorized to provide an official AAAAI or ACAAI interpretation of this guideline. Any request for information or interpretation of this practice parameter by the AAAAI or ACAAI should be directed to the executive offices of the AAAAI and the ACAAI. Practice parameters and guidelines are not designed for use by the pharmaceutical industry in drug development or promotion. The JTFFP understands that the cost of diagnostic tests and therapeutic interventions is an important concern that may appropriately influence the evaluation and treatment selected for a given patient. The JTFFP recognizes that the emphasis of our primary recommendations regarding a medication may vary, for example, depending on third-party payer issues and product patent expiration dates. However, because a given test or a therapeutic intervention's cost is so widely variable, and there is a relative paucity of pharmacoeconomic data, the JTFFP is not always able to consider cost when formulating recommendations. In extraordinary circumstances, when the cost benefit of an intervention is prohibitive as supported by pharmacoeconomic data, commentary may be provided.

Contributors: The JTFFP has made a concerted effort to acknowledge all contributors to this parameter. If any contributors have been excluded inadvertently, the JTFFP will ensure that appropriate recognition is provided.

Received for publication February 6, 2020; revised June 22, 2020; accepted for publication July 1, 2020.

Available online July 22, 2020.

Corresponding author: Mark S. Dykewicz, MD, Saint Louis University School of Medicine, Section of Allergy and Immunology, Department of Internal Medicine, 1402 S. Grand Boulevard, M157, St Louis, MO 63104. E-mail: mark.dykewicz@health.slu.edu.

 The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections

0091-6749/\$36.00

© 2020 American Academy of Allergy, Asthma & Immunology
<https://doi.org/10.1016/j.jaci.2020.07.007>

TABLE I. What is new or newly emphasized in Rhinitis 2020?

Four new algorithms based on a combination of evidence and expert opinion can guide the clinician in the treatment of intermittent and persistent AR and NAR.
New tables assist in making (1) the differential diagnosis for rhinitis based on patient history and (2) the diagnosis and treatment for rhinitis-associated conditions or conditions that mimic rhinitis.
Cough is emphasized as a common symptom present in both AR and NAR.
New information is presented about LAR, possibly present in up to 25% of patients with rhinitis, and its response to both SCIT and SLIT, although more research is needed.
We recommend that food allergy testing not be performed in the routine evaluation of possible AR (Recommendation 4).
We recommend that the oral LTRA montelukast should only be used for AR in patients who have an inadequate response or intolerance to alternative therapies. Serious neuropsychiatric events that may include suicidal thoughts or actions have been reported in patients taking montelukast (Recommendation 7).
Either INAH or INCS may be offered as first-line monotherapy for NAR (Recommendations 12, 32).
Since the 2008 rhinitis update, additional studies support the use of combination INCS and INAH in AR and NAR (Recommendations 22-24).
Oral decongestants should be avoided during the first trimester of pregnancy (Recommendation 19).
Additional information is presented as to why first-generation antihistamines should not be used in AR, especially on a chronic basis, due to potential sedation, performance impairment, poor sleep quality, anticholinergic-mediated symptoms, and increased risk of dementia (Recommendation 6).
We continue to suggest that the use of intranasal decongestants generally be limited to short-term use to prevent rebound congestion that may occur with longer use. However, in limited circumstances discussed in the document, patients on regimens that include an INCS may be offered combination therapy with addition of an intranasal decongestant for up to 4 wk (Recommendations 16, 26).
SCIT and SLIT tablets are both effective for the treatment of AR and may help prevent and/or treat allergic asthma (Recommendation 34).
Neither acupuncture nor herbal medications have adequate studies to support a recommendation to use them in the treatment of AR (Recommendations 36, 37).

awakened most days or every day, and up to 45% of children experience sleep disruption because of nasal allergy symptoms.^{3,11} Most studies indicate associations between nasal allergies and anxiety/mood syndromes.¹²

Limited available data report that health-related QOL is reduced in patients with NAR, with greatest reductions in patients with NARES.¹³ A decreased sense of smell, present in both AR and NAR, can lead to a significant decrease in QOL, including disturbing a patient's ability to appreciate flavors, losing the pleasures of eating, and increasing health risks such as not appreciating spoiled food or leaking gas and adding larger quantities of sugar and salt to highlight flavors, thus worsening general health.¹⁴

Economic and societal burden of rhinitis

While the total direct medical costs of rhinitis are tremendous,^{15,16} rhinitis is also a significant cause of lost work and school days and decreased work productivity/presenteeism (work interference) and school performance. Up to 10% of workers reported absenteeism because of their nasal allergies, and up to 25% reported presenteeism, with an estimated 23% to 33% decrease in productivity on days when allergies were at their worst compared with days when the respondent experienced no symptoms.³ Increased symptom severity, decreased sleep quality and quantity, adverse effects on mental function, and treatment with soporific antihistamines negatively impact work productivity.¹⁷ Appropriate therapy can substantially reduce both societal and employer costs. Lack of treatment, undertreatment, or nonadherence to treatment have been shown to increase direct and indirect costs.¹⁸ AR can, by itself, introduce significant inattention, impairment of cognition, and decreased daytime school performance.¹⁹

AR, notably present in about 75% to 80% of all patients with asthma and in nearly 100% with allergic asthma, is associated with increased asthma-related hospitalizations and higher total annual medical costs.

Classification of AR: severity, frequency, and environmental exposure

Assessment of rhinitis by severity, frequency, and exposure can assist the clinician in developing the most appropriate treatment strategies for an individual patient. Mild rhinitis severity is present when symptoms are not interfering with QOL such as impairment of daily activities, work or school performance, leisure activities, and sleep. Moderate/severe rhinitis is present when symptoms are troublesome or there is negative impact on any of these QOL parameters.^{1,20} Other groups have proposed a division into mild, moderate, and severe,²¹ but as this division does not clearly translate into a change in therapy, the most accepted division is still the dual one, which is also used in the majority of clinical trials.

Symptom frequency has been divided by some into intermittent (<4 days/week or <4 consecutive weeks/year) and persistent (≥4 days/week and ≥4 consecutive weeks/year).^{20,22} This strict definition has some limitations; for example, a patient who has symptoms 3 days/week year-round would be classified as "intermittent" although they might more closely resemble a "persistent" patient.

The preceding definitions of severity and frequency may be applied to AR, NAR, or mixed rhinitis (when both allergic and nonallergic components contribute to rhinitis symptoms).

AR may also be classified by the temporal pattern of environmental exposure to a triggering allergen: seasonal (International Classification of Diseases, 10th Revision, J30.2, eg, from pollens, J30.1), perennial (year-round, eg, dust mites, J30.89 "other allergic rhinitis" and J30.9 "allergic rhinitis, unspecified"), or from episodic allergen exposures not normally encountered in the patient's environment, such as visiting a home with pets.¹ AR from animals (J30.81) therefore may be perennial with ongoing exposure, or occur only with episodic exposure.

In the United States, AR has traditionally been viewed as either seasonal (SAR) or perennial (PAR), and it is this classification system that the US Food and Drug Administration (FDA)²³ uses when approving new medications for AR. The reality is that a

patient may have both SAR and PAR, SAR or PAR with NAR (International Classification of Diseases, 10th Revision, J30 “vasomotor and allergic rhinitis”), intermittent symptoms with PAR, or persistent symptoms with SAR. It is also recognized that the distinction between SAR and PAR has limitations; in different climatic regions, the same aeroallergen can be either seasonal or perennial. Nonetheless, the recognition that an individual has SAR and is allergic to particular pollen allergens of known seasonality in a region may help guide administration of medications concurrent with (or in anticipation of) that defined seasonal exposure. That said, one must be mindful that nasal inflammation and thereby need for treatment may persist for weeks after a pollen season is over. The majority of patients are polysensitized to both pollens and perennial allergens. In a population of 6000 patients with AR, it was shown that 55% of patients with seasonal symptoms and 45% of those with perennial symptoms had intermittent AR; thus, the SAR-PAR classification is independent from the intermittent-persistent one.²⁴ Since then, numerous studies have duplicated these findings in other regions.^{25,26}

Local AR

In local allergic rhinitis (LAR), also referred to as entopy, there is (1) a clinical history of perennial and/or seasonal symptoms following allergen exposure, with (2) negative skin prick tests (and intradermal tests, when performed) and absence of serum-specific IgE (sIgE) antibodies but (3) a positive nasal allergen provocation test (NAPT) to aeroallergens.²⁷⁻³⁰

While a major study center in Europe has contributed the bulk of the research on LAR as discussed above, additional small studies from Australia,³¹ Sweden,³² Egypt,³³ and China^{34,35} have supported their findings. There have been limited US studies, not all confirming these findings.^{36,37}

A dual (immediate and late) response to NAPT had been noted in 37% to 70% of LAR.^{38,39} Although it would be expected that local sIgE would be detected in all patients with NAPT challenge-diagnosed LAR, some studies of LAR from pollens detect local sIgE in as few as 30% of patients.^{39,40} When present in patients with SAR, an increase in nasal sIgE is noted both during NAPT challenge and during pollen season.⁴⁰ Likewise, in 1 dust mite LAR study of patients who had a positive NAPT-dust mite challenge, only 22% had nasal sIgE to dust mites.³⁸ A recent method of detecting nasal sIgE by the direct application of the solid phase of a commercial ImmunoCAP test showed a sensitivity of 43% and high specificity and offers promise for future clinical use.⁴¹ Making the diagnosis can be challenging given the current low sensitivity of assays for the local sIgE and the need to conduct an in-office NAPT procedure.^{42,43} Studies have suggested that the basophil activation test might serve as a surrogate marker of LAR, although currently this is available only as a research tool. It has been shown that using the basophil activation test with *Dermatophagoides pteronyssinus* (DP) extract and olive tree identifies 50% to 66%, respectively, of patients with NAPT-established LAR with a specificity of 93% and showing identical specificity for both LAR and AR.⁴⁴

In some studies, using NAPT, up to 26% of all patients with rhinitis and up to 100% of patients with NAR have LAR.^{31,32,35,36,45-48} In a population-based observational study that categorized all patients with rhinitis, over 25% and 63% were diagnosed to have LAR and AR, respectively, indicating that <12% had other types of NAR.⁴⁹ The coexistence of dual

perennial LAR and SAR (skin prick test–positive) has also been described.^{50,51} However, prevalence rates of LAR in China have been reported to be much lower (eg, 7.7%).⁵² LAR is reported to be more prevalent in women, to be associated with a family history of atopy equal to or greater than that of AR, and to have a mean onset of 21 years; however, LAR may start in childhood 36% of the time.^{49,53,54} Local occupational rhinitis, diagnosed by nasal provocation studies, should be considered in workers with a convincing history but with negative immunological tests.⁵⁵

The most frequently reported symptoms in patients with LAR are watery rhinorrhea, sneezing and itching, compared with congestion and mucoid rhinorrhea for patients with NAR.^{49,56} While most patients with LAR are monosensitized, most commonly to dust mite, up to 37% are polysensitized to seasonal and/or perennial allergens.^{46,49,57} Of particular interest is a significantly lower incidence (2.7%) of animal dander sensitization in patients with LAR compared with in patients with AR (31%).⁴⁹ The majority of adult patients with LAR have moderate/severe, persistent, and perennial symptoms, with common comorbidities of conjunctivitis (50%-65%) and asthma (18%-47%). These studies show that the severity of LAR and associated comorbidities increase with disease duration.^{39,49,58-60}

The mainstay of current LAR treatment has consisted of avoidance and pharmacotherapy. However, recent well-controlled trials suggest that if the specific triggering allergen can be accurately identified, subcutaneous allergy immunotherapy (SCIT) or sublingual immunotherapy (SLIT) might be a reasonable consideration. SCIT has been successfully used to treat dust mite-, grass-, and birch-induced LAR in 2 different European centers.^{40,60-62} A randomized, double-blind, placebo controlled (DBPC) parallel group study demonstrated that SCIT with DP in patients with LAR who are DP-sensitized produced significant improvement with reduction in total symptom score (47%), reduction in total medication scores (51%), and reduced responses to NAPT-DP (with total suppression in 50% of patients) over a 24-month treatment period.⁶² Significant symptom improvement and nasal tolerance to NAPT-DP was noted as early as 6 months into treatment.⁶⁰ A small randomized DBPC 24-month trial of birch SCIT to patients with SAR produced a significant reduction in symptom medication score, a decrease in local sIgE, and an increase in IgG₄ levels.⁴⁰ In this study, local sIgE levels significantly increased during birch season in all patients, but a blunted seasonal increase was noted at 24 months in the active treatment group.⁴⁰ An observational study using preseasonal grass SCIT demonstrated significant clinical improvement and increased NAPT nasal tolerance in all patients.⁶¹ However, in this early study, 40% of the SCIT group developed positive skin prick tests after 6 months of treatment followed by sIgE and sIgG antibodies to grass after 12 months of treatment.⁶¹ The same group completed a randomized DBPC study involving 56 patients with LAR to grass, established by either a positive NAPT or nasal sIgE ≥ 0.35 kU/L.⁶³ There was significant improvement in combined symptoms medication score and Rhinoconjunctivitis Quality of Life Questionnaire after 6 months of preseasonal treatment. The effect was sustained during the second year when year-round SCIT was used. There was a significant increase in serum IgG₄ levels and allergen tolerance with 83% of patients completing at least 6 months of treatment tolerating over 50 times higher concentration of grass pollen during NAPT challenge, with 56% having a negative challenge.⁶³ In

this controlled study, only 7.4% of the active versus 3% of the control group developed sIgE to grass at the end of year 1, showing that active SCIT treatment is unlikely to be creating systemic atopy.⁶³ A larger, prospective 10-year cohort study (2005-2016) of untreated patients with LAR showed a progressive worsening of the rhinitis, increased development of asthma, reduced QOL, and loss of allergen tolerance.⁶⁴ While a significant change was noted after 5 years,⁵³ this becomes progressively worse throughout the entire 10 years. The development of systemic atopy was not found to be significantly greater in patients with LAR (9.7%) versus in matched healthy controls (7.8%).⁶⁴

While the literature supports LAR as a real entity, further large, multicenter, long-term, well-controlled studies with children and adults are needed to better define the prevalence, evolution, diagnosis, and treatment of LAR.

Nonallergic rhinitis

By definition NAR is defined as rhinitis that is independent of an IgE-mediated mechanism that includes VMR⁶⁵ (sometimes referred to as nonallergic rhinopathy or idiopathic rhinitis), infectious rhinitis, food-induced rhinitis,⁶⁶ hormonal rhinitis,⁶⁷ drug-induced rhinitis,⁶⁸ nonallergic occupational rhinitis,⁶⁹ atrophic rhinitis,⁷⁰ NARES,²⁶ and rhinitis of the elderly.⁷¹ For this reason, “nonallergic noninfectious rhinitis” is a term sometimes used to describe this group of patients.⁷² In reality, NAR can be acute or chronic, is often present in conjunction with AR (“mixed rhinitis”)⁷³ and is frequently associated with hyperreactivity of the nasal mucosa.⁷⁴ In a study by Rondon et al,⁴⁹ compared with those with AR, patients with NAR were more likely to be older and to have severe congestion and rhinorrhea but less likely to have asthma. The exact prevalence of NAR is unknown, but some estimates suggest that worldwide up to 200 million people have NAR.⁷²

Vasomotor rhinitis

VMR, a subtype of NAR, can be acute or chronic and is often activated by temperature and humidity changes, especially cold dry air, airborne irritants, strong odors, including tobacco smoke, and/or exercise.⁷⁵ VMR, often a diagnosis of exclusion, is frequently referred to as idiopathic rhinitis.⁷⁶ The symptoms of VMR are variable, consisting mainly of nasal obstruction and increased clear secretion. Sneezing and pruritus are less common. Cough is also a common component of VMR.⁷⁷

“Idiopathic rhinitis” is sometimes used as an alternative term to VMR and usually excludes NARES.⁷⁸ However, the term is confusing as some studies have found high levels of eosinophils and mast cells in some patients categorized as having idiopathic rhinitis.⁷⁹ In this practice parameter we do not use the term.

The diagnosis of VMR is based on exclusion of other forms of rhinitis, especially AR, infectious rhinitis, and anatomic/surgical structural changes of the nose and sinuses. The history is the most important determinant leading to diagnosis. The physical exam findings can vary widely and laboratory tests, skin prick tests, and sIgE are helpful only to exclude AR. Nasal challenge for VMR, to determine nasal hyperresponsiveness (eg, using cold dry air or hypertonic saline in a challenge chamber), may be used in research to assess drug efficacy but is rarely used for clinical diagnosis.^{77,80} More recently, optical rhinometry with intranasal capsaicin challenge has been demonstrated to assist in the diagnosis of a subset of patients with VMR and nonallergic irritant rhinitis.⁸¹

While the pathophysiology of VMR is not fully understood, there is evidence that it involves a neurogenic pathway with an increase in neural efferent traffic to the nasal mucosa with an imbalance between parasympathetic and sympathetic nasal innervation.⁸² Support for this is partially based on the beneficial effects of ipratropium bromide and vidian neurectomy (the vidian nerve contains both the parasympathetic and the sympathetic innervation to the nasal mucosa).^{82,83} Subjects with predominant rhinorrhea (sometimes referred to as cholinergic rhinitis) appear to have enhanced cholinergic glandular secretory activity that can be effectively reduced with the use of atropine and ipratropium bromide.^{84,85} Patients with predominant symptoms of nasal congestion appear to have nociceptive neurons that have heightened sensitivity to stimuli such as temperature change, airborne irritants, foods (especially hot and spicy foods), alcoholic beverages, cold dry air, and exercise.⁸⁶⁻⁸⁹ Measurement of neuropeptides such as substance P in models of hypertonic saline and cold dry air-induced rhinitis further support a neurogenic mechanism for VMR.⁸⁰

However, somewhat conflicting research based on the response to intranasal capsaicin, a selective transient receptor potential vanilloid 1 (TRPV1) receptor agonist, suggests that nociceptive C fibers in the trigeminal nerve lead to hypersensitivity of the TRP ion channels on sensory afferent neurons innervating the nasal mucosa and that this can induce the symptoms of VMR.⁹⁰ In clinical studies, when compared with controls, patients with irritant rhinitis have higher TRPV1 expression in the nasal mucosa and higher concentrations of substance P in nasal secretions.⁹¹ From these data, the term “neurogenic rhinitis” has been proposed to replace VMR and idiopathic rhinitis to describe this type of NAR.

Infectious rhinitis

Infectious rhinitis and rhinosinusitis may be acute or chronic. Infectious rhinitis may range from self-limited rhinitis secondary to common viral upper respiratory infections to more severe disease caused by other pathogens, such as fungal infections in an immunocompromised patient.⁷⁵ Acute infectious rhinitis is usually a result of 1 of many viruses, but secondary bacterial infection with sinus involvement (bacterial rhinosinusitis) may be a complication.^{1,92} Viral infections account for as many as 98% of acute infectious rhinitis and the majority of rhinitis symptoms in the young child.¹ Symptoms of acute infectious bacterial rhinosinusitis include nasal congestion, mucopurulent nasal discharge, pain and pressure, headache, olfactory disturbance, postnasal drainage, and cough. While these symptoms may overlap and mimic those of AR, the presence of a recurrent seasonal pattern of symptoms, the presence of an obvious allergic trigger, and symptoms of nasal or ocular pruritus strongly suggest the diagnosis of AR. This diagnostic distinction is important to avoid inappropriate treatment of AR.⁹³

Inappropriate prescribing of antibiotics is often secondary to misinterpretation of the symptoms and signs of infectious viral rhinitis/rhinosinusitis with bacterial rhinosinusitis. This has led to overprescribing antibiotics and a subsequent increase in antibiotic resistance. Recent research demonstrates antibiotic prescribing rates as high as 69% to 79% for acute infectious rhinitis, which may account for up to 60% of all antibiotic prescriptions written by providers, despite often a lack of benefit and increased risk of adverse effects, including resistance.⁹⁴⁻¹⁰⁵

Symptoms distinguishing viral versus bacterial infectious rhinitis/rhinosinusitis are minimal and recent evidence suggests that separating viral from bacterial infections based on clinical presentation is often not possible.^{99,106-108} In addition, because viral-induced infectious rhinitis/rhinosinusitis can cause sinus computed tomography (CT) scan changes that mimic acute bacterial rhinosinusitis, a CT scan should be deferred unless complications are a concern.¹⁰⁹⁻¹¹¹ Up to 70% of children with viral infections¹¹² and as many as 87% of adults will have abnormalities on CT scan during the common cold.¹¹³ Similarly, nasal culture and cytology of nasal secretions provide minimal assistance in distinguishing nonbacterial infections from bacterial rhinosinusitis and often positive bacterial cultures from the nose or sinus may represent colonization and not a pathogen.^{93,114-116} The transition from viral infectious rhinitis to bacterial rhinosinusitis and appropriate treatment for the rhinosinusitis has been a focus of treatment guidelines due to the resistance of bacteria that are known to cause acute bacterial rhinosinusitis.^{93,114,117-124} Most guidelines suggest deferring antibiotic treatment for 7 to 10 days after onset of symptoms of infectious rhinosinusitis to avoid overuse of antibiotics. Controversies in the management of chronic rhinosinusitis (CRS) are addressed in the most recent Joint Task Force on Practice Parameters (JTFPP) publication on rhinosinusitis.⁹²

Unique populations susceptible to frequent or persistent and refractory infectious rhinitis include patients with anatomic abnormalities of the nares and sinuses, CRS with nasal polyps,¹²⁵ ciliary dysfunction, cystic fibrosis, primary immunodeficiency, acquired immunodeficiency, and children. The differential diagnosis of infectious rhinitis in children includes not only AR but foreign bodies, acute *Staphylococcus aureus* bacterial infection of the nares and enlarged or infected adenoids.¹²⁶

Food-induced rhinitis

Gustatory rhinitis. The main symptom is clear rhinorrhea after ingestion of food, especially hot and spicy foods.¹²⁷ The mechanism is thought to be a neurologic reflex of the noncholinergic, nonadrenergic system.

IgE-mediated food allergy and AR? Outside of the oral allergy syndrome (OAS),¹²⁸ discussed below, there is no evidence of IgE-mediated food-induced rhinitis symptoms without the presence of anaphylaxis with whole-body symptoms (eg, hives, difficulty breathing, or diarrhea); therefore, there is no indication to test for food allergens when evaluating patients presenting with symptoms of rhinitis.

Furthermore, there have been no published studies of oral food challenges producing isolated rhinitis symptoms. With the specificity of both skin prick testing and sIgE testing to foods being <50%,¹²⁹ and recognizing that sensitization does not equate to clinical allergy, unnecessary food testing can lead to unwarranted food avoidance resulting in a reduced QOL, uncalled-for financial expenditure, and possible nutritional deficiency.^{130,131} Testing with a “panel” of foods without attention to the medical history and epidemiology of AR, can result in mismanagement.¹³²

While a high rate of sensitization to certain food (fruits, nuts, and vegetables), as demonstrated by skin prick tests or sIgE, is reported in patients with pollen-induced AR (eg, birch, mugwort, ragweed, and grass), most of these patients will not experience symptoms when ingesting cross-reacting foods.¹³³ Patient-reported prevalence of the OAS in patients with AR varies

between 6% and 93%, generally being higher in adults versus children; females; patients having severe rhinoconjunctivitis symptoms, multiple pollen allergies, and longer duration of AR; and in geographical locations with high pollen levels.¹³³⁻¹³⁷ While there have been limited studies utilizing oral food challenges to diagnose OAS in patients with AR, these have reported a much lower prevalence rate of 0.1% to 4.3%.¹³⁸ There have been, unfortunately, no studies in the United States that have adequately studied the prevalence of OAS including the development of rhinitis symptoms on ingestion of pollen-related foods. In patients with OAS, symptoms of itching and swelling are usually mild and limited to the oropharyngeal area, but systemic reactions, including AR symptoms, have been reported. One large review reported that 9% of patients with OAS had systemic reactions beyond the gastrointestinal tract, which, at times, included nasal congestion, rhinorrhea, and sneezing.¹³⁹ In fact, compared with those without pollen-induced AR, patients with plant food reactions are at much lower risk of having systemic reactions if they have concurrent AR pollinosis.¹⁴⁰

Alcohol-induced rhinitis symptoms. Alcohol-induced upper airway symptoms are felt to be due to alcohol hyperresponsiveness (including vasodilator effects) and not due to “alcohol allergy.” Nasal congestion is the most common alcohol-induced upper airway symptom, followed by rhinorrhea. Alcohol-induced upper respiratory symptoms have been reported in up to 14% of healthy individuals, 33% of asthmatics, and 75% of patients with aspirin-exacerbated respiratory disease.¹⁴¹ Alcohol hyperresponsiveness correlates with the severity of the nasal inflammatory response, being greater in patients who have nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease or CRS with nasal polyps (with or without asthma) than in patients with AR or CRS without nasal polyps.^{141,142} In asthmatics, a corresponding increase in lower respiratory symptoms is also noted. While the triggering mechanism for alcohol-induced respiratory symptoms is unknown, the elevation of systemic cysteinyl leukotrienes observed following alcohol consumption may be at least 1 major contributing factor.¹⁴¹ In some patients with AR, alcohol-induced symptoms may be intermittent (eg, only present during seasonal exacerbations), may appear 1 hour or later following ingestion, have a duration of >1 hour but <1 day, and may require between 1 and 3 drinks for symptom provocation.¹⁴² For most affected patients, any alcoholic beverage can provoke symptoms; however, patients with CRS and without asthma have reported that wine may be worse than other alcoholic beverages.¹⁴² Alcohol-induced symptoms in patients with NSAID-exacerbated upper respiratory disease have been reported to diminish following aspirin desensitization.¹⁴³ With the above-noted association of alcohol-induced rhinitis symptoms with CRS with nasal polyps, CRS without nasal polyps, asthma, and NSAID-exacerbated respiratory disease, the clinical history of alcohol as a trigger for rhinitis symptoms should prompt the health care provider to consider these diagnoses and to pursue further diagnostic testing (eg, rhinoscopy or spirometry), if indicated.

Hormonal rhinitis

Estrogen- and progesterone-induced changes occurring with pregnancy, menstrual cycle, menopause, and puberty can all affect nasal congestion. Increase of estrogen can cause nasal vascular engorgement leading to congestion. In addition,

progesterone and estrogen can increase eosinophil migration into the nasal mucosa in contrast to testosterone, which decreases eosinophils in the nasal mucosa. This association of hormones with eosinophils may account for the greater prevalence and severity of rhinitis in females following puberty.¹⁴⁴ Rhinitis associated with pregnancy presents with congestion and while this may be secondary to an increase in estrogen and progesterone, the exact mechanism is not known.^{145,146} Other endocrine diseases such as hypothyroidism and acromegaly also have been associated with nasal congestion.⁷²

Drug-induced rhinitis

Drug-induced rhinitis can be classified based on proposed mechanism of action as local inflammatory, neurogenic, and idiopathic.¹⁴⁷ An acute inflammatory response may be induced following the ingestion of acetylsalicylic acid or other NSAIDs with isolated nasal symptoms or nasal symptoms as part of the NSAID-exacerbated respiratory disease with acute asthma symptoms and associated CRS with nasal polyposis. Disruption of the sympathetic and parasympathetic tone by alpha- and beta-adrenergic blockers produce rhinorrhea and nasal congestion through a neurogenic mechanism. The responsible pharmacological agents may be (1) centrally acting sympatholytic (eg, clonidine, reserpine, and methyldopa); (2) peripherally acting sympatholytic (eg, guanethidine and phentolamine); (3) ganglion-blocking (eg, trimethaphan); or (4) vasodilators, phosphodiesterase type-5 inhibitors (eg, sildenafil).¹⁴⁷ No mechanism has been clearly identified because there are many drugs that can produce nasal symptoms, such as calcium channel blockers, angiotensin-converting enzyme inhibitors, gabapentin, and psychotropics (eg, risperidone and chlorpromazine).^{147,148} The effect of exogenous estrogens and oral contraceptives on nasal physiology is uncertain although it has been suggested that oral contraceptives may reduce allergen-provoked nasal congestion during ovulation but increase sneezing at the end of the menstrual cycle.¹⁴⁹⁻¹⁵¹ Overuse of topical decongestants can result in rhinitis medicamentosa, a form of drug-induced rhinitis, which is further discussed in the intranasal decongestants section.

Work-related rhinitis

Work-related rhinitis comprises (1) *de novo* occupational rhinitis (due to exposures from a particular occupational environment, not usually encountered outside the work environment) and (2) work-exacerbated rhinitis (preexisting or concurrent AR or NAR that is worsened by workplace exposures). Most occupational rhinitis is due to high molecular weight agents (>10 kDa) and is IgE- and T_H2 cell-driven. Low molecular weight (<10 kDa) occupational sensitizers may also induce occupational rhinitis symptoms through mechanisms without associated IgE.^{72,152} Following specific inhalation challenge, when compared with low molecular weight agents, high molecular weight agents produced a significantly higher level of acute-phase reactant proteins, cell adhesion molecules, endothelial growth factors, and vitamin D binding proteins.¹⁵³ In work-exacerbated rhinitis, aggravation of rhinitis symptoms is often caused by nonallergic irritant triggers, such as from cold dry air, dust particles, smoke, chemicals, or strong odors. Rarely, when a single high-level exposure or multiple low-dose exposures to an irritant gas, vapor, dust, or smoke results in chronic rhinitis,

this is referred to as reactive upper airways dysfunction syndrome. In nasal mucosa biopsies of individuals exposed to chlorine dioxide, pathological changes found include lymphocytic inflammation of the lamina propria, epithelial desquamation, and increased number of nerve fibers.¹⁵⁴ Analogous to irritant-induced asthma/reactive airways dysfunction syndrome,¹⁵⁵ the predominant basis for making the diagnosis of reactive upper airways dysfunction syndrome is based on occupational history.

Atrophic rhinitis

Atrophic rhinitis is a chronic nasal condition associated with atrophy of the nasal mucosa and paradoxically presents with nasal congestion due to a sensation of decreased airflow, likely a result of decreased airflow resistance. Atrophic rhinitis can be categorized as primary or secondary. While the pathophysiology of primary atrophic rhinitis is unknown, it is associated with mucosal colonization, predominantly with *Klebsiella ozaenae*, although other organisms have also been described. Primary atrophic rhinitis is more commonly seen in young to middle-aged adults in developing countries with dry climates, such as Saudi Arabia, China, Africa, and India, and is uncommon in the United States and Europe.¹⁵⁶ One US study of patients with atrophic rhinitis categorized approximately 19% of them as having primary atrophic rhinitis; the mean age of this primary atrophic rhinitis group was 52 years.¹⁵⁶ It is characterized by progressive atrophy of the nasal mucosa, resorption of underlying bone and turbinates, nasal dryness, and foul-smelling nasal crusts associated with a constant awareness of a bad smell. Biopsy findings consist of squamous metaplasia, glandular cell atrophy, and loss of pseudostratified epithelium. By definition, there is no history of nasal surgery or trauma in primary atrophic rhinitis as is often the case in secondary atrophic rhinitis.

Secondary atrophic rhinitis is more common in the United States and less severe than primary atrophic rhinitis. Secondary atrophic rhinitis often develops as a result of excessive nasal surgery, trauma, irradiation, or chronic granulomatous nasal infections. Therefore, patients with secondary atrophic rhinitis for which an iatrogenic cause has not been determined should be evaluated for an underlying inflammatory systemic disease (eg, leprosy, sarcoidosis, or syphilis). Repeated, and often radical, sinonasal surgeries for CRS, allergic fungal rhinosinusitis, and/or nasal sarcoidosis produce a widening of the nasal vault, referred to as an “empty nose syndrome.”¹⁵⁷ The empty nose syndrome, as may occur after aggressive resection of the inferior and sometimes middle turbinates, is associated with the perception of severe nasal obstruction and inability to sense airflow through the nose. It is “paradoxical” because examination typically finds widely patent nasal cavities and nasal resistance as assessed by rhinomanometry is normal or low. Some patients sense profound dyspnea even though there is no pulmonary disease.^{158,159}

Treatment has traditionally focused on reduction of crusting.^{156,160} Conservative treatment can consist of nasal saline irrigation, glycerin-containing nose drops, nasal emollients, antibiotics, and vasodilators.¹⁵⁷ Surgical interventions attempt to decrease the size of the nasal cavities thereby promoting regeneration and increasing lubrication of the nasal mucosa and improving nasal vascularity. This can be achieved by surgically closing the nasal cavities (modified Young procedure) or implanting prostheses submucosally to decrease nasal cavity size.^{157,161}

However, a Cochrane review concluded there are no adequate randomized controlled studies of sufficient duration that compare these treatment options.¹⁶¹

NAR with eosinophilia syndrome

NARES was first used in 1981 as a term to describe a case series of patients who were nonasthmatic that reported perennial, intermittent symptoms of profuse clear rhinorrhea and paroxysms of sneezing as well as nasal or ocular pruritus, lacrimation, and nasal congestion without complete obstruction. Patients were characterized by elevated nasal eosinophils >20% but with the absence of sIgE by skin and blood testing in all but 3 of 52 subjects. The original cohort included no patients with clinical evidence of CRS with nasal polyps. Oral aspirin and inhaled methacholine challenges performed on limited numbers of subjects were negative.¹⁶² Onset of symptoms ranged from the first to fifth decades.

However, other systematic evaluations of nonallergic subjects with eosinophilic NAR showed significant associations with rhinosinusitis with nasal polyps, sinus mucosal thickening, and asthma leading to speculation that NARES may be a prelude to the onset of CRS, asthma, or perhaps NSAID-exacerbated respiratory disease.^{7,163}

Blood eosinophilia is occasionally present in patients with NARES and the term “blood eosinophilic NAR” had been proposed but not routinely used to represent this possible condition.¹⁶⁴ The prevalence of NARES is unknown but is suspected to represent 1% to 5% of children and from 5% to 15% of adults with rhinitis.^{7,165,166} One cluster analysis from a single center in Beijing characterized NARES in 23.6% of predominately adult subjects with chronic rhinitis.¹⁶⁷ Nasal eosinophilia persisted in children without allergies who were followed throughout the year including the winter season when not exposed to allergens.¹⁶⁶ Total nasal resistance and mucociliary transport time is increased in patients with NARES versus in healthy controls.¹⁶⁸

The differential diagnosis of persistent nasal eosinophilia includes PAR with positive allergy skin or IgE blood tests, LAR, rhinosinusitis with nasal polyps, CRS without polyps, eosinophilic granuloma, allergic fungal rhinosinusitis, and NSAID-exacerbated respiratory disease.¹⁶⁹

NARES is particularly responsive to corticosteroids.⁷ In 1 uncontrolled study, montelukast 10 mg daily reduced nasal obstruction, rhinorrhea, sneezing, and nasal pruritus in subjects with NARES and asthma.¹⁷⁰ Intranasal cromolyn was studied and found to have no benefit in NARES.¹⁷¹

To date there has not been consensus regarding the specific clinical criteria for diagnosis of NARES. The lower limits of nasal eosinophilia required for diagnosis have been variable, ranging from 5% to 25% and the percentage may vary depending on specimen type.^{172,173} Current clinical guidelines have not recommended routine assessments of nasal eosinophils.¹ The diagnosis of NARES should be considered in patients who are nonallergic and presenting with prominent symptoms of perennial rhinorrhea and sneezing in the absence of facial pain, nasal obstruction, rhinosinusitis with nasal polyps on rhinoscopy, and sinus mucosal thickening in individuals with notable response to nasal steroids or with eosinophilia in blood or if assessed in nasal secretions.

DIAGNOSIS AND MANAGEMENT OF RHINITIS

Methods and overview of the practice parameter guideline development process

This guideline contains systematically developed recommendations intended to optimize care of adult and adolescent patients (≥12-15 years of age) and to assist physicians and/or other health care practitioners and patients to make decisions regarding diagnosis and therapy for rhinitis. Even though many treatments are approved for younger children, the application of recommendations to children would be partially based on data extrapolation from adult studies and would therefore be less certain. This guideline updates “The diagnosis and management of rhinitis: an updated practice parameter” published in 2008.¹ This guideline was not intended to be a Grading of Recommendations, Assessment, Development and Evaluation (GRADE) document such as we published in 2017 to update for a limited number of questions for SAR.¹⁷⁴ Because GRADE documents require a comprehensive literature search, systematic review, and meta-analysis for each question, they require substantial resources, making it cost prohibitive to attempt to conduct a GRADE analysis for all of the questions for which clinicians would like an answer. In addition, for many questions, there is very limited evidence and the work group/Joint Task Force on Practice Parameters (JTFPP) must rely on expert evidence and opinion. Therefore, in this guideline, the only GRADE recommendations are those that were previously published in the 2017 rhinitis guideline update. The remainder of the recommendations are consensus-based statements (CBS), which are based, at best, on a recent literature search of PubMed to update or add to the 2012 rhinitis document. We have changed our method of grading our recommendations to be more transparent, choosing words that are used in a formal GRADE document, (eg, strong and conditional), to be consistent in terminology and to maintain a common thread. However, the use of these words do not imply that we are equating our recommendations to the rigor required by a GRADE document.

The strength of the CBSs is determined to be either strong or conditional as defined below. The certainty of evidence for each recommendation is determined to be high, moderate, low, or very low as defined below. When the JTFPP did not have adequate published evidence with which to determine the certainty of evidence but recognized, nonetheless, the need to provide guidance to the clinician, the CBSs were based on the collective expert opinion and experience of the work group and JTFPP. We have provided the tabulated vote for and against each such statement.

The guideline development process involves several stages. The work group begins the process by developing a list of key clinical questions and topics to be addressed. At least 2 work group members are assigned to write and review each section. A PubMed literature search is completed to determine the most updated information for each CBS and discussion. The draft sections are reviewed by the work group chair and co-chair with subsequent revision by the authors. Subsequently, all sections are reviewed and revised by the entire work group through several rounds of electronic and teleconference reviews. The guideline is reviewed in detail by the JTFPP and revisions, when needed, are made in conjunction with the work group. The external review follows as described above under “resolving conflict of interest” in the preface (Tables II, III, and IV).

TABLE II. Grading the strength of the Consensus Based Statements (CBSs)**Strong CBS**

The work group and JTFPP are confident that the desirable effects of adherence to the statement outweigh the undesirable effects. This CBS may be appropriate to be used as a practice standard indicator. When making a strong CBS, the wording is “We recommend,” implying that the clinician “should” follow the recommendation.

The implications of a strong CBS are

- For patients—most people in your situation would want the recommended course of action and only a small proportion would not; request discussion if the intervention is not offered.
- For clinicians—most patients should receive the recommended course of action.
- For policy makers—the recommendation can be adopted as a policy in most situations.

Conditional CBS

The work group and JTFPP reach a decision that the desirable effects of adherence to a CBS probably outweigh the undesirable effect. When making a conditional CBS, the wording is “We suggest,” implying that the clinician “may” follow the recommendation.

The implications of a conditional CBS are

- For patients—most people in your situation would want the recommended course of action, but many would not.
- For clinicians—you should recognize that different choices will be appropriate for different patients and that you must help each patient to arrive at a management decision consistent with her or his values and preferences. It is likely that shared decision making will play a major role in arriving at the management decision.
- For policy makers—policy making will require substantial debate and involvement of many stakeholders.

TABLE III. Grading the certainty of evidence for each CBS

High = Further research is very unlikely to change our confidence in the estimate of effect. The recommendation is based on high-quality evidence, such as multiple highly rated randomized controlled trials, systematic reviews, or meta-analyses.

Moderate = Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. The recommendation would likely be based on somewhat limited evidence, such as reduced number or quality of randomized controlled trials or controlled trials without randomization.

Low = Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. The recommendation would likely be based on very weak evidence, such as nonexperimental studies, registries, or comparative studies.

Very low = Any estimate of effect is very uncertain. The recommendation is based largely on very low quality studies and/or on expert opinion.

CBS without determination of certainty:

When there are either no published studies, or very limited and/or very weak evidence, a consensus statement without any category of certainty of evidence was developed. The degree of agreement by all JTFPP and work group members is indicated, with voting details provided if there were dissenting votes.

Clinical history and physical examination

Recommendation 1. CBS: We recommend that the clinician complete a detailed history and a physical examination in a patient presenting with symptoms of rhinitis.

Strength of recommendation: Strong

Certainty of evidence: Low

Recommendation 2. CBS: We recommend that for patients presenting with rhinitis symptoms, a review of all current medications should be completed to assess whether drug-induced rhinitis may be present.

Strength of recommendation: Strong

Certainty of evidence: Ungraded due to lack of studies addressing this specific issue.

Note: Unanimous vote in favor by work group and JTFPP.

Clinical history in patients with rhinitis. The most important single element for establishing the diagnosis of rhinitis, allergic or nonallergic, and differentiating it from other conditions with overlapping symptoms, is the clinical history.^{1,20,175} The age of onset, duration, frequency, severity, timing during the year, suspected triggers, pattern of presentation, and progression of each patient-specific symptom should be obtained and recorded. The history should include the success or failure of past therapeutic interventions, including self-prescribed over-the-counter medications, homeopathic agents, or physician-prescribed treatments. The family history and personal history of comorbid respiratory conditions (eg, asthma and chronic rhinitis with or without

CRS) should be discussed. Because patients may not recognize symptoms of asthma, a history of symptoms suggestive of asthma (eg, wheezing, shortness of breath, chest tightness, and cough) should be sought, and if appropriate from symptoms, spirometry obtained. As noted earlier, AR coexists in about 75% to 80% of all patients with asthma, in nearly 100% of those with allergic asthma, and is a marker for more difficult-to-control or severe asthma. The overall medical, social, and psychiatric history; medication history (current and past); environmental exposures in the home or workplace; and family views on disease state and health care should be included in the patient history. As the final therapeutic decisions will involve shared decision making, the history should explore the wishes and desires of both the patient and family in selecting diagnostic procedures and therapeutic interventions, including their willingness to adhere to these therapies.

In clinical practice, especially in primary care, the diagnosis of AR is often made solely by history.¹⁷⁶ The use of validated questionnaires is more beneficial for excluding than for confirming AR. The use of a validated 4-question screening tool has been shown to have a high negative predictive value for positive skin prick tests to common aeroallergens.¹⁷⁷ Furthermore, if a patient has a late onset of symptoms (age >45 years); no family history of allergies; no seasonality of symptoms or symptoms around cats, dogs, or other furry pets; and has trouble with nonallergic triggers such as deodorants/fragrances, the likelihood of having a

TABLE IV. JTFPP practice parameter CBSs and GRADE recommendations on the diagnosis and management of rhinitis

Recommendation no.	CBS or GRADE recommendation	Strength of recommendation	Certainty of evidence
1	CBS: We recommend that the clinician complete a detailed history and a physical examination in a patient presenting with symptoms of rhinitis.	Strong	Low
2	CBS: We recommend that for patients presenting with rhinitis symptoms, a review of all current medications should be completed to assess whether drug-induced rhinitis may be present.	Strong	Ungraded
3	CBS: We recommend that aeroallergen skin prick testing or sIgE testing be completed to confirm the diagnosis of AR in a patient with a history consistent with AR.	Strong	High
4	CBS: We recommend that the clinician not perform food skin prick testing or sIgE for foods in their routine evaluation of a patient presenting with the signs and symptoms compatible with the diagnosis of AR.	Strong	Ungraded
5	CBS: We suggest that the use of a validated instrument (eg, scoring system, scale, or questionnaire) be considered to help determine the severity of rhinitis and to monitor the degree of disease control.	Conditional	Low
6	CBS: We recommend against prescribing a first-generation antihistamine and are in favor of a second-generation antihistamine when prescribing an oral antihistamine for the treatment of AR.	Strong	High
7	CBS: We suggest that the clinician not select the oral LTRA montelukast for the initial treatment of AR due to reduced efficacy when compared with that of other agents. Furthermore, serious neuropsychiatric events that may include suicidal thoughts or actions have been reported in some patients taking montelukast. As advised by the FDA, montelukast should be used to treat AR only in patients who are not treated effectively with or cannot tolerate other alternative therapies.	Conditional	Very low
8	CBS: We recommend that the clinician not select an oral LTRA for the treatment of NAR.	Conditional	Ungraded
9	CBS: We suggest that for the treatment of very severe or intractable AR, the clinician may consider a short course (5-7 d) of oral corticosteroids.	Conditional	Very low
10	CBS: We suggest that for the treatment of very severe or intractable AR, the clinician not prescribe a depot parenteral corticosteroid for AR due to the potential risks of systemic and local corticosteroid side effects.	Conditional	Low
11	CBS: We recommend that the clinician offer INAH as an initial treatment option for patients with SAR.	Strong	High
12	CBS: We recommend that the clinician offer INAH as a first-line monotherapy option for patients with NAR.	Strong	High
13	CBS: We recommend that the clinician offer INAH as a first-line option for patients with intermittent AR.	Conditional	Ungraded
14	CBS: We recommend that when choosing monotherapy for persistent AR, INCS be the preferred medication.	Strong	High
15	GRADE: We recommend that for the initial treatment of moderate/severe SAR in patients ≥ 15 y of age, the clinician use an INCS over an LTRA. (Also see Recommendation 7.)	Strong	High
16	CBS: We suggest that the use of intranasal decongestants be short term and used for intermittent or episodic therapy of nasal congestion. (However, see also Recommendation 26.)	Conditional	Low
17	CBS: We suggest that in patients having severe mucosal edema, which impairs the delivery of other intranasal agents, an intranasal decongestant be considered for up to 5 d of use.	Conditional	Ungraded
18	CBS: We suggest that oral decongestant agents be used with caution in older adults and children younger than 4 y old, and in patients of any age who have a history of cardiac arrhythmia, angina pectoris, cerebrovascular disease, uncontrolled hypertension, bladder outlet obstruction, glaucoma, hyperthyroidism, or Tourette syndrome.	Conditional	Low
19	CBS: We recommend that oral decongestants be avoided during the first trimester of pregnancy.	Strong	Low
20	CBS: We suggest that in patients with PAR and NAR who have rhinorrhea as their main nasal symptom be offered intranasal ipratropium.	Conditional	Low for PAR; moderate for NAR
21	CBS: We suggest that intranasal cromolyn be offered as an option to be taken just prior to allergen exposure to reduce symptoms of AR from episodic allergen exposures.	Conditional	Very low
22	GRADE: We suggest that the clinician consider the combination of an INCS and an INAH for the initial treatment of moderate/severe nasal symptoms of SAR in patients ≥ 12 y old.	Conditional	High
23	CBS: We suggest that the clinician consider the combination of an INCS and an INAH for moderate/severe SAR and PAR that is resistant to pharmacologic monotherapy.*	Conditional	Moderate
24	CBS: We suggest that the clinician consider the combination of an INCS and an INAH for moderate/severe NAR that is resistant to pharmacologic monotherapy.*	Conditional	Low
25	CBS: We suggest that for patients taking an INCS who have persistent rhinorrhea, the clinician may consider the addition of intranasal ipratropium.	Conditional	Moderate
26	CBS: We suggest that patients with persistent nasal congestion unresponsive to an INCS or to an INCS-INAH combination be offered combination therapy with addition of an intranasal decongestant for up to 4 wk.	Conditional	Low

(Continued)

TABLE IV. (Continued)

Recommendation no.	CBS or GRADE recommendation	Strength of recommendation	Certainty of evidence
27	CBS: We suggest that for patients with AR and nasal congestion uncontrolled with an oral antihistamine, the clinician consider the addition of pseudoephedrine, when tolerated. (See Recommendation 18.)	Conditional	Moderate
28	CBS: We suggest that for SAR the clinician not combine the oral LTRA montelukast with an oral antihistamine for symptoms not controlled with an oral antihistamine. (See Recommendation 7.)	Conditional	Moderate
29	GRADE: We recommend that the clinician not prescribe, as initial treatment, a combination of an oral antihistamine and an intranasal steroid in preference to monotherapy with an intranasal steroid in patients ≥ 12 y of age with symptoms of SAR.	Strong	Moderate
30	CBS: We suggest that the clinician not prescribe the combination of an oral antihistamine and an INCS in preference to monotherapy with an intranasal steroid in all patients with SAR and PAR.	Conditional	Very low
31	CBS: We suggest against the addition of the oral LTRA montelukast to an INCS for AR, due to the lack of adequate evidence of improved efficacy and concerns for serious neuropsychiatric events from montelukast. (See Recommendation 7.)	Conditional	Very low
32	CBS: We suggest that the clinician offer an INCS as a first-line therapy for NAR.	Conditional	Low
33	CBS: We suggest that the clinician offer an INAH as a first-line therapy for NAR.	Conditional	Very low
34	CBS: We suggest that AIT (subcutaneous or sublingual tablets) be offered through shared decision making to patients with moderate/severe AR who (1) are not controlled with allergen avoidance and/or pharmacotherapy or (2) choose immunotherapy as the preferred method of treatment (eg, due to the desire to avoid the adverse effects, costs, or long-term use of pharmacotherapy) and/or (3) desire the potential benefit of immunotherapy to prevent or reduce the severity of comorbid conditions, such as asthma.	Conditional	Moderate
35	CBS: We suggest that AIT (subcutaneous or sublingual tablets) be considered for patients with controlled mild/moderate asthma with coexisting AR.	Conditional	Moderate
36	CBS: We cannot make a recommendation for or against the use of acupuncture for the treatment of AR.	N/A	Very low
37	CBS: We cannot make a recommendation for or against the use of specific herbal products for the treatment of AR.	N/A	Very low

N/A, Not applicable.

*“Resistant to pharmacologic monotherapy” assumes that the patient has been compliant and taken medication for adequate duration.

component of NAR before diagnostic skin or serologic testing is 98% predictive.¹⁷⁸ While the history has greater reliability and predictive value than solely relying on the physical exam, the combination of history and physical exam is still advised (Table V).¹⁷⁹

Cough and rhinitis

Chronic cough, often defined as cough persisting for >4 weeks (children)¹⁸⁰ or >8 weeks (adults),¹⁸¹ in patients who are immunocompetent and nonsmoking is usually due to upper airway cough syndrome (UACS), formerly referred to as postnasal drip syndrome; asthma; and/or gastrointestinal reflux disease, with UACS being the most common cause.¹⁸²⁻¹⁸⁶ While the pathogenesis of chronic cough has often been attributed to some combination of upper airway inflammation, nasobronchial reflex, cold dry air stimulation, inflammatory mediators from the systemic circulation, or central and peripheral neuroplasticity, a clear pathway has not been shown experimentally.¹⁸⁷⁻¹⁸⁹

Cough as a consequence of rhinitis, especially AR, is often underappreciated, due in large part to a lack of high-level evidence. Overall, guidelines minimize or conclude that there is low-level evidence associating AR with cough without the presence of concurrent asthma.^{179,190} Cough is often considered to be a comorbidity of AR rather than viewed as a direct symptom of AR. In 1 study, rhinitis was found to be an independent risk factor for the development of cough in adults.¹⁹¹ Furthermore, in 1

large multinational observational study, 47% of patients with AR frequently reported cough as a symptom, although only 11% had cough as the main reason for seeking medical attention.¹⁹² In a prospective study, cough as a symptom increased from mild intermittent to moderate/severe persistent AR.¹⁹³ Cough sensitivity has been described to be heightened in patients with AR, both during and outside of pollen season.^{194,195} With up to 23% of patients with chronic cough having at least 2 contributing comorbidities (eg, AR with postnasal drip and gastroesophageal reflux disease), the complexity of managing chronic cough becomes magnified.¹⁹⁶

The mechanism of cough in AR has often been explained both as a rhinobronchial reflex and as part of the UACS. In nasal challenge studies of patients with AR, cough was described most frequently in patients with PAR.¹⁹⁷ Patients with persistent AR report more postnasal drip along with more cough.¹⁹⁸ The mechanisms of cough from UACS in children may differ from adults and may differ among children of different age groups. In 1 Chinese study, rhinitis was the major pathogenesis in the school-age children, whereas it was adenoid hypertrophy in a group of pre-school children, indicating that mechanical obstruction may be a major cause of UACS in some children.¹⁹⁹

Frequently, cough in a patient with AR is related to concomitant asthma or nonspecific bronchial hyperreactivity, often undiagnosed. Furthermore, bronchial biopsy studies in patients with AR and without asthma have shown inflammatory cell infiltrate and active structural remodeling of the lower airways

TABLE V. Patient-reported symptoms and likely diagnosis

Symptom	AR	NAR	Acute upper respiratory tract infection	CRS without nasal polyps	CRS with nasal polyps
Rhinorrhea, sniffing	Very common, can be intermittent AR or persistent AR, most common symptom, clear watery	Common, but less than AR overall, but some subtypes have rhinorrhea as a major symptom	Common clear to purulent, watery to mucoid, associated with crust formation	Common, clear to mucoid	Common, clear to mucoid
Sneezing	Very common, intermittent and persistent AR, almost universal	Common, intermittent, less common than in AR, rarely persistent	Common	Very uncommon	Very uncommon
Hyposmia/anosmia	Occasional	Occasional	Common	Common	Very common
Nasal congestion/blocked nose, mouth breathing	Very common, persistent AR more than intermittent AR	Very common, usually persistent	Common	Very common	Very common, chronic, almost universal
Mouth breathing	Common	Common	Common	Occasional	Common
Ocular pruritus, watery discharge, red eyes	Very common	Uncommon	Uncommon	Very uncommon	Very uncommon
Postnasal drip	Uncommon, persistent more than intermittent AR	Very common	Common	Common	Occasional
Nasal/palate/ear itching	Common	Very uncommon	Very uncommon	Very uncommon	Very uncommon
Sore throat	Occasional, persistent more than intermittent	Uncommon	Common	Occasional	Uncommon
Constant clearing of throat	Uncommon	Common	Common	Common	Uncommon
Chronic cough	Common, persistent more than intermittent	Common, unless postnasal drip treated (persistent more than intermittent)	Common	Occasional	Uncommon
Bleeding of nose	Very uncommon	Uncommon	Very uncommon	Very uncommon	Very uncommon
Facial or sinus pain/pressure	Very uncommon, persistent more than intermittent	Common	Common	Common	Uncommon
Eustachian tube dysfunction	Occasional	Occasional	Common	Uncommon	Uncommon
Snoring	Uncommon, persistent more than intermittent AR	Common	Common	Common	Common
Sleep disturbance/sleep apnea	Common, persistent more than intermittent AR	Common	Common	Common	Common
Headache as part of symptomology	Occasional	Common	Common	Common	Common

This table is developed based predominantly on expert opinion. Frequencies—very common, common, occasional, uncommon, very uncommon—are based on expert evidence and opinion.

similar to that of patients with asthma, thereby potentially contributing to cough in these patients.^{200,201}

While intranasal corticosteroids (INCS) are often used to treat UACS, high-quality evidence is lacking. INCS have been shown to reduce cough sensitization in patients with AR.²⁰² Nasal-pharyngeal saline irrigation, compared with INCS, was shown to be more effective at reducing daytime and nighttime cough score and in lowering nasal lavage histamine and LTC₄.²⁰³

Physical examination

For a patient with rhinitis symptoms, a physical exam should be completed that encompasses not only the upper airway but also the lower airway, eyes, ears, and skin to identify findings that may suggest the presence of a comorbid allergic or nonallergic condition (see Table VI for more details).^{1,20,179} These comorbid conditions may include accompanying allergic

conjunctivitis, otitis, eustachian tube dysfunction, CRS with and without nasal polyps, asthma, and/or atopic dermatitis.^{1,204-206} Documentation of normal findings (eg, no septal perforation) is important to establish baseline exam findings prior to the prescribing of medications that might lead to adverse events. While specific nasal and oropharyngeal physical exam findings (eg, pale, boggy nasal mucosa, allergic shiners, and pharyngeal hyperplasia) may support the diagnosis of AR, there are no pathognomonic findings that distinguish allergic versus nonallergic versus infectious rhinitis.^{1,179,207,208} Furthermore, a patient with a history of rhinitis who is asymptomatic or minimally symptomatic at the time of the physical exam, may have minimal or no abnormal findings.²⁰⁹ While conducting a physical exam is recommended by all major rhinitis guidelines to make the diagnosis of AR,^{1,20,175} the very limited, low-quality research evidence that is available demonstrates a much lower sensitivity and specificity and high interpreter variability for

TABLE VI. Physical examination of patient presenting with symptoms compatible with rhinitis

Vital signs (including weight and height): Record on all patients.
General observations: facial pallor, elongated facies, preferred mouth breathing, and any evidence of systemic disease.
Eyes: Excessive lacrimation, erythema, and swelling of the bulbar and/or palpebral conjunctiva, cobblestoning of the tarsal conjunctiva, swelling or dermatitis of outer eyelids, Dennie-Morgan lines, or venous stasis below the lower eyelids ("allergic shiners," which may occur in AR or NAR).
Nose: Reduced patency of nasal valve; alar collapse; transverse external crease; external deformity such as saddle nose (loss of nasal bridge that may occur from nasal trauma or systemic disorders such as relapsing polychondritis, granulomatosis with polyangiitis, cocaine abuse, or some systemic infections); septal deviation or perforation, spurs, ulcers, perforation, prominent vessels, or excoriation; nasal turbinate hypertrophy, edema, pallor or erythema, and crusting; discharge (amount, color, consistency), and nasal polyps. The presence of tumors or foreign bodies should be noted.
Ears: Tympanic membrane dullness, erythema, retraction, perforation, reduced or increased mobility, and air-fluid levels.
Oropharynx: Halitosis, dental malocclusion or high arched palate associated with chronic mouth breathing, tonsillar or AH, cobblestoning of the oropharyngeal wall, pharyngeal postnasal discharge, temporomandibular joint pain or clicking with occlusion, furrowing, coating, or ulceration of tongue or buccal mucosa.
Neck: Lymphadenopathy, or tenderness, thyroid enlargement or nodule.
Chest: Signs of asthma such as wheezing or other abnormal or diminished sounds by auscultation.
Skin: Rashes, especially eczematous or urticarial (distribution and description), or dermatographism.
Other organ systems: When history or general observation indicate these should be included.

This list is not intended to be totally inclusive. Elements of the examination that will assist in the differential diagnosis of rhinitis or that may indicate complications of treatment are included. Documentation of presence or absence of these elements should be considered. This table is modified from Table V in the 2008 rhinitis practice parameter.¹

the physical exam when compared with the patient's history for making a diagnosis of AR, suggesting that both are essential to increase diagnostic accuracy.^{179,209,210} Considering both the high prevalence of AR and NAR and the large number of differential diagnoses for rhinitis, perhaps the greatest benefit of completing the physical exam is to exclude the rare, but potentially life-threatening diagnosis, intranasal tumor), which may even co-exist with AR.

The nasal-pharyngeal exam can usually be accomplished with the use of a nasal speculum with appropriate lighting or an otoscope with a nasal adapter,¹ although these provide a more limited view of the nasal cavity than a nasopharyngolaryngoscope does. For mucosal edema that prohibits an adequate exam, the use of a topic nasal decongestant may reduce turbinate mucosal edema, allowing for better visibility and delineation of abnormal findings (eg, distinguishing nasal polyps from polypoidal mucosal hypertrophy). A pneumatic otoscope allows for the assessment of tympanic membrane mobility and presence of transudative fluid. At times, an impedance tympanometer may also be of benefit to assess tympanic membrane mobility and the presence/absence of middle ear fluid. A nasopharyngolaryngoscope exam should be completed when a more extensive nasal/pharyngeal/laryngeal exam is required due to suspected structural or functional abnormalities, inadequate therapeutic response, or a suspected complication (eg, deviated septum, rhinosinusitis with or without nasal polyps, foreign body, nasal septal perforation, or vocal cord dysfunction).

Differential diagnosis of rhinitis

The differential diagnosis of chronic rhinitis symptoms includes AR, NAR, mixed rhinitis, including the rhinitis-specific subtypes discussed in previous sections; common conditions that mimic rhinitis such as rhinosinusitis with or without nasal polyps and nasal septal deviation (NSD); and more uncommon conditions (Table VII). A comprehensive history, physical examination, and appropriate testing is important to ascertain the correct diagnosis as this will help direct the therapeutic approach recognizing that some diseases mimicking rhinitis can lead to substantial morbidity and even mortality. Furthermore, >1 cause of nasal

symptoms can be present concurrently and contribute to the rhinitis-induced morbidity.

Selected conditions that may mimic rhinitis

Nasal septal deviation. NSD is a common cause of fixed nasal obstruction leading to nasal congestion.²¹¹ It appears to be as common an anatomical cause of congestion as nasal valve collapse and turbinate hypertrophy.²¹² It may cause bilateral or unilateral congestion and is often associated with nasal valve collapse and compensatory turbinate hypertrophy.²¹²⁻²¹⁴ The importance and effectiveness of septoplasty for NSD does not appear to be universally accepted.^{215,216}

Nasal valve collapse. The internal nasal valve is the narrowest portion of the nasal cavity and is the anatomical area bounded medially by the nasal septum and laterally by the inferior edge of the upper lateral cartilage and the anterior aspect of the inferior turbinate. As such the nasal valve is the area most commonly associated with the subjective perception of obstruction and is responsible for more than two-thirds of the airflow resistance produced by the nose.²¹⁷ Nasal valve collapse refers to any weakness or further narrowing of the nasal valve and can result in change of airflow that is perceived as nasal congestion. The nasal examination should note the patency of the nasal valve and any alar collapse. If there is improvement in breathing when performing the Cottle maneuver—pulling the patient's cheek laterally to open the nasal valve angle—this may suggest nasal valve pathology.

Turbinate hypertrophy. Hypertrophy, with or without concha bullosa, can account for severe unilateral or bilateral obstruction and accounts for severe congestion equally as commonly as nasal valve collapse and septal deviation do.²¹² Hypertrophy can be primary (eg, from AR and NAR) or compensatory, often being associated with congenital or traumatic septal deviation.²¹³ While medical treatment for some causes of turbinate hypertrophy (eg, AR) can be very effective, not infrequently a surgical approach will be required for other causes. The consensus for treatment in refractory cases can include turbinate reduction.²¹⁸⁻²²⁰ When performing septoplasty for unilateral NSD, it is often necessary to also perform turbinate reduction

TABLE VII. Diagnosis and treatment of rhinitis-associated conditions or conditions that mimic rhinitis

Condition	History that may differentiate from rhinitis	Physical exam findings	Diagnostic studies	Treatment
CRS with nasal polyps	May have reduced sense of smell/taste; chronic congestion, nocturnal mouth breathing, NSAID-induced respiratory symptoms	Mucosal polypoidal changes that will not shrink with topical decongestant, nonpainful growths	Fiberoptic nasopharyngoscopy, sinus CT	Saline irrigation, consider short course oral corticosteroids, INCS, LTRAs, surgery, anti-IL-4/13 (dupilumab). Aspirin desensitization in aspirin/NSAID-exacerbated respiratory disease Research ongoing: anti-IL-5, IL-5 receptor antagonist, anti-IgE.
CRS without nasal polyps	Facial pain/pressure, headache, mucopurulent discharge, decreased sense of smell, postnasal drip, fatigue, poor sleep quality, depression	Mucopurulent discharge, facial tenderness, cobblestoning posterior pharyngeal wall	Fiberoptic nasopharyngoscopy, sinus CT, consider immune system evaluation	Evidence for treatment effectiveness may differ between CRS with and CRS without nasal polyps. Options include INCS, saline irrigation, chronic macrolide antibiotics (conflicting evidence), acute antibiotics for superimposed infection, surgery
Septal wall abnormalities, such as deviated septum, septal erosion, nasal septal perforation	Severity worse unilateral side, previous surgery, trauma, history of abuse of cocaine (perforation)	Septal deviation noted, septal erosion and/or perforations, septal spurs, asymmetrical nasal vault openings	Fiberoptic nasopharyngoscopy, sinus CT	Surgery, such as septoplasty or surgical correction of perforations, septal button (for septal perforation)
Nasal valve collapse	Nasal congestion as main symptom, poor response to medication	Improvement in breathing when performing the Cottle maneuver (ie, pulling the patient's cheek laterally to open the nasal valve angle)	Fiberoptic nasopharyngoscopy and anterior rhinoscopy	Adhesive spring-like externally applied nasal strips, nasal cones, surgery
Turbinate hypertrophy: with or without concha bullosa	Severe unilateral or bilateral obstruction. Hypertrophy can be primary or compensatory and often associated with congenital or traumatic septal deviation	Turbinate hypertrophy	Fiberoptic nasopharyngoscopy, Sinus CT	INCS, surgery
Adenoidal hypertrophy	Child with recurrent ear infections and/or snoring, congestion as main or only symptom, possible sleep disturbance	Posterior nasal, pharyngeal fullness may be noted, adenoids may not be visualized on regular exam	Tympanogram, fiberoptic nasopharyngoscopy, lateral neck radiological studies, CT scan	INCS, LTRAs, Consider short-course oral steroids, surgery
Foreign body	History of possible foreign body placement by child or impaired adult (with or without direct observation), mucopurulent discharge	Unilateral halitosis, mucopurulent discharge, use topical decongestant during exam for visualization and possible dislodgment	May require otolaryngologist referral for rigid rhinoscopy for both diagnosis and treatment (possibly under sedation for child)	Removal of foreign body
Nasal tumors (benign or malignant)	Progressive unilateral congestion, bloody discharge, nasal or ear pain	Unilateral mass incompatible with normal mucosal edema or polyps	Consider fiberoptic nasopharyngoscopy, CT scan, and/or referral to otolaryngologist for examination, possible biopsy, and treatment	Surgery usually required, variable depending on diagnosis
Cerebral spinal fluid leak	Unilateral clear discharge, intermittent, increased with dependent head position, recent surgery or trauma	Clear discharge unilateral —may or may not be noted on exam	Test nasal discharge for beta-2 transferrin and if positive refer to otolaryngologist	Otolaryngologist to evaluate whether there is need for surgical leak closure

(Continued)

TABLE VII. (Continued)

Condition	History that may differentiate from rhinitis	Physical exam findings	Diagnostic studies	Treatment
Primary ciliary dyskinesia syndrome	Recurrent rhinosinusitis, otitis, sinus surgeries, diagnosis of rhinosinusitis with nasal polyps, atypical asthma, bronchiectasis	Findings compatible with CRS with or without nasal polyps	Nasal nitric oxide; nasal brush biopsy and electron microscopic exam are definitive tests; consider genetic testing; consider chest x-ray	No effective medical treatment other than infection intervention with antibiotics, surgery frequently required for CRS or chronic otitis

This table was developed largely based on expert opinion and is intended to offer considerations for the clinician.

surgery due to compensatory hypertrophy of the contralateral inferior turbinate.²²¹

Cerebral spinal fluid leak. Cerebral spinal fluid leak usually presents as a unilateral clear rhinorrhea, without congestion, often worsened in the upright position, and increased in frequency following head trauma or surgery; however, some cases may be spontaneous.²²² Suggested diagnostic testing in the past included glucose determination, normally found in cerebral spinal fluid, but not in nasal secretions. A determination of beta-2 transferrin levels in nasal drainage is now the preferred test. Nasal drainage can be collected and remain stable at room temperature for a week or more.²²² For diagnostic confirmation and preparation for surgery, high-resolution CT and magnetic resonance cisternography are accurate, noninvasive, and complementary.²²³ Treatment is often surgical in the form of endoscopic or open repair to prevent complications, which include meningitis.^{222,224-226}

Adenoidal hypertrophy. Adenoidal hypertrophy (AH) is among the most common anatomic causes of nasal obstruction in children. Lateral x-ray of the nasopharynx is an effective tool to assess for AH in children and findings correlate well with symptoms.²²⁷ The combination of clinical assessment (good specificity) with lateral x-ray (good sensitivity) is a good method for assessment of the degree of AH.²²⁸ In addition, when feasible, the severity of AH can usually be adequately assessed by the nasopharyngolaryngoscope exam.²²⁹ Complications include acute and recurrent otitis, otitis media with effusion, hypoacusia, altered speech development, and sleep-disordered breathing. Prolonged mouth breathing may lead to defective dental growth and facial bone development. Medical therapy includes topical nasal corticosteroids, which are found to be effective with high-quality evidence, montelukast, or a combination of both; however, data suggest that single drug therapy may be just as effective as the combination.²³⁰⁻²³² When medical therapy fails, surgical removal should be considered. Young age and apnea hypopnea index >1 increase the likelihood that surgery will be necessary.²³³

Nasal foreign body. Nasal foreign bodies are common among young children.²³⁴⁻²³⁶ Most cases present with unilateral congestion and foul-smelling purulent rhinorrhea. Foreign bodies are estimated to account for 30% of ear, nose, and throat emergencies of which 19% are intranasal.²³⁴ Complications of nasal foreign bodies include infection, nasal perforation and epistaxis.²³⁵ Of particular importance is the increase of nasal impaction with button batteries that can be corrosive and lead to septal perforation.²³⁷ Removal may require general anesthesia, especially in cases of prolonged impaction because of associated inflammation.²³⁸

Ciliary dyskinesia. Ciliary dyskinesia can be primary or secondary. Secondary ciliary dysfunction can result from chronic infections, irritants, or multiple nasal surgeries and might be transient and reversible. Primary ciliary dyskinesia is a rare

genetic disorder, referred to as immotile-cilia syndrome, that may present with cough, nasal congestion and symptoms of asthma, CRS with nasal polyps (in children and adults), bronchiectasis, recurrent otitis, rhinitis, and rhinosinusitis. In addition, infertility and situs inversus may complicate immotile-cilia syndrome. Unfortunately, there is no “gold standard” for the diagnosis of primary ciliary dyskinesia.²³⁹ Most of the individual tests are subject to a false positive and/or a false negative result. An algorithmic-driven approach using a combination of tests has been published both by the European Respiratory Society and the American Thoracic Society.^{240,241} Given a suggestive history and the exclusion of cystic fibrosis and immunodeficiency disorders, screening tests start the diagnostic process. In the past, screening tests included saccharine transit time or nasal challenge with tagged particles but these tests are no longer recommended. Currently, the first step in the European Respiratory Society algorithmic-driven approach is to obtain nasal nitric oxide and a nasal mucosal brushing for high-speed videomicroscopy analysis.²⁴⁰ If these are equivocal or normal, a nasal mucosal brush specimen is sent for transmission electron microscopy and for cell culture and repeat high-speed videomicroscopy analysis.²⁴⁰ If the results are still equivocal, genetic testing for known primary ciliary dyskinesia variants is then completed.²⁴⁰ However, it is possible for the patient to have an unrecognized genetic defect. Many of the tests above described are only available in specialty centers. Additional testing methods (eg, inhalation of colloid albumin-tagged technetium Tc 99) are available only as a research tool.

Pharyngonasal reflux. Pharyngonasal reflux secondary to prematurity or neuromuscular diseases may present as congestion in early life. In addition, esophageal reflux can cause nasal symptoms in adults and children and may even predispose to obstructive sleep apnea.²⁴² The most common symptom of eosinophilic esophagitis is reflux, and eosinophilic esophagitis is frequently associated with rhinitis and especially symptoms of AR.²⁴³ Testing for and treatment of reflux in sinonasal disease lacks consensus, and most available data refer to reflux causing pharyngeal and laryngeal disease without focus on isolated nasal symptoms.^{244,245}

Nasal/sinus tumor. Two recent documents from the World Health Organization address ear, nose, and throat tumors. A 2018 document discusses the classification of ear, nose, and throat tumors.²⁴⁶ An earlier World Health Organization document from 2017 addresses clinical characteristics and imaging findings of benign masses of the nose and sinuses.²⁴⁷

Vasculitis, sarcoidosis, and other systemic diseases. The differential diagnosis of systemic diseases that can cause nasal symptoms is not included in this section; however,

1. **During the past week, how often did you have nasal congestion?**

Never	Rarely	Sometimes	Often	Extremely often
<input type="checkbox"/> 5	<input type="checkbox"/> 4	<input type="checkbox"/> 3	<input type="checkbox"/> 2	<input type="checkbox"/> 1

2. **During the past week, how often did you sneeze?**

Never	Rarely	Sometimes	Often	Extremely often
<input type="checkbox"/> 5	<input type="checkbox"/> 4	<input type="checkbox"/> 3	<input type="checkbox"/> 2	<input type="checkbox"/> 1

3. **During the past week, how often did you have watery eyes?**

Never	Rarely	Sometimes	Often	Extremely often
<input type="checkbox"/> 5	<input type="checkbox"/> 4	<input type="checkbox"/> 3	<input type="checkbox"/> 2	<input type="checkbox"/> 1

4. **During the past week, to what extent did your nasal or other allergy symptoms interfere with your sleep?**

Not at all	A little	Somewhat	A lot	All the time
<input type="checkbox"/> 5	<input type="checkbox"/> 4	<input type="checkbox"/> 3	<input type="checkbox"/> 2	<input type="checkbox"/> 1

5. **During the past week, how often did you avoid any activities (for example, visiting a house with a dog or cat, gardening) because of your nasal or other allergy symptoms?**

Never	Rarely	Sometimes	Often	Extremely often
<input type="checkbox"/> 5	<input type="checkbox"/> 4	<input type="checkbox"/> 3	<input type="checkbox"/> 2	<input type="checkbox"/> 1

6. **During the past week, how well were your nasal or other allergy symptoms controlled?**

Completely	Very	Somewhat	A little	Not at all
<input type="checkbox"/> 5	<input type="checkbox"/> 4	<input type="checkbox"/> 3	<input type="checkbox"/> 2	<input type="checkbox"/> 1

FIG 1. Rhinitis Control Assessment Test. Reprinted with permission from Meltzer et al²⁶⁵ and Nathan.²⁶⁸

questioning for constitutional symptoms in all patients with rhinitis can be justified as a way to help exclude a systemic disease manifesting with rhinitis-type symptoms.

Recommendation 3. CBS: We recommend that aeroallergen skin prick testing or sIgE testing be completed to confirm the diagnosis of AR in a patient with a history consistent with AR.

Strength of recommendation: Strong

Certainty of evidence: High

Recommendation 4. CBS: We recommend that the clinician not perform food skin prick testing or sIgE for foods in their routine evaluation of a patient presenting with the signs and symptoms compatible with the diagnosis of AR.

Strength of recommendation: Strong

Certainty of evidence: Ungraded due to lack of studies addressing this specific issue.

Note: Unanimous vote in favor by work group and JTFPP.

Diagnostic testing

Diagnosing rhinitis may be possible combining the patient's history and physical findings. However, in most cases, laboratory and/or skin tests will confirm the diagnosis. Classically this was done by conjunctival challenge to grass pollen by Noon²⁴⁸ as he pioneered allergen immunotherapy (AIT). Throughout the early part of the 20th century, skin tests, both puncture and intradermal,

were the rule. Once IgE was discovered, *in vitro* laboratory tests could identify antibodies to specific allergens.

The 2008 Practice Parameters Allergy Diagnostic Tests⁷⁶ stated: "Prick/puncture tests or intracutaneous tests are the preferred techniques for IgE-mediated hypersensitivity. It is advisable to use prick/puncture devices, which are relatively non-traumatic and elicit reproducible results when placed on specific areas of the body (ie, arms or back). Optimal results depend on use of potent test extracts and proficiency of the skin tester (ie, demonstration of coefficient of variation 30% at different periods). Intracutaneous tests are generally used for specific allergens (ie, Hymenoptera venoms and penicillin), but they may also be applied if prick/puncture test results are negative and there is a strong historical likelihood of clinical allergy to specific allergens." A 2016 meta-analysis of 7 studies with 430 patients found that skin prick testing sensitivity was 85% and specificity 77%.²⁴⁹ Intradermal studies were too few to give significant results. A large study from Turkey²⁵⁰ compared intradermal with skin prick tests. Among 4223 patients with AR and/or asthma, prick tests were positive in 57% of subjects. Intradermal tests were applied to 344 patients with marked allergic symptoms; 44% were positive: 33% to dust mites, 22% to fungal spores. These were not compared with nasal challenge results. Other studies have suggested that in the presence of negative skin prick tests, positive intradermal tests to aeroallergens may often indicate

Intermittent Allergic Rhinitis Pharmacologic Treatment - Age 12 and older *




FIG 2. Algorithm for intermittent AR. *While most of the meds listed in the algorithm are approved for use in children <12 years old, comparative trials have, for the most part, been limited to those ≥12 years of age. The principles of treatment of children are the same as for adults, but special care must be given to dosage adjustment, adverse effects, and long-term safety. **Severity of rhinitis, based on symptoms and degree of overall control can be assessed by the patient using a VAS of 1 to 10, with 10 being the most severe. Alternatively, the patient and provider can define “mild” as normal daily activities, sport, leisure, work, school, sleep, and no troublesome symptoms. “Moderate/severe” would indicate that ≥1 of these items are abnormal or impaired. ***Medications are listed in the order suggested by JTFPP expert opinion based on major considerations noted. @See Table VIII for more details. ¹Order considers onset of action as well as relative efficacy. INCS monotherapy may be preferred when avoidance of adverse taste from INAH is desired. INCS may also be preferred over INAH monotherapy when dosed over several days as INCS may become more effective with longer use. ²PSE if tolerated without significant adverse effects, such as insomnia, irritability, or aggravation of hypertension and cardiac arrhythmias. ³IND, caution advised when used >5 days due to risk for rhinitis medicamentosa (rebound congestion), although some evidence that concomitant INCS use can minimize risk of rebound. Consider INCS + IND if IND is to be used >5 days. ⁴IN cromolyn is recommended for 4-times-a-day dosing for persistent symptoms, has a slow onset of action of 1 to 2 weeks, has limited efficacy, but is very safe and may be preferred by some patients. However, it may be used just prior to episodic allergen exposure to blunt acute allergic response, with protective effect within 15 minutes. ⁵No studies compare INCS/INAH administered in a single device as 1 spray in each nostril twice daily versus individual medications administered consecutively, each dosed as 1 spray in each nostril twice daily. Preference for using a single device is based primarily on convenience. Using the 2 individual medications would be preferred primarily due to affordability. There are no studies for onset using 2 devices; therefore, data from INAH are listed. However, onset may be similar to that of IN(AH & CS). ⁶OAH 2G + INCS have not been shown to have any additive benefit over using just INCS. ⁷Because serious neuropsychiatric events that may include suicidal thoughts or actions have been reported in patients taking montelukast, montelukast should generally be reserved for patients who have an inadequate response or intolerance to alternative therapies. ⁸For OAH 2G + LTRA, there is lack of adequate evidence of added efficacy to make a specific recommendation for or against this combination versus monotherapy. However, with the serious neuropsychiatric events reported with montelukast, this combination should rarely be used. IN, intranasal; INAC, intranasal anticholinergic; IN(AH & CS), intranasal antihistamine and corticosteroid administered by a single device; INAH + INCS, these 2 preparations administered by separate devices; IND, intranasal decongestant; OAH 2G, oral antihistamine, second generation; OCS, oral corticosteroid; PRN, as needed; PSE, pseudoephedrine; Tx, treatment.




FIG 3. Algorithm for persistent AR. *While most of the medications listed in the algorithm are approved for use in children <12 years old, comparative trials have, for the most part, been limited to those ≥12 years of age. The principles of treatment of children are the same as for adults, but special care must be given to dosage adjustment, adverse effects, and long-term safety. **Severity of rhinitis, based on symptoms and degree of overall control can be assessed by the patient using a VAS of 1 to 10, with 10 being the most severe. Alternatively, the patient and provider can define “mild” as normal daily activities, sport, leisure, work, school, sleep, and no troublesome symptoms. “Moderate/severe” would indicate that ≥1 of these items are abnormal or impaired. ***Medications are listed in the order suggested by JTFPP expert opinion based on major considerations noted. @See Table VIII for more details about onset of action. ¹PSE if tolerated without significant adverse effects, such as insomnia, irritability, or aggravation of hypertension and cardiac arrhythmias. ²Unlikely to adequately control symptoms. ³IN cromolyn is recommended for 4-times-a-day dosing for persistent symptoms, has a slow onset of action of 1 to 2 weeks, has limited efficacy, but is very safe and may be preferred by some patients. However, it may be used just prior to episodic allergen exposure to blunt acute allergic response, with protective effect within 15 minutes. ⁴Because serious neuropsychiatric events that may include suicidal thoughts or actions have been reported in patients taking montelukast, montelukast should generally be reserved for patients who have an inadequate response or intolerance to alternative therapies. ⁵For IND, caution is advised when used >5 days due to risk for rhinitis medicamentosa (rebound congestion), although some evidence that concomitant INCS use can minimize risk of rebound. Consider INCS + IND if IND is to be used >5 days. ⁶No studies compare INCS/INAH administered in a single device as 1 spray in each nostril twice daily versus individual medications administered consecutively, each dosed as 1 spray in each nostril twice daily. Preference for using a single device is based primarily on convenience. Using the 2 individual medications would be preferred primarily due to affordability. There are no studies for onset using 2 devices; therefore, data from INAH are listed. However, onset may be similar to IN(AH & CS). ⁷Order considers onset of action as well as relative efficacy. INCS monotherapy may be preferred when avoidance of adverse taste from INAH is desired. ⁸OAH 2G + INCS have not been shown to have any additive benefit over using just the INCS. ⁹For OAH 2G + LTRA, there is lack of adequate evidence of added efficacy to make a specific recommendation for or against this combination versus monotherapy. However, with the serious neuropsychiatric events reported with montelukast, this combination should rarely be used. IM, intramuscular; OCS, oral corticosteroid; SQ, subcutaneous.




FIG 4. Algorithm for intermittent NAR. *Recommendations for perennial NAR, VMR, and/or idiopathic rhinitis do not necessarily apply to NARES, gustatory, senile, or atrophic rhinitis. Onset of action studies have not been conducted for NAR for most medications. While most of the medications listed in the algorithm are approved for use in children <12 years old, comparative trials have, for the most part, been limited to those ≥12 years of age. The principles of treatment of children are the same as for adults, but special care must be given to dosage adjustment, adverse effects, and long-term safety. **Severity of rhinitis, based on symptoms and degree of overall control can be assessed by the patient using a VAS of 1 to 10, with 10 being the most severe. Alternatively, the patient and provider can define “mild” as normal daily activities, sport, leisure, work, school, sleep, and no troublesome symptoms. “Moderate/severe” would indicate that one or more of these items are abnormal or impaired. ***Medications are listed in the order suggested by JTFPP expert opinion based on major considerations noted. ¹Order considers relative efficacy, but INCS monotherapy may be preferred when monotherapy and/or avoidance of adverse taste from INAH are desired. INCS may be preferred over INAH monotherapy when dosed over several days as INCS may become more effective with longer use. ²PSE if tolerated without significant adverse effects, such as insomnia, irritability, aggravation of hypertension, and cardiac arrhythmias. ³No evidence of benefit for the treatment of NAR. ⁴For IND, caution is advised when used >5 days due to risk for rhinitis medicamentosa (rebound congestion), although some evidence that concomitant INCS use can minimize risk of rebound. Consider INCS + IND if IND is to be used >5 days. ⁵No studies compare INCS/INAH administered in a single device as 1 spray in each nostril twice daily versus individual medications administered consecutively, each dosed as 1 spray in each nostril twice daily. Preference for using a single device is based primarily on convenience. Using the 2 individual medications would be preferred primarily due to affordability.

false positive results, and be unlikely to identify the presence of clinically significant sensitivity.^{251,252} In some cases of rhinitis, especially where LAR is suspected, a nasal allergen challenge can be helpful.^{14,253}

Severity assessment including QOL by survey instruments and questionnaires

Recommendation 5. CBS: We suggest that the use of a validated instrument (eg scoring system, scale, or questionnaire) be

considered to help determine the severity of rhinitis and to monitor the degree of disease control.

Strength of recommendation: Conditional

Certainty of evidence: Low

Assessment of AR severity as defined narratively under “classification of AR” can guide treatment. Some investigators have tried to translate the patient’s assessment of severity using a visual analog scale (VAS) scale (ie, 0 to 10 where 0 is no symptoms and 10 is worst possible symptoms). The VAS is sensitive to detect changes in QOL for patients with AR,²⁵⁴ but

Persistent Non-Allergic Rhinitis Pharmacologic Treatment - Age 12 and older *




FIG 5. Algorithm for persistent NAR. *Recommendations for perennial NAR, VMR, and/or idiopathic rhinitis do not necessarily apply to NARES, gustatory, senile, or atrophic rhinitis. Onset of action studies have not been conducted for NAR for most medications. While most of the medications listed in the algorithm are approved for use in children <12 years old, comparative trials have, for the most part, been limited to those ≥12 years of age. The principles of treatment of children are the same as for adults, but special care must be given to dosage adjustment, adverse effects, and long-term safety. **Severity of rhinitis based on symptoms and degree of overall control can be assessed by the patient using a VAS of 1 to 10, with 10 being the most severe. Alternatively, the patient and provider can define “mild” as normal daily activities, sport, leisure, work, school, sleep, and no troublesome symptoms. “Moderate/severe” would indicate that ≥1 of these items are abnormal or impaired. ***Medications are listed in the order suggested by JTFPP expert opinion based on major considerations noted. ¹Order considers relative efficacy, but INCS monotherapy may be preferred when avoidance of adverse taste from INAH are desired. INCS may be preferred over INAH monotherapy when dosed over several days as INCS may become more effective with longer use. ²For IND, caution is advised when used >5 days due to risk for rhinitis medicamentosa (rebound congestion), although some evidence that concomitant INCS use can minimize risk of rebound. Consider INCS + IND if IND is to be used >5 days. ³PSE if tolerated without significant adverse effects, such as insomnia, irritability, aggravation of hypertension, and cardiac arrhythmias. ⁴No studies compare INCS/INAH administered in a single device as 1 spray in each nostril twice daily versus individual medications administered consecutively, each dosed as 1 spray in each nostril twice daily. Preference for using a single device is based primarily on convenience. Using the 2 individual medications would be preferred primarily due to affordability. ⁵There is no evidence of benefit for the treatment of NAR.

the cutoff value for mild versus moderate/severe varies per study between 4 and 6.^{255,256} Bousquet et al²⁵⁵ identified 3052 patients with AR (1895 confirmed with testing) and classified their rhinitis severity based on ARIA guidelines. Patients were asked to answer the question “Overall, how much are your allergic symptoms bothering you today?” by making an “X” on a single 10-cm line that has no markings. The verbal anchors are “Not at all bothersome” (starting at 0) and “Very bothersome” (ending at 10 cm).²⁵⁷ Receiver-operating curves found that this simple 1-question VAS score correlated well with ARIA severity; a VAS

score <5 cm was classified as having “mild” AR, while a score >6 cm was “moderate severity.”²⁵⁵ Subsequently a score of ≥5 has been used to represent moderate/severe.

A variety of QOL questionnaires, some specific to rhinitis and others being generic QOL instruments, have been used to assess AR severity.¹⁹⁰ Generic QOL scales offer comparison between different disorders and patient populations,²⁵⁸ for example, adults with moderate/severe perennial rhinitis and moderate/severe asthma have equal functional impairment.^{259,260} In contrast, disease-specific QOL questionnaires, including those specific

for rhinitis, describe disease-associated problems more accurately and seem to be reflective of changes associated with therapeutic interventions.^{258,261} VASs may also correlate well with rhinitis symptom scores and QOL measures, leading to improved symptom control.²⁵⁴ There is also a highly significant correlation between a VAS and the Rhinoconjunctivitis Quality of Life Questionnaire. A subsequent study further validated the VAS and determined that changes in the VAS of 23 mm were found to be clinically significant.²⁵⁴ A large European study found a smart phone app using the MASK (Mobile Airways Sentinel network)-Rhinitis VAS to be a reliable indicator of AR control and this control correlated well to work productivity.^{262,263}

Control of AR

In addition to assessing AR severity and the impact on QOL, assessing control is an important goal. As has been shown to be helpful with asthma, AR severity can be measured in patients before treatment while measures of disease control are more applicable to optimize therapy in treated patients.²⁶⁴ The Rhinitis Control Assessment Test, is a simple, reliable, self-administered 6-item questionnaire utilizing a 5-point Likert scale (Fig 1).²⁶⁵⁻²⁶⁸ Developed to assist physicians in the assessment of patient rhinitis control in clinical practice, it also helps patients appreciate what rhinitis control is. The Rhinitis Control Assessment Test was developed and validated against total nasal symptom scores and the physician's global assessment. Subsequent work identified a cutoff score of 21 as representing good control, with a minimal important difference of 3. Downloadable forms for administering the Rhinitis Control Assessment Test are readily available online (eg, at AllergyAsthmaNetwork.org).

The Allergic Rhinitis Control Test is a validated 5-item self-assessment using a 5-point frequency scale with similarities to the Asthma Control Test.^{103,269,270} The Control of Allergic Rhinitis and Asthma Test²⁵ is a validated 10-item questionnaire that was tested in patients consulting an allergist.²⁷¹⁻²⁷³ Limitations exist for control-based classifications as it is not clear whether AR control varies as a function of the disease-inducing allergen, and these questionnaires have not been validated in children.^{32,264}

PHARMACOTHERAPY

Review of monotherapy and then combination pharmacologic therapeutic options for rhinitis (with an emphasis on treatment of AR) is presented first. Thereafter a stepwise pharmacologic treatment of AR will be presented, using algorithms for intermittent (Fig 2) and persistent (Fig 3) AR. Similarly, pharmacologic treatment algorithms have been developed for the management of intermittent (Fig 4) and persistent (Fig 5) NAR.

Review of pharmacotherapy classes for rhinitis

Oral antihistamines. Recommendation 6. CBS: We recommend against prescribing a first-generation antihistamine and are in favor of a second-generation antihistamine when prescribing an oral antihistamine for the treatment of AR.

Strength of recommendation: Strong

Certainty of evidence: High

Oral antihistamines are of established benefit in AR. The overall efficacy of first-generation antihistamines (eg,

diphenhydramine, hydroxyzine, chlorpheniramine) compared with less sedating or nonsedating second-generation antihistamines (eg, cetirizine and levocetirizine, fexofenadine, loratadine and desloratadine) for the management of AR symptoms has not been adequately studied. However, selecting a second-generation antihistamine reduces the potential side effects including sedation, performance impairment, poor sleep quality, and anticholinergic-mediated symptoms (eg, dry eyes, dry mouth, constipation, urinary hesitancy, and retention) that have been associated with the first-generation antihistamines.¹

First-generation antihistamines may produce performance impairment in school²⁷⁴⁻²⁷⁶ and while driving²⁷⁷⁻²⁸¹ that can exist without subjective awareness of sedation,²⁸² and the use of first-generation antihistamines has been associated with increased automobile and occupational accidents.^{277-281,283} Individual variation exists with respect to development of sedative effects with first-generation antihistamines.^{276,284,285} One systematic review of first-generation antihistamines concluded that they induced nonamnesic deficits in attention and information processing.²⁸⁶ One early study compared chlorpheniramine with placebo and found that drowsiness and dry mouth were greater with chlorpheniramine for the first 2 weeks, but after this time point, doses of chlorpheniramine <24 mg/day, compared with placebo, resulted in no significant difference in subjective drowsiness, dizziness, irritability, or dry mouth over the remaining 6 weeks of the study.²⁸⁷ Other studies using chlorpheniramine as a comparator have reported similar increased symptoms of drowsiness, dry mouth, and dizziness for the first few days but tolerance to these subjective side effects of this medication occurred over time.²⁸⁸⁻²⁹⁰ Tolerance to adverse central nervous system effects in an individual may or may not occur with regular daily use.²⁹¹ Although bedtime dosing of first-generation oral antihistamines has been suggested as a strategy to avoid daytime sedation, there can be residual central nervous system effects the next day because some agents have a very long terminal elimination half-life (>24 hours for chlorpheniramine).²⁹² Bedtime administration of first-generation antihistamines undesirably increased the latency to onset of restful rapid eye movement sleep and reduces the duration of rapid eye movement sleep.^{291,293}

Beyond concerns about subjectively perceived side effects, among the anticholinergic side effects more recently reported in association with first-generation antihistamines is an associated higher risk of dementia. A 2015 US prospective population-based cohort study suggested a link between higher cumulative use of strong anticholinergics and the risk of developing dementia, with over 70% being diagnosed with Alzheimer's disease.²⁹⁴ For dementia, adjusted hazard ratios for 10 years of cumulative anticholinergic use (including first-generation antihistamines, tricyclic antidepressants, and bladder antimuscarinics) compared with nonuse were 0.92 (95% CI, 0.74-1.16) for total standardized daily doses for 1 to 90 days, with a proportional increased risk for longer daily use, with a cumulative 3 years of daily use being 1.54 (95% CI, 1.21-1.96).²⁹⁴ A longitudinal study showed that the use of anticholinergics in the elderly was associated with both reduced immediate recall and reduced executive functioning, which was associated in conjunction with increased brain atrophy manifest as reduced total cortical volume and temporal lobe cortical thickness and greater lateral ventricle and inferior lateral ventricle volumes.²⁹⁵ These findings further support use of second-generation antihistamines over first-generation antihistamines for AR.

Use of first-generation antihistamines in the treatment of NAR

Patients with NAR and AR experience similar symptoms including nasal congestion, postnasal drainage and rhinorrhea although through different mechanistic pathways.²⁹⁶ Responses to various treatments in NAR and AR may vary.²⁹⁷ A major symptom of patients with NAR that is frequently not well controlled despite combination topical nose sprays with anticholinergic activity is postnasal drainage.²⁹⁶ There are no DBPC trials evaluating the therapeutic efficacy and safety of first-generation oral antihistamines such as chlorpheniramine maleate for the treatment of NAR/VMR. In a risk/benefit assessment, mindful of (1) the considerable concerns about safety of first-generation antihistamines as reviewed under discussion for Recommendation 6, and (2) recognition that it is not possible in a standard office setting to accurately assess development of some clinical adverse effects from these agents (eg, development of subtle changes in cognition or other potential central nervous system side effects such as decreased reaction time), some clinicians suggest that monitored use of first-generation oral antihistamines as an adjunctive anticholinergic agent may be considered in patients with NAR who have bothersome postnasal drainage refractory to other therapies. The decision to use first-generation antihistamines for NAR remains controversial, should be individualized, and should involve a physician and patient–shared decision-making discussion, reviewing the potential risks and benefits, and patient preferences. If first-generation oral antihistamines are used to treat postnasal drip in VMR/NAR, patients should be carefully monitored for any clinically observable side effects, the lowest effective dose should be used, and these agents should be discontinued when side effects are identified. Special consideration/caution should be taken into account using these agents in frail elderly patients,²⁹⁸ individuals with existing known chronic disorders (dementia, Alzheimer's, benign prostatic hyperplasia) that would be complicated by their use or those working in occupations involving heavy machinery, driving, or flying.

Oral leukotriene receptor antagonists

Recommendation 7. CBS: We suggest that the clinician not select the oral leukotriene receptor antagonist (LTRA) montelukast for the initial treatment of AR due to reduced efficacy when compared with that of other agents. Furthermore, serious neuropsychiatric events that may include suicidal thoughts or actions have been reported in some patients taking montelukast. As advised by the FDA, montelukast should be used to treat AR only in patients who are not treated effectively with or cannot tolerate other alternative therapies.

Strength of recommendation: Conditional

Certainty of evidence: Very low

Recommendation 8. CBS: We recommend that the clinician not select an oral LTRA for the treatment of NAR.

Strength of recommendation: Conditional

Certainty of evidence: Ungraded as there are no studies.

Note: Unanimous vote in favor by work group and JTFPP.

LTRAs are modestly effective in the treatment of SAR and PAR.^{299–302} Multiple systematic reviews have concluded that LTRAs have effectiveness similar to oral antihistamines with loratadine as the usual comparator,^{301,303–306} but others find that LTRAs are less effective than antihistamines.³⁰⁶ LTRAs are less effective than INCS.^{301,304–306} Considering that the LTRA

montelukast is equally or less effective than oral antihistamines for AR and is less effective than INCS (which would be preferred therapy for more severe AR because of greater effectiveness), clinicians should not routinely offer an LTRA as preferred therapy for patients with AR. Furthermore, as discussed below, serious neuropsychiatric events that may include suicidal thoughts or actions have been reported in some patients taking montelukast. As advised by the FDA, montelukast should be used to treat AR only in patients who are not treated effectively with or cannot tolerate other alternative therapies.³⁰⁷ In such patients, when considering montelukast, a shared-decision making conversation should be utilized.

The use of an oral LTRA in combination with an oral antihistamine may be more effective than monotherapy with an LTRA (montelukast) for AR, although not all study results are consistent with this finding.^{304,308,309} The combination of an oral LTRA and an oral antihistamine is similarly effective as monotherapy with an INCS for AR though it is likely more costly and burdensome to maintain.^{310,311}

There is no evidence to support the use of LTRAs in NAR. There is no mechanistic rationale or expert opinion that supports the use of an LTRA in NAR.

Montelukast has been approved down to 6 months of age. It is not associated with somnolence and side effects are uncommon.^{312,313} However, there are postmarketing reports of rare drug-induced neuropsychiatric events including sleep disturbances, depression, anxiety, aggression, psychotic reactions, and suicidal thinking and behavior. Infants are more prone to drug-associated sleep disturbances; children present most often with symptoms of depression and anxiety; and adolescents are more prone to symptoms of depression, anxiety, and suicidal behavior.^{314–317} Unexpectedly, a worldwide review of Individual Case Safety Reports associated with montelukast determined that completed suicides were reported more frequently for children than for adolescents or the total population.³¹⁶ Most studies are low-quality evidence, (eg, case reports or observational studies), mainly in children and adolescents; high-quality epidemiological studies are needed to evaluate the association and quantify the risk of neuropsychiatric adverse events, not only in children and adolescents, but also in adults.³¹⁷ It is advised that clinicians monitor patients who may be at elevated risk for suicidal ideation or psychiatric symptoms.

In patients with AR comorbid with asthma, compared with placebo, montelukast could result in significant improvements in both conditions and therefore can be considered an option for patients with both conditions.^{310,318} However, due to the only modest efficacy and also the potential increased risks of montelukast compared with those of oral antihistamines, for the management of AR and comorbid asthma, the clinician should weigh the benefits of montelukast monotherapy versus an inhaled corticosteroid for asthma and an antihistamine or INCS for AR.

Systemic corticosteroids

Recommendation 9. CBS: We suggest that for the treatment of very severe or intractable AR, the clinician may consider a short course (5–7 days) of oral corticosteroids.

Strength of recommendation: Conditional

Certainty of evidence: Very low

Recommendation 10. CBS: We suggest that for the treatment of very severe or intractable AR, the clinician not prescribe a

depot parenteral corticosteroid for AR due to the potential risks of systemic and local corticosteroid side effects.

Strength of recommendation: Conditional

Certainty of evidence: Low

While most clinicians will use a short course (5-7 days) of oral corticosteroids for severe or intractable AR, depot parenteral corticosteroids may be viewed as attractive because the duration of action of a single injection is 3 weeks or longer and is often adequate to treat an entire allergy season. However, there is concern that depot corticosteroids may lead to a higher risk for adrenal suppression than short courses of short-acting corticosteroids (eg, prednisone) dosed once daily. While head-to-head comparisons of short courses of oral corticosteroids versus single injections of depot corticosteroids have not been completed, studies have shown adrenal suppression following a single intramuscular injection of methylprednisolone acetate for AR.^{319,320} The suppression is usually maximal at 72 hours but persists for up to 3 weeks.^{319,320} Two systematic reviews looking at adrenal suppression from various administration forms, dosages, duration, and disease states found that while higher doses for longer duration increased the risk of adrenal suppression, there is no method of delivery, dosage, or duration for which the risk of adrenal suppression can be safely excluded.^{321,322}

A large retrospective study of Danish National Registries found that in patients with AR, a minimum of 1 depot corticosteroid injection for at least 3 consecutive years was associated with an increased risk of osteoporosis and diabetes, with the largest risk increase seen within the first 2 years of annual use.³²³ Although rare, local muscle atrophy and fat necrosis has also been described.^{324,325} With such variability in the development of adrenal suppression, diabetes, osteoporosis, local side effects, and other steroid-induced adverse effects from one patient to another, the clinician is advised to always use the lowest dose of corticosteroids for the shortest period of time.

INTRANASAL AGENTS

Intranasal antihistamines

Recommendation 11. CBS: We recommend that the clinician offer intranasal antihistamines (INAH) as an initial treatment option for patients with SAR.

Strength of recommendation: Strong

Certainty of evidence: High

Recommendation 12. CBS: We recommend that the clinician offer INAH as a first-line monotherapy option for patients with NAR.

Strength of recommendation: Strong

Certainty of evidence: High

Recommendation 13. CBS: We recommend that the clinician offer INAH as a first-line option for patients with intermittent AR.

Strength of recommendation: Conditional

Certainty of evidence: Ungraded due to lack of studies addressing this specific issue.

Note: There was a unanimous vote in favor by work group and JTFPP.

For relief of nasal symptoms of SAR, INAH are equal to or superior to oral antihistamines³²⁶⁻³²⁸ and may benefit patients for whom oral antihistamine treatment fails.^{328,329} INAH have a more rapid onset of action than INCS and oral antihistamines do,³²⁶⁻³³² are more effective than oral antihistamines in the control of nasal congestion,^{320,327,331} and provide a favorable safety profile.

Comparisons of INCS to INAH for reduction of nasal symptoms are conflicting, with some showing equality³³³⁻³³⁵ and some showing superiority of INCS.³³⁶ In a systematic review of INCS and INAH, INAH provide comparable relief of allergic eye symptoms.³³⁷ Two INAH, azelastine and olopatadine, are approved by the FDA for the treatment of SAR. Azelastine is also approved for the treatment of PAR and VMR.

Azelastine has high binding affinity to H1 receptors and can also inhibit H2 antihistamine receptors, as well as the synthesis or expression of mediators of allergic inflammation and neuropeptides.³³⁸⁻³⁴⁰ Azelastine may also work in part by desensitizing TRPV1 ion channels, which are triggered by hot stimuli, such as capsaicin, and are important in the pathophysiology of NAR.⁹⁰ In contrast to azelastine, intranasal olopatadine is a selective H1 receptor antagonist that has also been shown to have some mast cell-inhibitory properties, described with the olopatadine eye drop preparation.³⁴¹

INAH have a rapid onset of action in AR ranging from 15 to 30 minutes, compared with an average of 150 minutes for oral antihistamines.^{326-332,338} They have been shown to improve nasal as well as nonnasal AR symptoms and QOL.^{330,331,342} Azelastine has also been shown to be clinically effective in controlling symptoms of NAR.³⁴³ Although olopatadine has been demonstrated to significantly reduce nasal symptoms induced by a hyperosmolar mannitol challenge in patients with vasomotor NAR, there are no placebo-controlled trials to support its efficacy in relief of NAR symptoms.³⁴⁴

Nineteen percent of patients treated with azelastine in the initial clinical trials reported bitter taste lasting around 30 minutes.³⁴³ Subsequent studies found that using azelastine as 1 puff each nostril twice daily reduced total nasal symptoms scores and was associated with less somnolence and bitter taste (0.4% and 8.3%, respectively) compared with what was reported in the pivotal trials (11.5% and 19.7%, respectively).³⁴⁵ Reformulating azelastine nasal spray with sucralose to mask the bitter taste demonstrated similar safety and tolerance profile to the original formulation and a reduction in bitter taste (from 8% to 7%).^{65,346} In contrast to the pivotal SAR studies, somnolence was not an issue for patients with NAR using azelastine with sucralose compared with those using placebo (3.2% vs 1.0%).^{338,340,343} While the initial clinical trials using a larger dose reported somnolence in around 11%,³⁴⁷ more recent studies have found rates of 0.4% to 3%, which were equal or only slightly greater than in placebo groups.^{346,348-351} Intranasal olopatadine was well tolerated with the most common adverse events reported being bitter taste, headache, epistaxis, and pharyngolaryngeal pain with a relatively low incidence of somnolence (<1%).³⁵²⁻³⁵⁵

Intranasal olopatadine and azelastine have been compared in a placebo-controlled multicenter trial in patients with SAR and were shown to be equally effective in controlling symptoms.³⁵⁶ Moreover, their side effect profiles were comparable except for bitter taste, which was more pronounced for azelastine.³⁵⁶ A randomized, double-blind, parallel-group, multicenter noninferiority study showed no significant difference between intranasal olopatadine and intranasal azelastine in controlling nasal symptoms in patients with nonallergic VMR.³⁵⁷ No significant differences were observed for adverse events, including taste, or treatment satisfaction between treatment groups.³⁵⁷ While taste aversion has been demonstrated to all INAH, taste varies between formulations. Therefore, a trial of a second formulation may

identify a preferred alternative formulation in patients who have had symptomatic benefit from an INAH.

Intranasal corticosteroids

Recommendation 14. CBS: We recommend that when choosing monotherapy for persistent AR, INCS be the preferred medication.

Strength of recommendation: Strong

Certainty of evidence: High

Recommendation 15. GRADE:¹⁷⁴ We recommend that for the initial treatment of moderate/severe SAR in patients 15 years of age and older, the clinician use an INCS over an LTRA. (Also see Recommendation 7.)

Strength of the recommendation: Strong

Certainty of evidence: High

INCS remain the most effective monotherapy for AR and are therefore recommended as preferred monotherapy for moderate/severe AR that have negative impact on QOL.^{1,310,311,358-360} More recent guidelines continue to support this recommendation.^{175,361} Not only are these agents effective in controlling nasal symptoms in patients with AR, but they have also been shown to be effective in the control of allergic ocular symptoms.^{1,362,363}

The sensory attributes of INCS (aftertaste, nose runout, throat rundown, and smell) play an important role in patient preference and adherence to therapy.³⁶⁴ To address some of these concerns, nonaqueous intranasal preparations with hydrofluoroalkane aerosol are now available for the treatment of AR in the United States.³⁶⁵⁻³⁶⁷

When given in recommended doses, INCS are not generally associated with clinically significant systemic side effects.¹ They have not been shown to affect the hypothalamic–pituitary–adrenal axis.¹ A meta-analysis of relevant trials relating to growth in children suggests that short-term use of INCS may decrease short-term growth velocity (using knemometry), but there was no such effect on longer-term growth velocity (using stadiometry).³⁶⁸ The heterogeneity of the studies was high in the stadiometry trials. Therefore, when using INCS in children, it is prudent to use the lowest effective dose and monitor growth carefully.

There have been reports of a possible association between the development of posterior subcapsular cataracts and the use of intranasal or inhaled corticosteroids in older patients. Case reports of increased ocular pressure from INCS have been published;³⁶⁹ however, adequately powered, blinded studies have not confirmed this adverse effect.^{1,370} A meta-analysis of 10 clinical trials with 2226 patients did not show a significant risk of elevating intraocular pressure or developing a posterior subcapsular cataract in patients with AR using INCS.³⁷¹

The most common side effects of INCS are local and include dryness, burning, stinging, blood tinged secretions, and epistaxis. The incidence of epistaxis ranges from 4% to 8% over short treatment periods (2 to 12 weeks) and can reach 20% in studies carried over a year.^{1,175} Nasal bleeding with long-term use of topical nasal corticosteroids may approach 28%.³⁷⁰ The epistaxis reported from INCS can be worsened by the use of anticoagulant agents.³⁷²⁻³⁷⁵

Septal perforations, although rare, have been reported.^{1,175} Biopsy specimens from the nasal mucosa of patients with perennial rhinitis who have been treated with INCS continuously for 1 to 5 years showed no evidence of atrophy.^{1,175}

Intranasal capsaicin

Capsaicin, a pungent compound found in hot red peppers, topically applied to the nasal mucosa has been shown to reduce nasal hyperreactivity. While capsaicin has not been approved by the FDA for the treatment of rhinitis, it has been used for the treatment of NAR or mixed rhinitis to reduce nasal congestion, rhinorrhea, postnasal drainage, sinus pressure, sinus pain, and headache. Capsaicin is a selective TRPV1 ion channel agonist that reduces nerve conduction of nociceptive C fibers, thereby reducing parasympathetic hyperactivity and neuropeptide release, resulting in attenuation of nasal congestion, rhinorrhea, and postnasal drainage symptoms.^{90,91,296,376-381} Clinical trials investigating the therapeutic benefit of capsaicin on patients with AR did not find a significant effect in reducing nasal hyperreactivity or in improving rhinorrhea.³⁸² Cochrane analysis for AR found only 1 small trial where intranasal capsaicin had a therapeutic benefit.³⁸³ For the treatment of idiopathic NAR, a recent Cochrane analysis found that capsaicin appears to improve nasal symptoms, which can last 36 weeks after treatment, but this assessment is based on only a few small studies of low scientific evidence quality.³⁸⁴ When used to treat NAR and VMR compared with placebo therapies, some studies have described significant therapeutic efficacy and safety of chronic usage of local capsaicin formulations.³⁸⁵⁻³⁹⁰ Because all of these trials used different study designs and dosing regimens, the ability to compare primary endpoints is significantly limited.^{385,387,388,391,392} Recent data comparing idiopathic and mixed rhinitis treated with capsaicin demonstrated a slightly increased symptom reduction in the idiopathic treatment group than in the mixed rhinitis group (79% and 68%, respectively).³⁹³ Future well-conducted, large, randomized controlled trials are required to further assess the effectiveness of capsaicin using different concentrations and in patients with NAR who have mild, moderate, and severe symptoms.

Intranasal decongestants

Recommendation 16. CBS: We suggest that the use of intranasal decongestants be short term and used for intermittent or episodic therapy of nasal congestion.

Strength of the recommendation: Conditional

Certainty of evidence: Low

Recommendation 17. CBS: We suggest that in patients having severe mucosal edema, which impairs the delivery of other intranasal agents, an intranasal decongestant be considered for up to 5 days of use.

Strength of recommendation: Conditional

Certainty of evidence: Ungraded due to lack of studies addressing this specific issue.

Note: There was a unanimous vote in favor by work group and JTFPP.

Intranasal decongestants, such as oxymetazoline and xylometazoline, are alpha-adrenergic agonists. They cause improvement in nasal conductance for up to 10 hours resulting in nasal vasoconstriction and decreased nasal edema but they do not block allergen-provoked mediator release.^{394,395} Oxymetazoline and xylometazoline cause similar decongestive effects with statistically significant beneficial changes in nasal resistance, nasal airflow, and nasal cross-sectional areas that provide clinically meaningful improvement in nasal congestion.³⁹⁶ On average, the effect of oxymetazoline begins within 30 seconds.³⁹⁷ Xylometazoline was found to have superior efficacy for nasal

decongestion compared with INCS in a 28-day AR study.³⁹⁸ However, intranasal decongestants are not routinely recommended for continuous use because of the potential development of alpha-receptor tachyphylaxis and subsequent rhinitis medicamentosa.³⁹⁹ The development of rhinitis medicamentosa is highly variable; it may develop within 3 days of use or fail to develop after 6 weeks of daily use.^{399–404} Intranasal decongestants have no effect on itching, sneezing, or nasal secretion and can be associated with local stinging or burning, sneezing, and dryness of the nose and throat.

Concomitant administration of intranasal decongestants and corticosteroids

Recent placebo-controlled studies of PAR and SAR demonstrated that concurrent administration of INCS and intranasal decongestants provided additional efficacy both subjectively in rapidity of onset compared with the corticosteroid alone and in magnitude of nasal congestion symptom score improvement compared with oxymetazoline alone and objectively as measured by acoustic rhinometry increases in volume. Furthermore, when the decongestant was given along with the intranasal steroid once a day for up to 4 weeks, the development of rhinitis medicamentosa did not occur.^{405,406} (Also see Recommendation 24 for related recommendation about combined use of intranasal decongestants and corticosteroids.)

Safety concerns about use of intranasal decongestants in pregnancy are discussed in the later section on rhinitis in pregnancy.

Oral decongestants

Recommendation 18. CBS: We suggest that oral decongestant agents be used with caution in older adults and children younger than 4 years old, and in patients of any age who have a history of cardiac arrhythmia, angina pectoris, cerebrovascular disease, uncontrolled hypertension, bladder outlet obstruction, glaucoma, hyperthyroidism, or Tourette syndrome.

Strength of recommendation: Conditional

Certainty of evidence: Low

Recommendation 19. CBS: We recommend that oral decongestants be avoided during the first trimester of pregnancy.

Strength of recommendation: Strong

Certainty of evidence: Low

The oral decongestant pseudoephedrine, an alpha-adrenergic agonist, is effective at relieving nasal congestion. It is indicated for nasal congestion due to AR, rhinosinusitis, and the common cold.⁴⁰⁷ For the management of concomitant SAR and mild/moderate asthma, the combination of an oral decongestant and a second-generation oral antihistamine, compared with placebo, significantly reduced both rhinitis and asthma symptoms.⁴⁰⁸

Pseudoephedrine is a key ingredient used in making methamphetamine. In an effort to reduce illicit production of methamphetamine, restrictions have been placed on the sale of pseudoephedrine in the United States.⁴⁰⁹ This has promoted substitution of oral phenylephrine for pseudoephedrine in many allergy and cold and cough remedies. However, oral phenylephrine has been demonstrated to be ineffective at reducing nasal congestion at doses up to 40 mg.^{410–412}

Pseudoephedrine can result in adverse effects such as insomnia, loss of appetite, irritability, and palpitations.⁴¹³ Elevation of blood pressure after taking an oral decongestant is very rarely noted in normotensive patients and only occasionally in patients with controlled hypertension. A meta-analysis of 24 trials

showed a statistically significant elevation of systolic blood pressure in both patients who are normotensive and those with controlled hypertension, but these small values, 0.99 mm Hg and 1.2 mm Hg, respectively, are unlikely to be clinically significant in most patients.⁴¹⁴ However, because of the variation in patient response, patients receiving oral decongestants should be followed for changes in blood pressure. Because of the potential for drug interactions, oral decongestants should be avoided in patients taking monoamine oxidase inhibitors,⁴¹⁵ used for psychiatric disorders and Parkinson's disease. Oral decongestants should be used with caution in patients with rhinitis with certain conditions, such as cerebrovascular or cardiovascular disease, hyperthyroidism, closed-angle glaucoma, bladder outlet obstruction, and Tourette syndrome. The problem of rebound congestion is not a factor with the use of orally administered nasal decongestants.⁴⁰⁷

Oral decongestants, when used in appropriate doses, are usually well tolerated in children over the age of 6 years of age. However, use in infants and young children has been associated with agitated psychosis, ataxia, hallucinations, and even death.^{416–418} At times, even at recommended doses, these agents may cause increased stimulatory effects resulting in tachyarrhythmias, insomnia, and hyperactivity, especially when combined with other stimulants.⁴¹⁹ Therefore, the risks and benefits should be carefully considered before using oral decongestants in both adults and children.

Safety concerns about use of oral decongestants in pregnancy are discussed in the later section on rhinitis in pregnancy.

Intranasal ipratropium

Recommendation 20. CBS: We suggest that in patients with PAR and NAR who have rhinorrhea as their main nasal symptom be offered intranasal ipratropium.

Certainty of evidence: Low for PAR, moderate for NAR.

Ipratropium bromide at either 0.03% or 0.06% concentrations is safe, well-tolerated, and is effective for the treatment of rhinorrhea related to PAR (0.03%) and NAR (0.03%), as well as for the common cold (0.06%).^{420–422} While ipratropium bromide 0.06% is FDA-approved for the treatment of SAR in both children and adults, no randomized controlled trials have been completed to study its effectiveness.⁴²³ Rhinorrhea is significantly reduced in chronic perennial rhinitis, VMR, gustatory rhinorrhea, and cold-induced rhinorrhea (eg, skiers nose), but with no significant effect on congestion or sneezing.^{420,424–428} When ipratropium bromide was administered prior to nasal methacholine challenge in patients with AR and NAR there was reduced rhinorrhea and sneezing but there was no significant effect on airway resistance.^{422,429} Rhinorrhea was significantly reduced not only in cold air exposure but also following ingestion of hot soup, leading the investigators to suggest that the nasal discharge is reflex-mediated.⁴³⁰ In PAR, ipratropium bromide was effective in reducing rhinorrhea for 1 year when used on a continuous basis.⁴²⁷ The efficacy of ipratropium appears to especially benefit anterior rhinorrhea. It has not been shown to be of significant value when postnasal drainage is the dominant complaint. The most common adverse effects reported are nasal dryness and epistaxis, although these are usually mild and rarely lead to discontinuation of treatment.^{427,428} As discussed under the section on combination therapy, when ipratropium bromide is

combined with an INCS or an oral second-generation antihistamine, an additive benefit has been demonstrated.

Intranasal cromolyn

Recommendation 21. CBS: We suggest that intranasal cromolyn be offered as an option to be taken just prior to allergen exposure to reduce symptoms of AR from episodic allergen exposures.

Strength of recommendation: Conditional

Certainty of evidence: Very low

The primary benefit of cromolyn sodium is to stabilize mast cells and thus inhibit the release of mast cell mediators that promote IgE-mediated AR.^{431,432} Intranasal administration of cromolyn sodium, compared with placebo, improves symptoms of SAR.⁴³³⁻⁴³⁵ In PAR, with marked skin test responses,⁴³⁶ benefit has been found in some but not all studies of patients with PAR.⁴³⁷ Intranasal cromolyn may reduce nasal eosinophils in patients with AR.⁴³⁸ Ten milligrams of intranasal cromolyn inhibited allergen-induced nasal airway resistance in 80% and 50% of subjects at 4 and 8 hours, respectively, after the administration of cromolyn, suggesting efficacy for around 6 hours.⁴³⁹ A large 2-week multicenter, randomized, DBPC, parallel-group design study of the over-the-counter use of intranasal cromolyn sodium demonstrated efficacy (reduction in overall symptoms, sneezing, and nasal congestion) and concluded intranasal cromolyn was safe and effective for over-the-counter use.^{431,435}

Nasal cromolyn administered just before allergen exposure can reduce development of symptoms of AR.⁴⁴⁰⁻⁴⁴² Therefore, nasal cromolyn can be useful in short-term prevention of development of episodic AR symptoms if administered just prior to anticipated exposure to an allergen not normally present in a patient's home or work environment. However, there have been no direct comparative trials between intranasal cromolyn and other treatments for such use.

Cromolyn is reported to have an excellent safety record and has been studied and also reported to be safe in pregnancy.^{431,435,443} However, there are a very limited number of cases suggesting the possibility of immediate, possibly IgE-mediated, reactions to disodium cromoglycate.^{444,445}

The treatment effect of intranasal cromolyn in SAR is not robust and some have advocated temporary use of a nasal decongestant while initiating intranasal cromolyn in subjects with near total nasal obstruction.¹ Intranasal cromolyn was studied and found to have no benefit in NARES.¹⁷¹ A placebo-controlled trial of intranasal cromolyn showed no benefit in VMR, although some anecdotal cases suggest benefit in isolated individuals with VMR.⁴⁴⁶ Intranasal cromolyn was found to have no benefit on nasal polyps.⁴⁴⁷

Intranasal cromolyn has similar efficacy to oral antihistamines in the treatment of AR. However, intranasal cromolyn reduced nasal eosinophils in comparison to oral antihistamines.⁴³⁸ Intranasal cromolyn may be less efficacious than levocabastine nasal spray in SAR.⁴⁴⁸ Intranasal cromolyn is less efficacious than intranasal steroid sprays in SAR.⁴⁴⁹

Nasal saline

Nasal saline is commonly used as a treatment for rhinitis and rhinosinusitis in both children and adults. Nasal saline can be beneficial for moisturizing dry nasal passages and clearing out mucus. The preferred method of delivery—nose spray, bottle,

pump, irrigation, or nebulizer; the volume; whether isotonic or hypertonic; and the dose frequency have not been established. The use of topical saline is associated with minimal side effects, such as burning, irritation, and nausea; has low cost; and has overall good patient acceptance.^{450,451}

There is a risk of transmission of bacteria and parasites including development of fatal primary amebic meningoencephalitis from using tap water contaminated with *Naegleria fowleri*. The Centers for Disease Control and Prevention and FDA recommend that if tap water is used to prepare saline for nasal irrigation, water should be boiled for 1 to 5 minutes before cooling and use.^{452,453}

A systematic review of studies on nasal sinus irrigation concluded that when performed regularly over a limited period of up to 7 weeks, there was a positive effect on all investigated outcome parameters in adults and children with AR.⁴⁵⁴ A 2018 Cochrane review on saline irrigation for AR concluded that it may reduce patient-reported disease severity compared with no saline irrigation at up to 3 months in both adults and children with AR.⁴⁵⁵ However, saline nasal irrigation alone is less effective than INCS alone for AR in children.^{456,457}

Combination therapy

Combination therapy is often used in clinical practice either as directed by the physician or by patient self-treatment. Only a few rhinitis therapeutic combinations have been subjected to rigorous study. The scientific evidence will be presented, when available, but the AR and NAR treatment algorithms are based on both scientific evidence and expert opinion. The algorithms were developed to assist the clinician in selecting the preferred monotherapy and determining when to consider specific agents for combination therapy.

INCS and INAH combined

Recommendation 22. GRADE:¹⁷⁴ We suggest that the clinician consider the combination of an INCS and an INAH for the initial treatment of moderate/severe nasal symptoms of SAR in patients age ≥ 12 years.

Strength of the recommendation: Conditional

Certainty of evidence: High

Recommendation 23. CBS: We suggest that the clinician consider the combination of an INCS and an INAH for moderate/severe SAR and PAR that is resistant to pharmacologic monotherapy.

Strength of recommendation: Conditional

Certainty of evidence: Moderate

Recommendation 24. CBS: We suggest that the clinician consider the combination of an INCS and an INAH for moderate/severe NAR that is resistant to pharmacologic monotherapy.

Strength of recommendation: Conditional

Certainty of evidence: Low

DBPC trials in AR have demonstrated that the combination of an INCS and INAH is more effective at reducing symptoms of AR and has a faster onset of action than the individual components do.¹⁷⁴ This has been demonstrated in 5 DBPC trials with a fixed combination of intranasal azelastine and fluticasone propionate in a single device (MP29-02, Dymista; Mylan, Canonsburg, Pa), in patients with moderate/severe SAR, ages ≥ 12 years⁴⁵⁸⁻⁴⁶⁰ and 1 DBPC trial showed its superiority over

placebo in children 6 to 11 years old.⁴⁶¹ Its superior efficacy in reducing the PM 12 hour-reflective (daytime) total nasal symptom score over intranasal fluticasone was also demonstrated over the whole range of a 12-month randomized, open-label trial in patients with chronic rhinitis (PAR and NAR), although no NAR-subgroup analysis was presented.⁴⁶² A 6-week randomized trial of 162 patients with NAR demonstrated significantly greater ($P < .01$) reduction in nasal obstruction score with the combination of an INCS and an INAH compared with monotherapy with an INCS.⁴⁶³

However, as reviewed in the 2017 rhinitis GRADE document,¹⁷⁴ all these studies were designed to compare the use of combination therapy versus monotherapy as initial treatment of SAR and not as add-on therapy. The JTFPP recognizes that in clinical practice, in most cases, the combination will be used when monotherapy has failed to relieve symptoms in patients with SAR, PAR, and NAR in all ages for which the product has been approved. However, for PAR and NAR, the recommendations are based predominantly on expert opinion.

MP29-02 contains a combination of 2 active substances, fluticasone propionate and azelastine. Slightly higher fluticasone area under the curve (AUC)_{0-tlast} and C_{max} have been reported compared with those of commercially available intranasal fluticasone propionate.⁴⁶⁴ Of note are the safety data reported from the above-mentioned 12-month trial, with MP29-02 1 spray per nostril twice a day, in which 8 of 404 patients were discontinued at 6 months, because of an adverse event (3 decreased serum cortisol, 3 cataract, 2 acne) versus 1 of 207 in the commercially available fluticasone group (cataract).^{462,465} Other additional combination devices, currently not FDA-approved, including those that contain different INCS and INAH, have been studied.⁴⁶⁶⁻⁴⁷² Several of these studies confirm additive benefit over intranasal monotherapies.

INCS with intranasal ipratropium for control of rhinorrhea

Recommendation 25. CBS: We suggest that for patients taking an INCS who have persistent rhinorrhea, the clinician may consider the addition of intranasal ipratropium.

Strength of the recommendation: Conditional

Certainty of evidence: Moderate

In patients with rhinorrhea not fully responsive to INCS therapy, the addition of ipratropium bromide is beneficial. Intranasal ipratropium bromide plus intranasal beclomethasone was more effective than either active agent alone in reducing the average severity and duration of rhinorrhea in AR and NAR.⁴⁷³

INCS with intranasal decongestant

Recommendation 26. CBS: We suggest that patients with persistent nasal congestion unresponsive to an INCS or to an INCS/INAH combination be offered combination therapy with addition of an intranasal decongestant for up to 4 weeks.

Strength of the recommendation: Conditional

Certainty of evidence: Low

In PAR and SAR, concurrent administration of INCS and intranasal decongestants provides greater reduction in nasal congestion symptoms and greater improvement in nasal volume than that of an intranasal decongestant alone.^{405,406} Furthermore, the combination tended to reduce nasal congestion faster than the INCS alone. When intranasal decongestant was given along with the intranasal steroid once a day for up to 2 weeks, the development of rhinitis medicamentosa, a concern with intranasal decongestant use as monotherapy, did not occur.^{405,406} In addition, in a small study where 19 healthy subjects received intranasal decongestant for 2 weeks followed by the addition of INCS for 3 days, oxymetazoline-induced tachyphylaxis and rebound congestion were reversed by intranasal fluticasone.⁴⁷⁴ In a 4-week, DBPC trial involving 50 patients with chronic rhinitis taking INCS and cetirizine with persistent nasal congestion, the addition of oxymetazoline provided significant reduction in nasal congestion scores compared with placebo without the development of rhinitis medicamentosa.⁴⁷⁵ A *post hoc* analysis demonstrated that the addition of oxymetazoline afforded significantly greater nasal congestion reduction in the AR compared with in the NAR subgroup.⁴⁷⁵ Whereas the combination of an INCS and an INAH remains the preferred and most supported option in patients with AR with persistent symptoms after monotherapy (see above), it might be reasonable to consider adding an intranasal decongestant to an intranasal steroid for the first few days of therapy in patients with AR and significant nasal congestion. At this time, existing evidence is scant and is not sufficient to support the prolonged use of the above-mentioned combination.

Oral antihistamine with oral decongestant

Recommendation 27. CBS: We suggest that for patients with AR and nasal congestion uncontrolled with an oral antihistamine, the clinician consider the addition of pseudoephedrine, when tolerated. (See Recommendation 18.)

Strength of recommendation: Conditional

Certainty of evidence: Moderate

Controlled studies demonstrate that combination of oral antihistamine and oral decongestant is more effective in reducing symptoms of AR, including nasal congestion, than the individual components are,⁴⁷⁶⁻⁴⁷⁸ but adverse effects of oral decongestants are a concern. Given the evidence that this combination is effective, if this regimen is prescribed, the clinician should take into account the dose-response relationship of the side effect profile for oral decongestants and titrate to the lowest effective dose. As indicated in Figs 2 and 3, pharmacologic options other than an oral antihistamine with an oral decongestant (eg, INCS or INAH) generally are preferred, but the selection to use an oral antihistamine with an oral decongestant may be made in a shared decision-making discussion. As presented in the rhinitis 2008 practice parameter,⁴⁰⁹ pseudoephedrine is far superior to other decongestants; however, there are limited antihistamine-pseudoephedrine combinations (eg, fexofenadine/pseudoephedrine). If a fixed combination is chosen, side effects such as insomnia should be taken into account. If side effects with the fixed combination are an issue for the patient, the dose should be adjusted, if possible, or the fixed combination stopped and either separate monotherapy products selected to

allow for dose titration, or a different therapeutic class of rhinitis agents chosen (eg, INCS).

Intranasal decongestant with intranasal ipratropium

There is no published literature on the effect of combination intranasal decongestant with intranasal ipratropium for the treatment of AR and therefore no recommendation for or against this combination can be made. In 1 short-term study (<10 days), there was no rhinitis medicamentosa or rebound congestion noted with the combination; however, there was no clinically important differences in ciliary motility and mucociliary clearance observed.⁴⁷⁹

Oral antihistamines with oral LTRAs

Recommendation 28. CBS: We suggest that for SAR, the clinician not combine the oral LTRA montelukast with an oral antihistamine for symptoms not controlled with an oral antihistamine. (Also see Recommendation 7.)

Strength of recommendation: Conditional

Certainty of evidence: Moderate

Some studies find the concomitant use of LTRA with various oral antihistamines provide additive benefit in reducing symptoms and improving QOL in patients with SAR,^{301,480-484} while others have shown inconclusive or conflicting results, or no benefit over individual medications.^{485,486} One study showed prophylactic treatment with the combination of montelukast and cetirizine together to be more effective than cetirizine alone in preventing symptoms and reducing allergic inflammation.⁴⁸⁷

Although some studies find that the concomitant administration of an oral LTRA and an oral antihistamine can have an additive effect, this approach is usually less efficacious than administering INCS as monotherapy.^{304,305,309,310} The decision to use this combination rather than an intranasal agent should be made following a shared decision-making discussion.

As many as 40% of patients with AR have coexisting asthma.³⁰¹ The combination of montelukast and a second-generation antihistamine may protect against seasonal decrease in some measures of lung function (eg, forced expiratory flow at 25% to 75% of forced vital capacity (FEF₂₅₋₇₅) in patients with AR.⁴⁸⁸ However, the combined mediator antagonism of montelukast with cetirizine is less effective than combined intranasal and inhaled corticosteroids in attenuating nasal and bronchial inflammatory markers.⁴⁸⁹

COMBINATION THERAPIES THAT HAVE NOT BEEN SHOWN TO BE CONVINCINGLY SUPERIOR TO MONOTHERAPY

Oral antihistamine with INCS

Recommendation 29. GRADE:¹⁷⁴ We recommend that the clinician not prescribe, as initial treatment, a combination of an oral antihistamine and an intranasal steroid in preference to monotherapy with an intranasal steroid in patients ≥ 12 years of age with symptoms of SAR.

Strength of the recommendation: Strong

Certainty of evidence: Moderate

Recommendation 30. CBS: We suggest that the clinician not prescribe the combination of an oral antihistamine and an INCS in preference to monotherapy with an intranasal steroid in all patients with SAR and PAR.

Strength of recommendation: Conditional

Certainty of evidence: Very low

The evidence, as reviewed in the JTFPP 2017 rhinitis GRADE guideline,¹⁷⁴ looks at the initial use of monotherapy with an INCS or combination therapy of an INCS and an oral antihistamine for SAR in patients ≥ 12 years of age.¹ That review did not find significant increased symptom relief from the combination compared with relief from INCS monotherapy. There was insufficient evidence that looked at add-on therapy. Therefore, the certainty of evidence is very low for the approach normally taken by clinicians, which is to add combination therapy when monotherapy fails. Furthermore, there is a very low certainty of evidence that children with SAR and patients with PAR should likewise be prescribed INCS monotherapy rather than combination therapy.

Oral LTRAs with INCS

Recommendation 31. CBS: We suggest against the addition of the oral LTRA montelukast to an INCS for AR, due to the lack of adequate evidence of improved efficacy and concerns for serious neuropsychiatric events from montelukast. (Also see Recommendation 7.)

Strength of recommendation: Conditional

Certainty of evidence: Very low

There is no strong evidence to support use of oral LTRA in addition to an INCS. One study found no further benefit when an oral LTRA was added to an INCS for the treatment of AR.⁴⁹⁰ One study found that montelukast add-on therapy to fluticasone nasal spray is more efficacious in controlling nighttime symptoms but similar in efficacy in controlling total symptom score.⁴⁹¹ With very weak evidence, suggesting on one hand a possible benefit and on the other no benefit, but with concerns for serious neuropsychiatric events from montelukast, the JTFPP suggests against the use of this combination.

AR pharmacologic treatment algorithms

In making decisions about selection of therapies for AR, we recommend that a clinician use guidance from an algorithm (see Figs 2 and 3) that is based on multiple considerations including relative effectiveness, onset of action, potential for adverse effects, patient preference, cost to patient, symptom severity, and whether a patient has intermittent or persistent AR. The stepwise progression and decision tree is based largely on expert opinion and cannot account for variable patient adherence in real-life experience. This algorithm was developed for clinical guidance and should be viewed as suggested, conditional recommendations. The certainty of the evidence for the various decision steps in the algorithm varies from being very low to high, based on the evidence for each drug or combination of drugs. The algorithm also considers onset of action of the various agents. The following section reviews data about onset of action of agents used for the treatment of AR. See discussion for each drug class or combination of drug classes for detailed review of data considered.

AR PHARMACOTHERAPY: ONSET OF ACTION

Onset of action for symptom relief may be an important consideration in selection of treatment (see Table VIII). There are relatively few head-to-head trials that directly compare time to onset of symptom relief from different agents. Typically, data from studies using environmental exposure units find quicker

TABLE VIII. Onset of action of pharmacological agents for AR

Agent	Study design	Onset of action	Maximal effect	First measure of onset	References for onset	References for peak action
Intranasal steroid/antihistamine	EEU	5 min (azelastine/fluticasone propionate)	2 wk or greater	5 min	495	333
Intranasal decongestant-oxymetazoline	Peak nasal airflow	<10 min	? within an hour	10 min	496	
INAH	EEU	15 min (azelastine)	1 d to 4 wk	15 min	497,498	331,354
	EEU	30 min (olopatadine)	1 d to 4 wk	30 min	332,498,499	354
Intranasal anticholinergic	Methacholine challenge	15 min (ipratropium)	1 h	15 min	500	500
Oral antihistamine	EEU	30-90 min (desloratadine)		30 min	501	
	EEU	45 min (levocetirizine)		15 min	502	
	EEU	60 min (cetirizine)	1-8 d	15 min	497	503
	EEU	60-75 min (loratadine)	1-8 d	15 min	497,502,504	505
Oral antihistamine with decongestant	Single-dose park setting	30 min (loratadine/PSE)	Unknown	15 min	506	
INCS	EEU	1-6 h (ciclesonide)	2-4 wk	1 h	507,508	509
	EEU	2.5 h (mometasone)	4 wk	30 min	499	510
	EEU	3-8 h (budesonide)	2-4 wk	1 h	472,511	512,513
	2-wk seasonal study	8 h (fluticasone furoate)	2 wk	30 min	514	509,510,513
	Not EEU, park study or other	2-12 h (fluticasone propionate)	2-4 wk	2, 4, 12 h (meta-analysis)	515	512
LTRA	EEU	Within 5 h (montelukast)	By wk 2	5 h	516,517	518
Intranasal mast cell stabilizer	2-wk seasonal study	2 wk (cromolyn)	At least 2 wk	1 wk	435	435,519
Intranasal mast cell stabilizer before allergen exposure	EEU, nasal allergen challenge	Application 1-7 min before allergen exposure	N/A	≥10 min	442	N/A

EEU, Environmental exposure unit.

onset of action than outdoor park challenges do, and traditional field studies do not measure symptom relief until ≥ 12 hours after commencing treatment.⁴⁹²⁻⁴⁹⁴ One cannot rely on a clinical trial to give firm estimates of action onset of a specific pharmacological class or product. For patients with mild intermittent symptoms and minimal congestion, oral antihistamines provide symptom relief in 1 to 2 hours. When combined with oral pseudoephedrine, nasal congestion can be improved within 30 minutes. Topical decongestants such as oxymetazoline improve nasal airflow in under 10 minutes, but possible rebound congestion limits long-term use of these medications (this may be mitigated with concomitant use of a nasal steroid). INAH offer a quicker onset of action within 15 minutes along with greater overall efficacy, and intranasal ipratropium provides relief of rhinorrhea within 15 minutes. INCS give the greatest long-term relief for persistent symptoms with peak results taking up to 2 weeks, but significant improvement can be seen within 2 to 4 hours. When an INAH is added to an INCS, the onset of action is reduced to only 5 minutes, offering almost immediate symptom relief along with long-term control. Montelukast offers similar symptom relief to some oral antihistamines, but with a much slower onset of action making as needed use unhelpful. While cromolyn may be helpful for preexposure prophylaxis, treatment of current symptoms requires 1 to 2 weeks of treatment 3 to 4 times per day to see a benefit.

The time to peak symptom relief is even more difficult to discern from the literature. No studies are designed to look at time to maximal symptom relief, and few studies even note when maximal relief is achieved. In addition, the studies reviewed for maximal efficacy are a mix of seasonal and perennial studies with different allergens and pollen counts and thus cannot be compared. The only conclusions that can be drawn are that

INCS take at least 2 weeks of regular use to achieve maximal benefit, while oral antihistamines are maximally effective within 1 to 8 days. INAH achieve maximal results in 1 day in one study, but incremental gains were seen up to 4 weeks in another. Montelukast probably achieves peak effectiveness by the second week.

The time for onset of action and maximum effect as described in Table VIII^{331-333,354,436,442,495-519} are based on representative studies in SAR with pollen as the allergen, using symptom scores except for ipratropium, which used methacholine and the amount of nasal secretions, and oxymetazoline, which used maximal nasal airflow in patients with preexisting turbinate hypertrophy.

Pharmacotherapy for NAR

Recommendation 32. CBS: We suggest that the clinician offer an INCS as a first-line therapy for NAR.

Strength of the recommendation: Conditional

Certainty of evidence: Low to moderate

Recommendation 33. CBS: We suggest that the clinician offer an INAH as a first-line therapy for NAR.

Strength of the recommendation: Conditional

Certainty of evidence: Very low

The effectiveness of INCS has been reported in studies that have involved a large number of patients with NAR,¹ especially those with NARES.³⁵³⁻³⁵⁵ INCS have also been reported to be effective in the treatment of VMR.^{1,353,356} While INCS are generally recommended for treatment of NAR, their efficacy for some subsets of NAR is uncertain and is less than that which is achieved for AR.⁵²⁰ There is conflicting clinical research on whether inflammatory NAR responds better to INCS than does noninflammatory NAR.^{521,522} A 2019 Cochrane review concluded that it

is unclear whether INCS, compared with placebo, reduce patient-reported disease severity in patients with NAR.⁵²³

Topical INAH, azelastine and olopatadine, have been shown to reduce symptoms of NAR.⁵²⁴ Two 3-week multicenter, randomized, DBPC, parallel-group clinical trials (n = 223 study 1; n = 203 study 2) conducted in patients with VMR revealed numerical improvements in total VMR symptom score for azelastine compared with placebo from baseline (mean numerical change 1.54 vs 84, $P = .002$ in study 1; mean numerical change 1.54 vs 0.88, $P = .005$ in study 2). There were no statistical differences in study dropout rate for azelastine versus placebo in either study and the only difference in adverse events between azelastine versus placebo was bitter taste (19% vs 2%).³⁴³ In a randomized, double-blind, parallel-group, multicenter comparison study of olopatadine versus azelastine administered over 14 days in subjects ≥ 12 years of age with chronic VMR, both medications were found to equally reduce symptoms. The main adverse event was taste disturbance in approximately 10% with azelastine and 5% with olopatadine.³⁵⁷ In this study, the investigators acknowledge that a limitation of this study was that subjects could have previously been on either study drug and enrolled after a washout period of 7 days.³⁵⁷ In a study that measured substance P after administering nasal lavage hypertonic saline before and after treatment with azelastine versus placebo, azelastine was able to reduce substance P secretion to a statistically significant degree ($P < .05$).⁸⁰ Another short-term non-placebo-controlled study compared intranasal azelastine to intranasal triamcinolone in NAR and AR and found both to be equally effective in both groups at improving nasal symptom scores, nasal peak inspiratory flow rate, Epworth sleepiness scale, and QOL.⁵²⁵

Less used and non-FDA-approved treatments include topically applied capsaicin (see intranasal capsaicin section), botulinum toxin A⁵²⁶ injected or topically applied, and vidian neurectomy for severe refractory cases of VMR.¹ Botulinum toxin A⁵²⁶ applied on the nasal mucosa or injected submucosally has been demonstrated to be effective in reducing hypersecretions and nasal congestion in VMR⁵²⁷⁻⁵³⁰ but to a lesser degree than ipratropium bromide.⁵²⁷ In severe, refractory cases of VMR, vidian neurectomy has been used, although there has been concern regarding potential adverse events. In a recent systemic review, endoscopic vidian neurectomy compared with the traditional transantral approach was not associated with any long-term sequelae and provided improvement in rhinorrhea and nasal obstruction for several years following surgery.⁵³¹

NAR pharmacologic treatment algorithm

As with AR, we recommend that a clinician use guidance from an algorithm (see Figs 4 and 5) that is based on multiple considerations including relative effectiveness, onset of action, potential for adverse effects, patient preference, symptom severity, and whether a patient has intermittent or persistent rhinitis. The stepwise progression and decision tree is based largely on expert opinion and cannot account for variable patient adherence in real-life experience. Compared with the evidence for making treatment decisions in AR, the evidence for making recommendations for treatment of NAR is generally more limited, and there are fewer treatment options.

AIT and AR

Recommendation 34. CBS: We suggest that AIT (subcutaneous or sublingual tablets) be offered through shared decision making to patients with moderate/severe AR who (1) are not controlled with allergen avoidance and/or pharmacotherapy or (2) choose immunotherapy as the preferred method of treatment (eg, due to the desire to avoid the adverse effects, costs, or long-term use of pharmacotherapy), and/or (3) desire the potential benefit of immunotherapy to prevent or reduce the severity of comorbid conditions, such as asthma.

Strength of recommendation: Conditional

Certainty of evidence: Moderate

Recommendation 35. CBS: We suggest that AIT (subcutaneous or sublingual tablets) be considered for patients with controlled mild and moderate asthma with coexisting AR.

Strength of recommendation: Conditional

Certainty of evidence: Moderate

The basis for the preceding consensus statements about AIT is discussed below. Much more detailed discussion and additional recommendations about AIT are found in recent JTFPP parameter documents on AIT. (See allergyparameters.org.)

AIT is effective for the treatment of AR.⁵³²⁻⁵³⁴ AIT should be considered for patients with AR who have specific IgE antibodies to clinically relevant allergens, and its use depends on the degree to which symptoms can be reduced by avoidance and medication, the amount and type of medication required to control symptoms, the adverse effects of medications, and patient preference.⁵³²⁻⁵³⁴ A high-quality meta-analysis from 2017 reported doubtful evidence that AIT can prevent the development of new allergen sensitizations (as this could not be confirmed in the sensitivity analysis);⁵³⁵ however, its short-term potential to reduce the risk for the development of asthma in patients with AR could be confirmed.⁵³⁵

A previous 2013 Agency for Healthcare Research and Quality meta-analysis reviewed 74 references and concluded that allergen SCIT is effective for reducing symptoms of AR and allergic conjunctivitis in adults (high strength of evidence).⁵³⁶ Reviewing 60 studies, the investigators concluded that SLIT reduces the symptoms of allergic rhinoconjunctivitis in adults (moderate strength of evidence).⁵³⁶ The 8 studies that indirectly compared SCIT to SLIT in adults showed that SCIT is superior to SLIT for symptom reduction in allergic rhinoconjunctivitis (low strength of evidence).⁵³⁶ A more recent head-to-head double-dummy, double-blind randomized controlled trial with grass pollen SCIT versus tablet SLIT (SLIT-T) showed minor numeric superiority of SCIT over SLIT-T (not significant).⁵³⁷ In pediatric studies SCIT was effective in reducing rhinitis symptoms (moderate strength of evidence) and conjunctivitis symptoms (low strength of evidence) and SLIT reduced rhinoconjunctivitis symptoms (moderate strength of evidence).⁵³⁶ The overall body of evidence showed that both SCIT and SLIT were safe and effective treatments for AR (moderate to high strength of evidence).⁵³⁶

Currently in the United States, there are 4 tablet preparations for SLIT (SLIT-T): a single pollen grass tablet, a 5-grass pollen tablet, a ragweed tablet, and a dust mite tablet. Several meta-analyses conclude that SLIT is effective in the treatment of AR and allergic asthma in adults and children and SLIT has been included in the Global Initiative for Asthma treatment algorithm since 2017. Adverse reactions to SLIT, primarily local oral

mucosal, are very common; systemic reactions are rare; and there have been no reported fatalities due to SLIT.⁵³⁸

The following text is a quotation from the JTFPP's 2017 practice parameter on SLIT: "Although alternative regimens and preparations for SLIT have been proposed and may be used off-label in the United States (eg, use of liquid SCIT extract for sublingual delivery or use of specific sublingual drops or other sublingual tablets), these products and formulations do not have FDA approval at present and have not been systematically studied in a rigorous manner in US populations. Use of such products or formulations as prescribed SLIT therapy is currently off-label, at a practitioner's discretion, and is without recommendation for any current particular indication in the US populations. Therefore, off-label use of aqueous SLIT extracts or any other non-FDA approved SLIT formulation is not endorsed."⁵³⁸

No head-to-head trials of SLIT administered via tablets (SLIT-T) and SLIT administered via liquid drops (SLIT-D) have been conducted and variations among the trials in scoring of symptoms and medication use preclude direct comparisons of treatment effects.⁵³⁹ Four meta-analyses have provided indirect comparisons.^{532,540-542} The symptom treatment effect was greater for SLIT-T versus SLIT-D in all 4 of the meta-analysis comparisons. The medication use treatment effect of SLIT-T was greater than that of SLIT-D in 2 of the comparisons, was less than SLIT-D in 1 comparison, and was comparable to SLIT-D in 1 comparison.

A systematic review and meta-analysis of the economic impact of SCIT and SLIT in adults and children with SAR was undertaken by the National Institute for Health Research in the United Kingdom. Economic modeling suggested that, when compared with symptomatic treatment, both SCIT and SLIT may become cost-effective at a threshold of \$28,000 to \$42,000 per QALY after 5 to 6 years of treatment.⁵⁴³ In the United States, using a Florida Medicaid claims analysis, SCIT in children and adults conferred significant health care cost savings within 3 months of initiating treatment and a 38% lower 18-month mean total health care costs.⁵⁴⁴

A systematic review of the safety of SCIT (45 of 74 SCIT studies reported safety data) reviewed that the most common adverse effects, reported by 5% to 58% of patients were mild, local reactions.⁵³⁶ Pooled data, using a variety of grading systems, found that general symptoms (such as headache, fatigue, arthritis) were reported by 44% of patients and that respiratory-related systemic reactions were reported following 15% of the injections, a reaction rate far higher than that experienced by most US allergists.⁵³⁶ The same study reported 13 anaphylactic reactions, but no deaths.⁵³⁶ A recent survey of American Academy of Allergy, Asthma, and Immunology and American College of Allergy, Asthma, and Immunology members, using the World Allergy Organization's classification system for systemic reactions (grades 1-4) found an overall stable systemic reaction rate of 0.1% (grades 1-4), 1 per 1 million allergy injections had grade 4 (most severe) reactions, and 1 fatality per 23.3 million allergy injections.⁵⁴⁵

There is insufficient evidence to determine the efficacy or safety of SCIT in select subpopulations, such as the elderly, pregnant women, racial and ethnic minorities, inner-city residents, rural residents, in patients with immunodeficiency and autoimmune disorders, and individuals with severe asthma. However, consensus by experts is that there is no absolute lower or upper age limit for initiation of AIT, that

AIT can be continued but generally not be initiated in pregnancy, and that SCIT can be considered in patients with immunodeficiency and autoimmune disorders.⁵³⁴ Certified allergists' experience in large groups of such patients has been reported.⁵⁴⁶ Limited evidence suggests that SCIT may be more beneficial in patients with mild asthma than in those with severe asthma.⁵⁴⁵

In general, the clinical indications for AIT for AR and asthma are similar for adults and children. Studies of children receiving AIT have demonstrated significant improvement in symptom control for asthma and AR and a reduction in airway responsiveness to cat and house dust mite allergens and reduction in pharmacy, outpatient, and total health care costs.⁵³⁴ Discordant data about a decrease in the risk of developing asthma and new sensitizations has already been commented on above.⁵³³

When clinically indicated, the decision to initiate AIT depends on a number of factors, including but not limited to patient's preference/acceptability, adherence, medication requirements, response to avoidance measures, and the adverse effects of medications. The risks and benefits of administration of AIT with patients who are concurrently taking beta-adrenergic blocking agents and angiotensin-converting enzyme inhibitors and/or have serious underlying medical conditions needs to be assessed.⁵⁴⁶⁻⁵⁴⁸ SCIT should be administered in a setting where procedures that can reduce the risk of anaphylaxis are in place and where the prompt recognition and treatment of anaphylaxis is ensured.⁵³⁴ The first dose of SLIT is administered in a clinical setting under medical supervision but is, thereafter, administered by the patient at home. Clinical and physiological improvement can be demonstrated shortly after the patient reaches a maintenance dose.

Patients should be evaluated at least every 12 months while receiving AIT. While many patients experience sustained clinical remission of their allergic disease after discontinuing AIT, others may relapse. A decision about continuation of effective AIT should generally be made after the initial period of 3 to 5 years of treatment.⁵⁴⁹ At this point, for an individual patient, the decision to continue or discontinue treatment should be based on the severity of disease, benefits sustained from treatment, and convenience of treatment.

ALTERNATIVE MEDICINE THERAPIES

There is a body of literature reporting on the use of alternative medicine in AR. While alternative trials show promise as other optional therapies for AR, they suffer from many limitations. These include the lack of standardized acupuncture protocols, lack of standardized outcome evaluations, methodological deficiencies, and small trial numbers. These limitations suggest that these positive outcomes should be interpreted with caution and that further research is needed before recommending alternative therapies for AR.

Acupuncture

Recommendation 36. CBS: We cannot make a recommendation for or against the use of acupuncture for the treatment of AR.

Strength of recommendation: N/A

Certainty of evidence: Ungraded due to lack of adequate studies.

Developed in China 5000 years ago, acupuncture is among the oldest medical interventions, yet little is known about its mechanism of action. Researchers have postulated alterations in immune or nervous system function with release of endorphins and changes in inflammatory and regulatory cells and their cytokine profiles, but none have been convincingly demonstrated. A 2009 systematic review of randomized trials evaluated the effectiveness of acupuncture in preventing and treating allergic rhinitis.⁵⁵⁰ Compared to sham acupuncture, only 1 of 4 SAR trials found acupuncture to be effective for reducing symptoms.⁵⁵⁰ For PAR, 2 of 4 trials demonstrated symptom improvement. The investigators concluded that the evidence for acupuncture is mixed and larger well-controlled studies are needed.

A more recent systematic review and meta-analysis of acupuncture for AR treatment included publications in both English and Chinese languages and identified 13 papers (of 174) that met inclusion criteria.⁵⁵¹ The studies involved 2365 participants with both SAR and PAR. The control groups included sham or no acupuncture and outcome measures included nasal symptom scores, relief medication scores, and QOL measures. Compared with control treatment, acupuncture led to significant reductions in nasal symptoms, intake of relief medications, and sIgE levels. There was a trend in favor of active therapy in ameliorating QOL measures. Another systematic review evaluated alternative health practices in both English and Chinese literature and identified 20 (of 1460) trials that met inclusion criteria and involved 2438 participants with AR where alternative health practices were compared with placebo or Western medicine.⁵⁵² In general, the analysis showed that alternative health practices were superior to placebo and not different from Western medicine in control of symptoms and QOL.

A randomized controlled trial with 12 sessions of acupuncture over 4 weeks in Australian patients with SAR showed improvements in symptom scores and QOL compared to sham acupuncture.⁵⁵³ An accompanying editorial questioned the clinical significance of these findings though, as only selected symptom scores of sneezing and itching were improved.⁵⁵⁴ In the largest and highest quality multicenter study, 422 patients allergic to birch and grass were randomized to 12 real or sham acupuncture sessions over 8 weeks. There was an improvement in QOL scores and antihistamine use, but these did not meet predefined levels for clinical significance.⁵⁵⁵ Finally, in the largest pediatric study to date, 72 Chinese children were randomized to twice weekly real or sham acupuncture for 8 weeks with an improvement in symptom scores but not medication use, IgE levels, or blood or nasal eosinophil levels.⁵⁵⁶

In conclusion, the results of acupuncture for AR are mixed, at best modest, and of uncertain clinical importance. However, it is very safe, with no serious adverse results reported in any studies.

Herbal medications

Recommendation 37. CBS: We cannot make a recommendation for or against the use of specific herbal products for the treatment of AR.

Strength of recommendation: N/A

Certainty of evidence: Ungraded due to lack of adequate studies.

One alternative medical therapy is Chinese herbal medicine (CHM), which has been used for centuries to treat nasal symptoms related to allergic conditions. Studies can be hard to

interpret as they use different products and methodologies, and many are industry-funded. A review of one such CHM, Yu ping feng san, identified 22 randomized controlled trials (of 1244 records) with 2309 participants with AR.⁵⁵⁷ Control groups included placebo, pharmacotherapy, and the combination of CHM and pharmacotherapy, and the treatment periods ranged from 2 to 8 weeks. Results were limited in the placebo-control trials and suggested a trend for benefit from CHM in a very small number of studies. When CHM was compared with pharmacotherapy, there was no superiority of CHM to antihistamines or intranasal steroids. There was also a hint of superiority of CHM when used in combination with pharmacotherapy compared with pharmacotherapy alone. Reported adverse events were mild and transient. Another review analyzed CHM in PAR and identified 7 randomized controlled trials (of 266 studies) including 533 patients treated between 2 weeks and 3 months.⁵⁵⁸ Compared with placebo, CHM significantly reduced nasal symptoms with a moderate side effect profile that lasted a short time.

A 2007 systematic review examined 16 randomized controlled trials with 10 different products and found evidence that *Petasites hybridus* (butterbur) improves symptoms and QOL comparably with a nonsedating antihistamine.⁵⁵⁹ A proposed mechanism of action for *P hybridus* is inhibition of the synthesis of cysteinyl leukotrienes by an ingredient, petasin 1, but there is no evidence for the mechanisms of possible action for other proposed herbal remedies. Studies with Aller-7, a mixture of 7 Indian plants suggested improvement in some symptoms, but this was inconsistent across studies and contradicted in other studies.⁵⁵⁹ Studies of 3 Chinese herbal preparations showed some positive results in symptom scores; however, in one study only sneezing was significant.⁵⁵⁹ Furthermore, another study reported that it required 5 weeks of herbal treatment to reach statistical significance.⁵⁵⁹ The investigators state there is moderately strong evidence to support the use of butterbur but that for Chinese herbal products independent replication is necessary.⁵⁵⁹ More recently, a 2012 meta-analysis of 7 trials showed an improvement in symptom scores with traditional CHM,⁵⁵⁸ but in a 2018 meta-analysis of 11 trials, there was improvement in QOL but not in symptom scores.⁵⁶⁰

The 2012 National Health Interview Survey showed 34% of US adults used complementary health approaches, including herbal medicines, in the previous year.⁵⁶¹ Physicians need to question patients on their use of these products as they can have toxicity and drug-herb interactions. The National Institutes of Health have a webpage devoted to butterbur stating that raw, unprocessed butterbur plant contains pyrrolizidine alkaloids, which can cause liver injury, and recommending that only products certified pyrrolizidine alkaloids-free should be used. There is potential for allergic reactions to butterbur in patients sensitized to ragweed, chrysanthemums, marigolds, and daisies.⁵⁶² While butterbur has the most promising data, more studies are needed to demonstrate the efficacy and safety of herbal medicines before we can endorse them.

SUBPOPULATIONS WITH RHINITIS

Pediatric patients and rhinitis

Rhinitis in children shares most of the pathophysiologic, clinical, diagnostic, and therapeutic characteristics observed in adults. The most frequent comorbidities of AR in children are allergic conjunctivitis, asthma, and atopic dermatitis.^{21,563} AR is

unusual below 2 years of age. Infectious rhinitis is discussed in the earlier section on that topic. Nonallergic, noninfectious rhinitis in children generally presents with chronic nasal symptoms. In addition to more common symptoms and signs of rhinitis such as nasal obstruction, rhinorrhea (anterior or posterior), sneezing, and itching, children with rhinitis may present with snorting, throat clearing, cough, gaping mouth, eye rubbing, and dark circles under the eyes. Physical exam findings are further reviewed in [Table VI](#). As discussed in the section on differential diagnosis, in infants and young children, nasal congestion or obstruction can result from structural problems, such as cleft palate and AH, or from functional processes, such as laryngopharyngeal reflux. Chronic mucopurulent drainage may suggest infectious rhinosinusitis. Purulent drainage, particularly if unilateral, bloody, or persistent, may result from an intranasal foreign body. The “allergic march” is a progressive natural history of atopic disease that may begin in infancy and early childhood with atopic dermatitis and food allergy, followed by AR and atopic asthma in older childhood and adolescence.

The therapeutic approach to treating children with rhinitis is similar to that of adults and includes allergen avoidance, AIT in appropriate cases (see Recommendations 34 and 35) for AR, and pharmacotherapy. Most pharmacologic treatments for AR are approved for children down to age 5 years, and many down to age 2 years or even younger. Special care must be given to dosage adjustment, adverse effects, and long-term safety. Controlled trials or real-world experience that have examined the comparative effectiveness, acceptance, and adherence of medication options are more limited in children than in adults. That said, there are data that adherence to nasal spray use may be a greater issue in younger children.⁵⁶⁴ Historically there has been a shift in guidelines from recommending that oral antihistamines generally should be the first-line agents for treatment of AR in children to a broader approach that positions other agents including INCS as first-line considerations in shared decision making with patients and families.⁵⁶⁵ Further discussion of considerations in children for different medication options are discussed within the recommendation discussion for each respective drug class.

Elderly patients and rhinitis

Rhinitis in the elderly may be caused by the same types and subtypes of rhinitis common in other age groups. It occurs in up to 30% of the elderly, with >40% of these patients rating their rhinitis as moderate/severe, and almost 70% experiencing ocular symptoms.⁷⁰ AR is the most common type of rhinitis in the elderly but is less frequent than its incidence in younger age groups. In addition to AR, because of the concomitant use of multiple medications in the elderly, drug-induced rhinitis is not infrequent. Alpha-1 adrenergic antagonists used for benign prostatic hyperplasia,⁵⁶⁶ angiotensin-converting enzyme inhibitors,^{148,567-569} and possibly beta-adrenergic inhibitors⁵⁷⁰ and phosphodiesterase inhibitors⁵⁷¹ can induce symptoms of rhinitis. (See earlier section on drug-induced rhinitis.)

Physiological changes due to aging result in alterations in neural, histologic, mucosal, and olfactory status that have direct impacts on the functioning of the nose.⁵⁷² While the mechanism for the clear rhinorrhea reported to be the major rhinitis symptom in over 70% of this older population is not fully understood, there appears to be an imbalance of the sympathetic and parasympathetic tone, resulting in cholinergic hyperreactivity and excessive

rhinorrhea.^{573,574} On the other hand, aging is also associated with reduced body water content and less effective nasal mucociliary clearance, leading, at times, to thicker mucous secretions, increased postnasal drip, and potentially, to increased respiratory infections.⁵⁷⁵⁻⁵⁷⁸ Structural changes due to aging can also reduce nasal cartilage elasticity and tip support that can further interfere with nasal airflow.⁵⁷⁸ Age-related reduced blood flow to the nasal mucosa, basement membrane thickening, and epithelial atrophy have also been described.^{579,580} Through a combination of these structural and physiological changes, the elderly are more susceptible to nasal dryness, intranasal crusting, epistaxis, ulceration, and atrophy of the nasal mucosa.⁵⁷⁸

Therapy for the elderly presenting with hyperactive cholinergic symptoms has not been well studied; however, because of the mechanism of action, intranasal ipratropium seems to be a logical intervention.⁵⁸¹ Second-generation oral antihistamines, INAH, leukotriene inhibitors, and INCS are effective and well tolerated in the elderly when used for an appropriate indication, but controlled data comparing efficacy in this population are lacking.⁵⁷⁶ Sedating antihistamines, secondary to their systemic anticholinergic effects, should be avoided in the elderly due to the risk of urinary retention, constipation, delirium, and ocular pressure changes.⁵⁸² As noted below in the oral antihistamines section, a 2015 US prospective population-based cohort study suggested a link between higher cumulative use of agents with stronger anticholinergic effects (including sedating oral antihistamines) and the risk of developing dementia.

Rhinitis in pregnancy

In summary, since the release of the 2008 rhinitis updated practice parameter,¹ interval information has become available that raises new safety concerns about use during pregnancy of intranasal triamcinolone and intranasal decongestants and additional evidence that supports and extends our previous recommendation to avoid oral decongestants. However, there is additional information that supports safety in pregnancy of most other common medications used for rhinitis.

FDA pregnancy classification. Starting in June 2015, the FDA replaced its old pregnancy (A, B, C, X) classification for newly approved medications with a more narrative discussion in the product information section for risk summary, clinical considerations, and data headers under the pregnancy subsection. Medications approved after June 2001 will be gradually phased in. Most AR medications were approved prior to this and will retain the old A through X classifications. Unfortunately, there is still little high-quality evidence from prospective randomized trials supporting the safe use of pharmacologic agents in pregnancy, but we do have some additional information from cohort studies and clinical reviews since our 2008 JTFPP rhinitis update.¹

Intranasal corticosteroids. As stated in the 2008 JTFPP rhinitis update,¹ budesonide carries the old B FDA classification based on the large Swedish birth registries that showed its safety. Other intranasal steroids still have the old C classification, but there is new data supporting the safety of mometasone and fluticasone during pregnancy. Although most INCS are generally considered safe during pregnancy, an exception is triamcinolone, which was associated with a higher rate of congenital respiratory defects in a large Canadian prospective cohort study,⁵⁸³ although a chance finding cannot be ruled out.

Intranasal antihistamines. There is little data on the safety of INAH in pregnancy.

Nasal saline. A randomized study of pregnant women with AR demonstrated that nasal saline lavage is safe and effective, with significant reduction in rhinitis symptom score, daily antihistamine use, and nasal resistance.⁵⁸⁴ Nasal saline therefore is a good first-line option.

Oral antihistamines. There is further evidence of the fetal safety of antihistamines and as a whole, oral antihistamines still appear to be safe for use in pregnancy. Cetirizine was not associated with increase rate of major malformations or increase teratogenic risk.⁵⁸⁵ A study using the UCB Pharma Patient Safety Database up to February 2015 reaffirmed the safety of cetirizine in pregnancy.⁵⁸⁶ A 2013 study using data from a multicenter case-control surveillance program of birth defects in North America did not support previously posited associations between antihistamines, notably diphenhydramine, loratadine, and chlorpheniramine, and major congenital anomalies.⁵⁸⁷ Loratadine does not appear to increase the risk of hypospadias in male offspring.⁵⁸⁸ A 2014 systematic review found the most safety data for loratadine, including that there is no evidence of increased risk of hypospadias.⁵⁸⁹

Oral and intranasal decongestants. Oral decongestants should be avoided because of the risk for gastroschisis.¹ The Sloan Birth Defects Study confirmed an association between oral pseudoephedrine and gastroschisis. This same review also found an association between topical decongestants such as oxymetazoline, when used in the first trimester, with gastroschisis and pyloric stenosis as well as second trimester renal collecting system anomalies. In addition, an association between first-trimester exposure to phenylephrine, an oral decongestant, and endocardial cushion defects was described.⁵⁹⁰ Epidemiologic studies have identified increased risk of birth defects involving the heart, eyes, ears, gut, abdominal wall, and feet when oral decongestants have been used during the first trimester of pregnancy. However, the number of reported cases is very small, considering the fact that up to 7.8% of pregnant women report using oral decongestants. There has been described a possible association of gastroschisis with the use of both pseudoephedrine (relative risk, 2.1-3.2)^{591,592} and phenylpropanolamine (relative risk, 10.0)⁵⁹² during the first trimester of pregnancy. Pseudoephedrine use in the first trimester of pregnancy has also been associated with limb reduction defects. Phenylephrine has also been associated with endocardial cushion defects (odds ratio, 8.0), ear defects (odds ratio, 7.8), and pyloric stenosis (odds ratio, 3.2).⁵⁹⁰ However, a Swedish prospective study looked at the use of these 2 decongestants during early and late pregnancy in 2474 and 1771 women, respectively, and no teratogenic effects were reported.⁵⁹³

The adverse effects of oral decongestants taken during the second and third trimesters appear to be much less compared with the effects during early pregnancy, but caution should be used throughout pregnancy and prolonged use should be avoided.

Based on the low or variable benefit of using decongestants during pregnancy and the potential catastrophic harm of having a birth defect, the work group and the JTFPP are making a strong recommendation against their use during the first trimester of pregnancy, despite the lack of a strong certainty of the evidence. The JTFPP is not making a recommendation for

or against their use during the second and third trimesters of pregnancy reflecting the lack of studies reporting catastrophic harm but the remaining low magnitude of benefit for their use. The clinician should involve shared decision making with each patient when considering the use of oral decongestants during pregnancy.

Leukotriene receptor antagonists. Montelukast carries the old B FDA pregnancy classification and has reassuring observational data mostly from asthma studies. Since the 2008 JTFPP rhinitis update¹ was published, a large Danish observational study from 1998 to 2009 found no increased risk of congenital malformations with montelukast. There was, however, an association with lower birth weight and gestational age in children and increased preeclampsia and gestational diabetes in mothers using montelukast. This may be explained by increased asthma severity in the montelukast group.⁵⁹⁴ Other human studies have shown montelukast and other LTRAs (eg, zafirlukast) are not associated with an increased rate of major malformations in offspring.⁵⁹⁵⁻⁵⁹⁷

Allergen immunotherapy. As previously stated, subcutaneous immunotherapy should not be started in pregnancy, but may be continued. While no recommendation on SLIT can be made yet, there is one prospective observational study in which 185 pregnant Indian patients were treated with SLIT (newly initiated in 24 and continued treatment in 161) with no increase in birth defects seen in 6 years of follow-up.⁵⁹⁸

REFERENCES

- Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and management of rhinitis: an updated practice parameter. *J Allergy Clin Immunol* 2008;122(2 suppl):S1-84.
- McCrory DC, Williams JW, Dolor RJ, Gray RN, Kolimaga JT, Reed S, et al. Management of allergic rhinitis in the working-age population. *Evid Rep Technol Assess (Summ)* 2003;(67):1-4.
- Meltzer EO, Blaiss MS, Naclerio RM, Stoloff SW, Derebery MJ, Nelson HS, et al. Burden of allergic rhinitis: allergies in America, Latin America, and Asia-Pacific adult surveys. *Allergy Asthma Proc* 2012;33(suppl 1):S113-41.
- Blaiss MS, Meltzer EO, Derebery MJ, Boyle JM. Patient and healthcare-provider perspectives on the burden of allergic rhinitis. *Allergy Asthma Proc* 2007;28(suppl 1):S4-10.
- Keith PK, Desrosiers M, Laister T, Schellenberg RR, Wasserman S. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. *Allergy Asthma Clin Immunol* 2012;8:7.
- Bousquet J, Fokkens W, Burney P, Durham SR, Bachert C, Akdis CA, et al. Important research questions in allergy and related diseases: nonallergic rhinitis: a GA²LEN paper. *Allergy* 2008;63:842-53.
- Mullarkey MF, Hill JS, Webb DR. Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia. *J Allergy Clin Immunol* 1980;65:122-6.
- Enberg RN. Perennial nonallergic rhinitis: a retrospective review. *Ann Allergy* 1989;63:513-6.
- Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. *J Allergy Clin Immunol* 1999;104:301-4.
- Settipane RA, Lieberman P. Update on nonallergic rhinitis. *Ann Allergy Asthma Immunol* 2001;86:494-507, quiz 507-8.
- Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. *J Allergy Clin Immunol* 2009;124(3 suppl):S43-70.
- Sansone RA, Sansone LA. Allergic rhinitis: relationships with anxiety and mood syndromes. *Innov Clin Neurosci* 2011;8:12-7.
- Hellgren J, Toren K. Nonallergic occupational rhinitis. *Clin Allergy Immunol* 2007;19:241-8.
- Stuck BA, Hummel T. Olfaction in allergic rhinitis: a systematic review. *J Allergy Clin Immunol* 2015;136:1460-70.

15. Meltzer EO. The role of nasal corticosteroids in the treatment of rhinitis. *Immunol Allergy Clin North Am* 2011;31:545-60.
16. Blaiss MS. Allergic rhinitis: direct and indirect costs. *Allergy Asthma Proc* 2010; 31:375-80.
17. Szeinbach SL, Seoane-Vazquez EC, Beyer A, Williams PB. The impact of allergic rhinitis on work productivity. *Prim Care Respir J* 2007;16:98-105.
18. Schoenwetter WF, Dupclay L Jr, Appajosyula S, Botteman MF, Pashos CL. Economic impact and quality-of-life burden of allergic rhinitis. *Curr Med Res Opin* 2004;20:305-17.
19. Jauregui I, Mullol J, Davila I, Ferrer M, Bartra J, del Cuvillo A, et al. Allergic rhinitis and school performance. *J Investig Allergol Clin Immunol* 2009; 19(suppl 1):32-9.
20. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy* 2008; 63(suppl 86):8-160.
21. Montoro J, Del Cuvillo A, Mullol J, Molina X, Bartra J, Davila I, et al. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: the PEDRIAL study. *Allergy* 2012;67: 1437-42.
22. Bousquet J, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. *J Allergy Clin Immunol* 2017;140:950-8.
23. Department of Health and Human Services. Food and Drug Administration [Docket No. FDA-2000-D-0277]. Allergic Rhinitis: Developing Drug Products for Treatment; Guidance for Industry; Availability. *Federal Register* 2018; 83(173):45259-60.
24. Demoly P, Allaert FA, Lecasble M, Bousquet J. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). *Allergy* 2003;58:672-5.
25. Bousquet J, Annesi-Maesano I, Carat F, Leger D, Rugina M, Pribil C, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. *Clin Exp Allergy* 2005;35:728-32.
26. Larenas-Linnemann D, Michels A, Dinger H, Arias-Cruz A, Ambriz Moreno M, Bedolla Barajas M, et al. In the (sub)tropics allergic rhinitis and its impact on asthma classification of allergic rhinitis is more useful than perennial-seasonal classification. *Am J Rhinol Allergy* 2014;28:232-8.
27. Jones NS, Carney AS, Davis A. The prevalence of allergic rhinosinusitis: a review. *J Laryngol Otol* 1998;112:1019-30.
28. International Rhinitis Management Working Group. International Consensus Report on the Diagnosis and Management of Rhinitis. *Allergy* 1994;49(suppl 19):1-34.
29. Carney AS, Jones NS. Idiopathic rhinitis: idiopathic or not? *Clin Otolaryngol Allied Sci* 1996;21:198-202.
30. Incorvaia C, Fuiano N, Canonica GW. Seeking allergy when it hides: which are the best fitting tests? *World Allergy Organ J* 2013;6:11.
31. Carney AS, Powe DG, Huskisson RS, Jones NS. Atypical nasal challenges in patients with idiopathic rhinitis: more evidence for the existence of allergy in the absence of atopy? *Clin Exp Allergy* 2002;32:1436-40.
32. Wedback A, Enbom H, Eriksson NE, Moverare R, Malcus I. Seasonal non-allergic rhinitis (SNAR)—a new disease entity? A clinical and immunological comparison between SNAR, seasonal allergic rhinitis and persistent non-allergic rhinitis. *Rhinology* 2005;43:86-92.
33. Refaat M, Melek N, Shahin R, Eldeeb I. Study for assessing prevalence of local allergic rhinitis among rhinitis patients. *J Allergy Clin Immunol* 2015;135: AB140.
34. Cheng KJ, Xu YY, Liu HY, Wang SQ. Serum eosinophil cationic protein level in Chinese subjects with nonallergic and local allergic rhinitis and its relation to the severity of disease. *Am J Rhinol Allergy* 2013;27:8-12.
35. Adinoff AD, Tsai KS, Steffen M. Entropy: where art thou entropy? *J Allergy Clin Immunol* 2015;135:AB190.
36. Reisacher WR, Bremberg MG. Prevalence of antigen-specific immunoglobulin E on mucosal brush biopsy of the inferior turbinates in patients with nonallergic rhinitis. *Int Forum Allergy Rhinol* 2014;4:292-7.
37. Wierzbicki DA, Majmudar AR, Schull DE, Khan DA. Multiallergen nasal challenges in nonallergic rhinitis. *Ann Allergy Asthma Immunol* 2008;100:533-7.
38. Rondon C, Romero JJ, Lopez S, Antunez C, Martin-Casanez E, Torres MJ, et al. Local IgE production and positive nasal provocation test in patients with persistent nonallergic rhinitis. *J Allergy Clin Immunol* 2007;119:899-905.
39. Rondon C, Fernandez J, Lopez S, Campo P, Dona I, Torres MJ, et al. Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. *J Allergy Clin Immunol* 2009;124:1005-11.e1.
40. Bozek A, Kolodziejczyk K, Jarzab J. Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis. *Ann Allergy Asthma Immunol* 2018;120: 53-8.
41. Campo P, Eguiluz-Gracia I, Bogas G, Salas M, Plaza Seron C, Perez N, et al. Local allergic rhinitis: implications for management. *Clin Exp Allergy* 2019; 49:6-16.
42. Pepper AN, Ledford DK. Nasal and ocular challenges. *J Allergy Clin Immunol* 2018;141:1570-7.
43. Auge J, Vent J, Agache I, Airaksinen L, Campo Mozo P, Chaker A, et al. EAACI Position paper on the standardization of nasal allergen challenges. *Allergy* 2018; 73:1597-608.
44. Gomez E, Campo P, Rondon C, Barrionuevo E, Blanca-Lopez N, Torres MJ, et al. Role of the basophil activation test in the diagnosis of local allergic rhinitis. *J Allergy Clin Immunol* 2013;132:975-6.e1-5.
45. Powe DG, Jagger C, Kleinjan A, Carney AS, Jenkins D, Jones NS. "Entropy": localized mucosal allergic disease in the absence of systemic responses for atopy. *Clin Exp Allergy* 2003;33:1374-9.
46. de la Rosa F, Blanca-Lopez N, Rondon C, Herrera R, Rodriguez-Bada JL, Canto G, et al. Seasonal local allergic rhinitis in areas with high exposure to grass pollen [abstract]. *J Allergy Clin Immunol* 2012;129:AB111.
47. Cruz ND, Ronda N, Almeida QL, Correa A, Castillo SR, Melendez L, et al. Evidence of local allergic rhinitis in areas of high and permanent aeroallergens exposure [abstract]. *J Allergy Clin Immunol* 2012;129:AB111.
48. Rondon C, Eguiluz-Gracia I, Campo P. Is the evidence of local allergic rhinitis growing? *Curr Opin Allergy Clin Immunol* 2018;18:342-9.
49. Rondon C, Campo P, Galindo L, Blanca-Lopez N, Cassinello MS, Rodriguez-Bada JL, et al. Prevalence and clinical relevance of local allergic rhinitis. *Allergy* 2012;67:1282-8.
50. Blanca M, Campo P, Rondon C, Sanchez EB, Blanca-Lopez N, Godineau V, et al. Dual systemic allergic rhinitis and local allergic rhinitis [abstract]. *World Allergy Organ J* 2015;8(suppl 1):A262.
51. Lopez S, Rondon C, Torres MJ, Campo P, Canto G, Fernandez R, et al. Immediate and dual response to nasal challenge with *Dermatophagoides pteronyssinus* in local allergic rhinitis. *Clin Exp Allergy* 2010;40:1007-14.
52. Shin YS, Jung CG, Park HS. Prevalence and clinical characteristics of local allergic rhinitis to house dust mites. *Curr Opin Allergy Clin Immunol* 2018; 18:10-5.
53. Rondon C, Campo P, Blanca-Lopez N, Salas M, Canamero MD, Sanchez MI, et al. Local allergic rhinitis and non-allergic rhinitis: different demographic and clinical phenotypes. *Allergy* 2014;69:65-6.
54. Duman H, Bostanci I, Ozmen S. Is nasal provocation test important for children with non-allergic rhinitis. *Allergy* 2013;68:274.
55. Gomez F, Rondon C, Salas M, Campo P. Local allergic rhinitis: mechanisms, diagnosis and relevance for occupational rhinitis. *Curr Opin Allergy Clin Immunol* 2015;15:111-6.
56. Campos G, Rondon C, Campo P, Galindo L, Blanca-Lopez N, Torres M, et al. Local versus systemic allergic rhinitis: clinical characteristics and comorbidities. *Allergy* 2011;66:31-2.
57. Demirturk M, Ulusan M, Gelincik A, Unal D, Buyukozturk S, Colakoglu B. The importance of mould sensitivity in nonallergic rhinitis patients. *Allergy* 2013;68: 185.
58. Rondon C, Campo P, Zambonino MA, Blanca-Lopez N, Torres MJ, Melendez L, et al. Follow-up study in local allergic rhinitis shows a consistent entity not evolving to systemic allergic rhinitis. *J Allergy Clin Immunol* 2014;133: 1026-31.
59. Rondon C, Campo P, Sanchez EB, De Leiva Molina C, Lifona LH, Guerrero MA, et al. Phenotyping non-allergic and local allergic rhinitis [abstract]. *J Allergy Clin Immunol* 2014;133:AB75.
60. Rondon C, Campo P, Blanca-Lopez N, Del Carmen Plaza Seron M, Gomez F, Ruiz MD, et al. Subcutaneous allergen immunotherapy in patient with local allergy sensitized to *Dermatophagoides pteronyssinus* [abstract]. *J Allergy Clin Immunol* 2015;135:AB171.
61. Rondon C, Blanca-Lopez N, Aranda A, Herrera R, Rodriguez-Bada JL, Canto G, et al. Local allergic rhinitis: allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen. *J Allergy Clin Immunol* 2011; 127:1069-71.
62. Rondon C, Campo P, Blanca-Lopez N, Gomez F, Ruiz MD, Canto G, et al. Subcutaneous allergen immunotherapy with *dermatophagoides pteronyssinus* in patient with local allergic rhinitis [abstract]. *World Allergy Organ J* 2015;8: A263.
63. Rondon C, Blanca-Lopez N, Campo P, Mayorga C, Jurado-Escobar R, Torres MJ, et al. Specific immunotherapy in local allergic rhinitis: a randomized, double-blind placebo-controlled trial with *Phleum pratense* subcutaneous allergen immunotherapy. *Allergy* 2018;73:905-15.
64. Rondon C, Campo P, Eguiluz-Gracia I, Plaza C, Bogas G, Galindo P, et al. Local allergic rhinitis is an independent rhinitis phenotype: the results of a 10-year follow-up study. *Allergy* 2018;73:470-8.

65. Kaliner MA. Classification of nonallergic rhinitis syndromes with a focus on vasomotor rhinitis, proposed to be known henceforth as nonallergic rhinopathy. *World Allergy Organ J* 2009;2:98-101.
66. Jovancevic L, Georgalas C, Savovic S, Janjevic D. Gustatory rhinitis. *Rhinology* 2010;48:7-10.
67. Orban N, Maughan E, Bleach N. Pregnancy-induced rhinitis. *Rhinology* 2013;51:111-9.
68. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al. Classification and practical approach to the diagnosis and management of hyper-sensitivity to nonsteroidal anti-inflammatory drugs. *Allergy* 2013;68:1219-32.
69. Hox V, Steelant B, Fokkens W, Nemery B, Hellings PW. Occupational upper airway disease: how work affects the nose. *Allergy* 2014;69:282-91.
70. Morais-Almeida M, Pite H, Pereira AM, Todo-Bom A, Nunes C, Bousquet J, et al. Prevalence and classification of rhinitis in the elderly: a nationwide survey in Portugal. *Allergy* 2013;68:1150-7.
71. Van Gerven L, Alpizar YA, Steelant B, Callebaut I, Kortekaas Krohn I, Wouters M, et al. Enhanced chemosensory sensitivity in patients with idiopathic rhinitis and its reversal by nasal capsaicin treatment. *J Allergy Clin Immunol* 2017;140:437-46.e2.
72. Hellings PW, Klimek L, Cingi C, Agache I, Akdis C, Bachert C, et al. Non-allergic rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. *Allergy* 2017;72:1657-65.
73. Bernstein JA. Allergic and mixed rhinitis: epidemiology and natural history. *Allergy Asthma Proc* 2010;31:365-9.
74. Van Gerven LBG, Jorissen M, Fokkens W, Hellings PW. Short-time cold dry air exposure: a useful diagnostic tool for nasal hyperresponsiveness. *Laryngoscope* 2012;122:2615-20.
75. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Allergic rhinitis: developing drug products for treatment guidance for industry 2018. Available at: <https://www.fda.gov/cder/rdmt/OTC/OTC%20Allergies/OTC%20Allergies%20Guidance%20for%20Industry.pdf>;153 6168130. Accessed August 6, 2020.
76. Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, et al. Allergy diagnostic testing: an updated practice parameter. *Ann Allergy Asthma Immunol* 2008;100(3 suppl 3):S1-148.
77. Singh U, Bernstein JA, Lorentz H, Sadowny T, Nelson V, Patel P, et al. A pilot study investigating clinical responses and biological pathways of azelastine/fluticasone in nonallergic vasomotor rhinitis before and after cold dry air provocation. *Int Arch Allergy Immunol* 2017;173:153-64.
78. Kaliner MA, Baraniuk JN, Benninger M, Bernstein JA, Lieberman P, Meltzer EO, et al. Consensus definition of nonallergic rhinopathy, previously referred to as vasomotor rhinitis, nonallergic rhinitis, and/or idiopathic rhinitis. *World Allergy Organ J* 2009;2:119-20.
79. Comoglu S, Keles N, Deger K. Inflammatory cell patterns in the nasal mucosa of patients with idiopathic rhinitis. *Am J Rhinol Allergy* 2012;26:e55-62.
80. Gawlik R, Jawor B, Rogala B, Parzynski S, DuBuske L. Effect of intranasal azelastine on substance P release in perennial nonallergic rhinitis patients. *Am J Rhinol Allergy* 2013;27:514-6.
81. Lambert EM, Patel CB, Fakhri S, Citardi MJ, Luong A. Optical rhinometry in nonallergic irritant rhinitis: a capsaicin challenge study. *Int Forum Allergy Rhinol* 2013;3:795-800.
82. Marshak T, Yun WK, Hazout C, Sacks R, Harvey RJ. A systematic review of the evidence base for vidian neurectomy in managing rhinitis. *J Laryngol Otol* 2016;130(suppl 4):S7-28.
83. Malmberg H, Grahne B, Holopainen E, Binder E. Ipratropium (Atrovent) in the treatment of vasomotor rhinitis of elderly patients. *Clin Otolaryngol Allied Sci* 1983;8:273-6.
84. Druce HM, Spector SL, Fireman P, Kaiser H, Meltzer EO, Boggs P, et al. Double-blind study of intranasal ipratropium bromide in nonallergic perennial rhinitis. *Ann Allergy* 1992;69:53-60.
85. Assanasen P, Baroodly FM, Rouadi P, Naureckas E, Solway J, Naclerio RM. Ipratropium bromide increases the ability of the nose to warm and humidify air. *Am J Respir Crit Care Med* 2000;162:1031-7.
86. Shusterman D, Balmes J, Murphy MA, Tai CF, Baraniuk J. Chlorine inhalation produces nasal airflow limitation in allergic rhinitic subjects without evidence of neuropeptide release. *Neuropeptides* 2004;38:351-8.
87. Cruz AA, Naclerio RM, Proud D, Togias A. Epithelial shedding is associated with nasal reactions to cold, dry air. *J Allergy Clin Immunol* 2006;117:1351-8.
88. Silvers WS, Poole JA. Exercise-induced rhinitis: a common disorder that adversely affects allergic and nonallergic athletes. *Ann Allergy Asthma Immunol* 2006;96:334-40.
89. Linneberg A, Berg ND, Gonzalez-Quintela A, Vidal C, Elberling J. Prevalence of self-reported hypersensitivity symptoms following intake of alcoholic drinks. *Clin Exp Allergy* 2008;38:145-51.
90. Singh U, Bernstein JA, Haar L, Luther K, Jones WK. Azelastine desensitization of transient receptor potential vanilloid 1: a potential mechanism explaining its therapeutic effect in nonallergic rhinitis. *Am J Rhinol Allergy* 2014;28:215-24.
91. Van Gerven L, Alpizar YA, Wouters MM, Hox V, Hauben E, Jorissen M, et al. Capsaicin treatment reduces nasal hyperactivity and transient receptor potential cation channel subfamily V, receptor 1 (TRPV1) overexpression in patients with idiopathic rhinitis. *J Allergy Clin Immunol* 2014;133:1332-9.e1-3.
92. Peters AT, Spector S, Hsu J, Hamilos DL, Baroodly FM, Chandra RK, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. *Ann Allergy Asthma Immunol* 2014;113:347-85.
93. Kaplan A. Canadian guidelines for acute bacterial rhinosinusitis: clinical summary. *Can Fam Physician* 2014;60:227-34.
94. Gulliford MC, Dregan A, Moore MV, Ashworth M, Staa T, McCann G, et al. Continued high rates of antibiotic prescribing to adults with respiratory tract infection: survey of 568 UK general practices. *BMJ Open* 2014;4:e006245.
95. Ahmad A, Khan MU, Patel I, Maharaj S, Pandey S, Dhingra S. Knowledge, attitude and practice of B.Sc. Pharmacy students about antibiotics in Trinidad and Tobago. *J Res Pharm Pract* 2015;4:37-41.
96. Eckel N, Sarganas G, Wolf IK, Knopf H. Pharmacoeconomics of common colds and upper respiratory tract infections in children and adolescents in Germany. *BMC Pharmacol Toxicol* 2014;15:44.
97. Kotwani A, Holloway K. Antibiotic prescribing practice for acute, uncomplicated respiratory tract infections in primary care settings in New Delhi, India. *Trop Med Int Health* 2014;19:761-8.
98. Alabidi AH, Ibrahim MI, Hassali MA. Antibiotics dispensing for URTIs by community pharmacists (CPs) and general medical practitioners in Penang, Malaysia: a comparative study using simulated patients (SPs). *J Clin Diagn Res* 2014;8:119-23.
99. Kenaley T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. *Cochrane Database Syst Rev* 2013;2013:CD000247.
100. Tabatabaei SA, Fahimzad SA, Shamshiri AR, Shiva F, Salehpour S, Sayyahfar S, et al. Assessment of a new algorithm in the management of acute respiratory tract infections in children. *J Res Med Sci* 2012;17:182-5.
101. Panasiuk L, Lukas W, Paprzycki P, Verheij T, Godycki-Cwirko M, Chlabicz S. Antibiotics in the treatment of upper respiratory tract infections in Poland. Is there any improvement? *J Clin Pharm Ther* 2010;35:665-9.
102. Nadeem Ahmed M, Muyot MM, Begum S, Smith P, Little C, Windemuller FJ. Antibiotic prescription pattern for viral respiratory illness in emergency room and ambulatory care settings. *Clin Pediatr (Phila)* 2010;49:542-7.
103. Centre for Clinical Practice at NICE. Respiratory tract infections—antibiotic prescribing: prescribing of antibiotics for self-limiting respiratory tract infections in adults and children in primary care. NICE Clinical Guidelines 69. London (UK): National Institute for Health and Clinical Excellence; 2008.
104. Hoa NQ, Larson M, Kim Chuc NT, Eriksson B, Trung NV, Stalsby CL. Antibiotics and paediatric acute respiratory infections in rural Vietnam: health-care providers' knowledge, practical competence and reported practice. *Trop Med Int Health* 2009;14:546-55.
105. El Sayed MF, Tamim H, Jamal D, Mumtaz G, Melki I, Yunis K, et al. Prospective study on antibiotics misuse among infants with upper respiratory infections. *Eur J Pediatr* 2009;168:667-72.
106. van den Broek MF, Gudden C, Kluijfhout WP, Stam-Slob MC, Aarts MC, Kaper NM, et al. No evidence for distinguishing bacterial from viral acute rhinosinusitis using symptom duration and purulent rhinorrhea: a systematic review of the evidence base. *Otolaryngol—Head Neck Surg* 2014;150:533-7.
107. Kaper NM, Breukel L, Venekamp RP, Grolman W, van der Heijden GJ. Absence of evidence for enhanced benefit of antibiotic therapy on recurrent acute rhinosinusitis episodes: a systematic review of the evidence base. *Otolaryngol Head Neck Surg* 2013;149:664-7.
108. Lemiengre MB, van Driel ML, Merenstein D, Young J, De Sutter AI. Antibiotics for clinically diagnosed acute rhinosinusitis in adults. *Cochrane Database Syst Rev* 2012;10:CD006089.
109. Cornelius RS, Martin J, Wippold FJ 2nd, Aiken AH, Anguaco EJ, Berger KL, et al. ACR appropriateness criteria sinonasal disease. *J Am Coll Radiol* 2013;10:241-6.
110. Esposito S, Marchisio P, Tenconi R, Tagliaferri L, Albertario G, Patria MF, et al. Diagnosis of acute rhinosinusitis. *Pediatr Allergy Immunol* 2012;23(suppl 22):17-9.
111. Bayonne E, Kania R, Tran P, Huy B, Herman P. Intracranial complications of rhinosinusitis: a review, typical imaging data and algorithm of management. *Rhinology* 2009;47:59-65.
112. Schwartz RH, Pitkaranta A, Winther B. Computed tomography imaging of the maxillary and ethmoid sinuses in children with short-duration purulent rhinorrhea. *Otolaryngol Head Neck Surg* 2001;124:160-3.
113. Gwaltney JM Jr, Phillips CD, Miller RD, Riker DK. Computed tomographic study of the common cold. *N Engl J Med* 1994;330:25-30.

114. Autio TJ, Tapiainen T, Koskenkorva T, Narkio M, Lappalainen M, Nikkari S, et al. The role of microbes in the pathogenesis of acute rhinosinusitis in young adults. *Laryngoscope* 2015;125:E1-7.
115. Walgama E, Thanasumpun T, Gander R, Batra PS. Comparison of endoscopically-guided swab vs aspirate culture techniques in post-endoscopic sinus surgery patients: blinded, prospective analysis. *Int Forum Allergy Rhinol* 2013;3:726-30.
116. Benninger MS, Payne SC, Ferguson BJ, Hadley JA, Ahmad N. Endoscopically directed middle meatal cultures versus maxillary sinus taps in acute bacterial maxillary rhinosinusitis: a meta-analysis. *Otolaryngol Head Neck Surg* 2006;134:3-9.
117. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg* 2015;152(2 suppl):S1-39.
118. Lau J, Zucker D, Engels EA, Barza M, Terrin N, Devine D, Chew P, Lang T, Liu D. Diagnosis and treatment of acute bacterial rhinosinusitis: Summary. 1999 Mar. In: AHRQ Evidence Report Summaries. Rockville (MD): Agency for Healthcare Research and Quality (US); 1998-2005. 9. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK11860/>. Accessed August 25, 2020.
119. Cronin MJ, Khan S, Saeed S. The role of antibiotics in the treatment of acute rhinosinusitis in children: a systematic review. *Arch Dis Child* 2013;98:299-303.
120. Lopardo G, Calmaggi A, Clara L, Levy Hara G, Mykietiak A, Pryluka D, et al. [Consensus guidelines for the management of upper respiratory tract infections]. *Medicina* 2012;72:484-94.
121. Lindstrand A, Bennet R, Galanis I, Blennow M, Ask LS, Dennison SH, et al. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine. *Pediatrics* 2014;134:e1528-36.
122. Olarte L, Hultén KG, Lamberth L, Mason EO Jr, Kaplan SL. Impact of the 13-valent pneumococcal conjugate vaccine on chronic sinusitis associated with *Streptococcus pneumoniae* in children. *Pediatr Infect Dis J* 2014;33:1033-6.
123. Murphy TF, Faden H, Bakaletz LO, Kyd JM, Forsgren A, Campos J, et al. Non-typeable *Haemophilus influenzae* as a pathogen in children. *Pediatr Infect Dis J* 2009;28:43-8.
124. Brook I, Foote PA, Hausfeld JN. Frequency of recovery of pathogens causing acute maxillary sinusitis in adults before and after introduction of vaccination of children with the 7-valent pneumococcal vaccine. *J Med Microbiol* 2006;55:943-6.
125. Bachert C, Van Bruaene N, Toskala E, Zhang N, Olze H, Scadding G, et al. Important research questions in allergy and related diseases: 3-chronic rhinosinusitis and nasal polyposis—a GALEN study. *Allergy* 2009;64:520-33.
126. Scadding GK, Kariyawasam HH, Scadding G, Mirakian R, Buckley RJ, Dixon T, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). *Clin Exp Allergy* 2017;47:856-89.
127. Georgalas C, Jovanovic L. Gustatory rhinitis. *Curr Opin Otolaryngol Head Neck Surg* 2012;20:9-14.
128. Webber CM, England RW. Oral allergy syndrome: a clinical, diagnostic, and therapeutic challenge. *Ann Allergy Asthma Immunol* 2010;104:101-8; quiz 9-10, 17.
129. Sampson HA. Food allergy. Part 2: diagnosis and management. *J Allergy Clin Immunol* 1999;103:981-9.
130. Lieberman JA, Sicherer SH. Diagnosis of food allergy: epicutaneous skin tests, in vitro tests, and oral food challenge. *Curr Allergy Asthma Rep* 2011;11:58-64.
131. Panel NI- SE, Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. *J Allergy Clin Immunol* 2010;126(6 suppl):S1-58.
132. Abrams EM, Sicherer SH. Diagnosis and management of food allergy. *CMAJ* 2016;188:1087-93.
133. Al-Rabia MW. Food-induced immunoglobulin E-mediated allergic rhinitis. *J Microsc Ultrastruct* 2016;4:69-75.
134. Moller C. Effect of pollen immunotherapy on food hypersensitivity in children with birch pollinosis. *Ann Allergy* 1989;62:343-5.
135. Dondi A, Tripodi S, Panetta V, Asero R, Businco AD, Bianchi A, et al. Pollen-induced allergic rhinitis in 1360 Italian children: comorbidities and determinants of severity. *Pediatr Allergy Immunol* 2013;24:742-51.
136. Brown CE, Katelaris CH. The prevalence of the oral allergy syndrome and pollen-food syndrome in an atopic paediatric population in south-west Sydney. *J Paediatr Child Health* 2014;50:795-800.
137. Bedolla-Barajas M, Kestler-Gramajo A, Alcalá-Padilla G, Morales-Romero J. Prevalence of oral allergy syndrome in children with allergic diseases. *Allergol Immunopathol (Madr)* 2017;45:127-33.
138. Zuidmeer L, Goldhahn K, Rona RJ, Gislason D, Madsen C, Summers C, et al. The prevalence of plant food allergies: a systematic review. *J Allergy Clin Immunol* 2008;121:1210-8.e4.
139. Ortolani C, Pastorello EA, Farioli L, Spano M, Pravettoni V, Berti C, et al. IgE-mediated allergy from vegetable allergens. *Ann Allergy* 1993;71:470-6.
140. Fernandez-Rivas M, van Ree R, Cuevas M. Allergy to Rosaceae fruits without related pollinosis. *J Allergy Clin Immunol* 1997;100:728-33.
141. Cardet JC, White AA, Barrett NA, Feldweg AM, Wickner PG, Savage J, et al. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. *J Allergy Clin Immunol Pract* 2014;2:208-13.
142. De Schryver E, Derycke L, Campo P, Gabriels E, Joos GF, Van Zele T, et al. Alcohol hyper-responsiveness in chronic rhinosinusitis with nasal polyps. *Clin Exp Allergy* 2017;47:245-53.
143. Calais CJ, Banks TA. Resolution of alcohol-induced respiratory symptoms following aspirin desensitization in aspirin-exacerbated respiratory disease. *Ann Allergy Asthma Immunol* 2015;114:429-30.
144. Wei J, Gerlich J, Genuit J, Nowak D, Vogelberg C, von Mutius E, et al. Hormonal factors and incident asthma and allergic rhinitis during puberty in girls. *Ann Allergy Asthma Immunol* 2015;115:21-7.e2.
145. Caparrosa FA, Gregorio LL, Bongiovanni G, Izu SC, Kosugi EM. Rhinitis and pregnancy: literature review. *Braz J Otorhinolaryngol* 2016;82:105-11.
146. Dzieciolowska-Baran E, Teul-Swiniarska I, Gawlikowska-Sroka A, Poziomkowska-Gesicka I, Zietek Z. Rhinitis as a cause of respiratory disorders during pregnancy. *Adv Exp Med Biol* 2013;755:213-20.
147. Varghese M, Glaum MC, Lockey RF. Drug-induced rhinitis. *Clin Exp Allergy* 2010;40:381-4.
148. Pinargote P, Guillen D, Guarderas JC. ACE inhibitors: upper respiratory symptoms. *BMJ Case Rep* 2014;2014:bcr2014205462.
149. Wolstenholme CR, Philpott CM, Oloto EJ, Murty GE. Does the use of the combined oral contraceptive pill cause changes in the nasal physiology in young women? *Am J Rhinol* 2006;20:238-40.
150. Wild DC, Philpott CM, Wolstenholme CR, Murty GE. Does hormone replacement therapy in post-menopausal women have any effect upon nasal physiology? *J Laryngol Otol* 2008;122:707-10.
151. Stubner UP, Gruber D, Berger UE, Toth J, Marks B, Huber J, et al. The influence of female sex hormones on nasal reactivity in seasonal allergic rhinitis. *Allergy* 1999;54:865-71.
152. Moscato G, Vandenplas O, Van Wijk RG, Malo JL, Perfetti L, Quirce S, et al. EAACI position paper on occupational rhinitis. *Respir Res* 2009;10:16.
153. Castano R, Yucelsoy B, Johnson VJ, Castellanos L, Cartier A. Inflammatory proteins in nasal lavage of workers exposed to occupational agents. *Clin Exp Allergy* 2017;47:1566-73.
154. Meggs WJ, Elsheik T, Metzger WJ, Albernaz M, Bloch RM. Nasal pathology and ultrastructure in patients with chronic airway inflammation (RADS and RUDS) following an irritant exposure. *J Toxicol Clin Toxicol* 1996;34:383-96.
155. Konraden JR, Nordlund B, Lidegran M, Pedroletti C, Gronlund H, van Hage M, et al. Problematic severe asthma: a proposed approach to identifying children who are severely resistant to therapy. *Pediatr Allergy Immunol* 2011;22:9-18.
156. Moore EJ, Kern EB. Atrophic rhinitis: a review of 242 cases. *Am J Rhinol* 2001;15:355-61.
157. Hildenbrand T, Weber RK, Brehmer D. Rhinitis sicca, dry nose and atrophic rhinitis: a review of the literature. *Eur Arch Otorhinolaryngol* 2011;268:17-26.
158. Houser SM. Empty nose syndrome associated with middle turbinate resection. *Otolaryngol Head Neck Surg* 2006;135:972-3.
159. Kuan EC, Suh JD, Wang MB. Empty nose syndrome. *Curr Allergy Asthma Rep* 2015;15:493.
160. Zohar Y, Talmi YP, Strauss M, Finkelstein Y, Shvilli Y. Ozena revisited. *J Otolaryngol* 1990;19:345-9.
161. Mishra A, Kawatra R, Gola M. Interventions for atrophic rhinitis. *Cochrane Database Syst Rev* 2012;(2):CD008280.
162. Jacobs RL, Freedman PM, Boswell RN. Nonallergic rhinitis with eosinophilia (NARES syndrome). Clinical and immunologic presentation. *J Allergy Clin Immunol* 1981;67:253-62.
163. Moneret-Vautrin DA, Wayoff M, Hsieh V, Wirtz, Maria Y, Jankowski R. [NARES syndrome: a developing link in the Fernand-Widal triad.]. *Ann Otolaryngol Chir Cervicofac* 1989;106:47-50.
164. Settipane GA, Klein DE. Nonallergic rhinitis: demography of eosinophils in nasal smear, blood total eosinophil counts and IgE levels. *N Engl J Allergy Proc* 1985;6:363-6.
165. Mullarkey MF. Eosinophilic nonallergic rhinitis. *J Allergy Clin Immunol* 1988;82:941-9.
166. Rupp GH, Friedman RA. Eosinophilic nonallergic rhinitis in children. *Pediatrics* 1982;70:437-9.
167. Meng Y, Lou H, Wang Y, Wang X, Cao F, Wang K, et al. Endotypes of chronic rhinitis: a cluster analysis study. *Allergy* 2019;74:720-30.

168. Zambetti G, Ciofalo A, Romeo R, Soldo P, Fusconi M, Greco A, et al. Nasal histamine responses in nonallergic rhinitis with eosinophilic syndrome. *Allergy Rhinol (Providence)* 2015;6:94-100.
169. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. *J Allergy Clin Immunol* 2004;114(6 suppl):155-212.
170. De Corso E, Anzivino R, Galli J, Baroni S, Di Nardo W, De Vita C, et al. Antileukotrienes improve naso-ocular symptoms and biomarkers in patients with NARES and asthma. *Laryngoscope* 2019;129:551-7.
171. Nelson BL, Jacobs RL. Response of nonallergic rhinitis with eosinophilia (NARES) syndrome to 4% cromolol sodium nasal solution. *J Allergy Clin Immunol* 1982;70:125-8.
172. Ellis AK, Keith PK. Nonallergic rhinitis with eosinophilia syndrome. *Curr Allergy Asthma Rep* 2006;6:215-20.
173. Howarth PH, Persson CG, Meltzer EO, Jacobson MR, Durham SR, Silkoff PE. Objective monitoring of nasal airway inflammation in rhinitis. *J Allergy Clin Immunol* 2005;115(3 suppl 1):S414-41.
174. Dykewicz MS, Wallace DV, Baroody F, Bernstein J, Craig T, Finegold I, et al. Treatment of seasonal allergic rhinitis: an evidence-based focused 2017 guideline update. *Ann Allergy Asthma Immunol* 2017;119:489-511.e41.
175. Seidman MD, Gurgel RK, Lin SY, Schwartz SR, Baroody FM, Bonner JR, et al. Clinical practice guideline: allergic rhinitis executive summary. *Otolaryngol Head Neck Surg* 2015;152:197-206.
176. Costa DJ, Amouyal M, Lambert P, Ryan D, Schunemann HJ, Daures JP, et al. How representative are clinical study patients with allergic rhinitis in primary care? *J Allergy Clin Immunol* 2011;127:920-6.e1.
177. Hammersley VS, Harris J, Sheikh A, Davidson E, Walker S. Developing and testing of a screening tool to predict people without IgE-mediated allergy: a quantitative analysis of the predictive value of a screening tool. *Br J Gen Pract* 2017;67:e293-9.
178. Brandt D, Bernstein JA. Questionnaire evaluation and risk factor identification for nonallergic vasomotor rhinitis. *Ann Allergy Asthma Immunol* 2006;96:526-32.
179. Wise SK, Lin SY, Toskala E, Orlandi RR, Akdis CA, Alt JA, et al. International consensus statement on allergy and rhinology: allergic rhinitis. *Int Forum Allergy Rhinol* 2018;8:108-352.
180. Chang AB, Glomb WB. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. *Chest* 2006;129(1 suppl):260S-83S.
181. Irwin RS, French CL, Chang AB, Altman KW, CHEST Expert Cough Panel. Classification of cough as a symptom in adults and management algorithms: CHEST guideline and expert panel report. *Chest* 2018;153:196-209.
182. Palombini BC, Villanova CA, Araujo E, Gastal OL, Alt DC, Stolz DP, et al. A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. *Chest* 1999;116:279-84.
183. Smyrniotis NA, Irwin RS, Curley FJ. Chronic cough with a history of excessive sputum production: the spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. *Chest* 1995;108:991-7.
184. Mello CJ, Irwin RS, Curley FJ. Predictive values of the character, timing, and complications of chronic cough in diagnosing its cause. *Arch Intern Med* 1996;156:997-1003.
185. Pratter MR. Overview of common causes of chronic cough: ACCP evidence-based clinical practice guidelines. *Chest* 2006;129(1 suppl):59S-62S.
186. Pratter MR, Bartter T, Akers S, DuBois J. An algorithmic approach to chronic cough. *Ann Intern Med* 1993;119:977-83.
187. Braunstahl GJ, Fokkens W. Nasal involvement in allergic asthma. *Allergy* 2003;58:1235-43.
188. Tatar M, Plevkova J, Brozmanova M, Pecova R, Kollarik M. Mechanisms of the cough associated with rhinosinusitis. *Pulm Pharmacol Ther* 2009;22:121-6.
189. Canning BJ, Chang AB, Bolser DC, Smith JA, Mazzone SB, McGarvey L, et al. Anatomy and neurophysiology of cough: CHEST Guideline and Expert Panel report. *Chest* 2014;146:1633-48.
190. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001;108:S147-334.
191. Guerra S, Sherrill DL, Baldacci S, Carrozzi L, Pistelli F, Di Pede F, et al. Rhinitis is an independent risk factor for developing cough apart from colds among adults. *Allergy* 2005;60:343-9.
192. Cho SH, Lin HC, Ghoshal AG, Bin Abdul Muttalif AR, Thanaviratananich S, Bagga S, et al. Respiratory disease in the Asia-Pacific region: cough as a key symptom. *Allergy Asthma Proc* 2016;37:131-40.
193. He S, Li YJ, Chen J. Clinical features of allergic rhinitis in children of Shanghai, China. *Genet Mol Res* 2016;15; <https://doi.org/10.4238/gmr.15028118>.
194. Pecova R, Vrlík M, Tatar M. Cough sensitivity in allergic rhinitis. *J Physiol Pharmacol* 2005;56(suppl 4):171-8.
195. Pecova R, Zucha J, Pec M, Neuschlova M, Hanzel P, Tatar M. Cough reflex sensitivity testing in seasonal allergic rhinitis patients and healthy volunteers. *J Physiol Pharmacol* 2008;59(suppl 6):557-64.
196. Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. *Am Rev Respir Dis* 1990;141:640-7.
197. Krzych-Falta E, Piekarska B, Sybilski A, Wojas O, Samolinski B. The safety of nasal allergen challenge test assessed in lower airways. *Iran J Allergy Asthma Immunol* 2015;14:581-8.
198. Schatz M. A survey of the burden of allergic rhinitis in the USA. *Allergy* 2007;62(suppl 85):9-16.
199. Gao F, Gu QL, Jiang ZD. Upper airway cough syndrome in 103 children. *Chin Med J (Engl)* 2019;132:653-8.
200. Chakir J, Laviolette M, Boutet M, Laliberte R, Dube J, Boulet LP. Lower airways remodeling in nonasthmatic subjects with allergic rhinitis. *Lab Invest* 1996;75:735-44.
201. Chakir J, Laviolette M, Turcotte H, Boutet M, Boulet LP. Cytokine expression in the lower airways of nonasthmatic subjects with allergic rhinitis: influence of natural allergen exposure. *J Allergy Clin Immunol* 2000;106:904-10.
202. Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. *Ann Allergy Asthma Immunol* 2003;90:416-21.
203. Lin L, Chen ZC, Cao YT, Sun GB. Normal saline solution nasal-pharyngeal irrigation improves chronic cough associated with allergic rhinitis. *Am J Rhinol Allergy* 2017;31:96-104.
204. Badhwar AK, Druce HM. Allergic rhinitis. *Med Clin North Am* 1992;76:789-803.
205. Skoner DP, Doyle WJ, Chamovitz AH, Fireman P. Eustachian tube obstruction after intranasal challenge with house dust mite. *Arch Otolaryngol Head Neck Surg* 1986;112:840-2.
206. Noble SL, Forbes RC, Woodbridge HB. Allergic rhinitis. *Am Fam Physician* 1995;51:837-46.
207. Beltrani VS. The clinical spectrum of atopic dermatitis. *J Allergy Clin Immunol* 1999;104:S87-98.
208. Beltrani VS, Boguniewicz M. Atopic dermatitis. *Dermatol Online J* 2003;9:1.
209. Ng ML, Warlow RS, Chrisanthan N, Ellis C, Walls R. Preliminary criteria for the definition of allergic rhinitis: a systematic evaluation of clinical parameters in a disease cohort (I). *Clin Exp Allergy* 2000;30:1314-31.
210. Raza SN, Yousuf K, Small P, Frenkiel S. Diagnosing allergic rhinitis: effectiveness of the physical examination in comparison to conventional skin testing. *J Otolaryngol Head Neck Surg* 2011;40:407-12.
211. Naclerio RM, Bachert C, Baraniuk JN. Pathophysiology of nasal congestion. *Int J Gen Med* 2010;3:47-57.
212. Clark DW, Del Signore AG, Raithatha R, Senior BA. Nasal airway obstruction: prevalence and anatomic contributors. *Ear Nose Throat J* 2018;97:173-6.
213. Korkut AY, Islim F, Gulseven Ciftci S, Dogan R, Gedikli O, Kahya V, et al. Evaluation of inferior turbinate hypertrophy in patients with congenital and traumatic nasal septum deviation. *J Laryngol Otol* 2012;126:784-8.
214. Demir D, Asil K, Guven M, Kayabasoglu G, Yilmaz MS. Assessment of the correlation between nasal septal deviation and compensatory hypertrophy of the middle turbinate. *Eur Arch Otorhinolaryngol* 2015;272:2847-51.
215. van Egmond M, Rovers MM, Tillema AHJ, van Neerbeek N. Septoplasty for nasal obstruction due to a deviated nasal septum in adults: a systematic review. *Rhinology* 2018;56:195-208.
216. Han JK, Stringer SP, Rosenfeld RM, Archer SM, Baker DP, Brown SM, et al. Clinical consensus statement: septoplasty with or without inferior turbinate reduction. *Otolaryngol Head Neck Surg* 2015;153:708-20.
217. Wang DY, Clement P. Pathogenic mechanisms underlying the clinical symptoms of allergic rhinitis. *Am J Rhinol* 2000;14:325-33.
218. Jose J, Coatesworth AP. Inferior turbinate surgery for nasal obstruction in allergic rhinitis after failed medical treatment. *Cochrane Database of Systematic Reviews* 2010;12:CD005235.
219. Feldman EM, Koshy JC, Chike-Obi CJ, Hatf DA, Bullocks JM, Stal S. Contemporary techniques in inferior turbinate reduction: survey results of the American Society for Aesthetic Plastic Surgery. *Aesthet Surg J* 2010;30:672-9.
220. Rao SUP, Basavaraj P, Yempalle SB, Ramachandra AD. A prospective study of different methods of inferior turbinate reduction. *J Clin Diagn Res* 2017;11:MC01-3.
221. Jun BC, Kim SW, Kim SW, Cho JH, Park YJ, Yoon HR. Is turbinate surgery necessary when performing a septoplasty? *Eur Arch Otorhinolaryngol* 2009;266:975-80.
222. Jiang ZY, McLean C, Perez C, Barnett S, Friedman D, Tajudeen BA, et al. Surgical outcomes and postoperative management in spontaneous cerebrospinal fluid rhinorrhea. *J Neurol Surg B Skull Base* 2018;79:193-9.

223. Vimala LR, Jasper A, Irodi A. Non-invasive and minimally invasive imaging evaluation of CSF rhinorrhoea—a retrospective study with review of literature. *Pol J Radiol* 2016;81:80-5.
224. Marchiano E, Carniol ET, Guzman DE, Raikundalia MD, Baredes S, Eloy JA. An analysis of patients treated for cerebrospinal fluid rhinorrhea in the United States from 2002 to 2010. *J Neurol Surg B Skull Base* 2017;78:18-23.
225. Mathias T, Levy J, Fatakia A, McCoul ED. Contemporary approach to the diagnosis and management of cerebrospinal fluid rhinorrhea. *Ochsner J* 2016;16:136-42.
226. Lobo BC, Baumanis MM, Nelson RF. Surgical repair of spontaneous cerebrospinal fluid (CSF) leaks: A systematic review. *Laryngoscope Invest Otolaryngol* 2017;2:215-24.
227. Adedeji TO, Amusa YB, Aremu AA. Correlation between adenoidal nasopharyngeal ratio and symptoms of enlarged adenoids in children with adenoidal hypertrophy. *Afr J Paediatr Surg* 2016;13:14-9.
228. Major MP, Saltaji H, El-Hakim H, Witmans M, Major P, Flores-Mir C. The accuracy of diagnostic tests for adenoid hypertrophy: a systematic review. *J Am Dent Assoc* 2014;145:247-54.
229. Pereira L, Monyror J, Almeida FT, Almeida FR, Guerra E, Flores-Mir C, et al. Prevalence of adenoid hypertrophy: a systematic review and meta-analysis. *Sleep Med Rev* 2018;38:101-12.
230. Tuhanioglu B, Erkan SO. Evaluation of the effects of montelukast, mometasone furoate, and combined therapy on adenoid size: a randomized, prospective, clinical trial with objective data. *Turk J Med Sci* 2017;47:1736-43.
231. Chohan A, Lal A, Chohan K, Chakravarti A, Gomer S. Systematic review and meta-analysis of randomized controlled trials on the role of mometasone in adenoid hypertrophy in children. *Int J Pediatr Otorhinolaryngol* 2015;79:1599-608.
232. Bhargava R, Chakravarti A. Role of mometasone furoate aqueous nasal spray for management of adenoidal hypertrophy in children. *J Laryngol Otol* 2014;128:1060-6.
233. Zhao G, Li Y, Wang X, Ding X, Wang C, Xu W, et al. The predictive value of polysomnography combined with quality of life for treatment decision of children with habitual snoring related to adenotonsillar hypertrophy. *Eur Arch Otorhinolaryngol* 2018;275:1579-86.
234. Awad AH, ElTaher M. ENT foreign bodies: an experience. *Int Arch Otorhinolaryngol* 2018;22:146-51.
235. Abou-Elfadl M, Horra A, Abada RL, Mahtar M, Roubal M, Kadiri F. Nasal foreign bodies: results of a study of 260 cases. *Eur Ann Otorhinolaryngol Head Neck Dis* 2015;132:343-6.
236. Sinikumpu JJ, Serlo W. Confirmed and suspected foreign body injuries in children during 2008-2013: a hospital-based single center study in Oulu University Hospital. *Scand J Surg* 2017;106:350-5.
237. Huang T, Li WQ, Xia ZF, Li J, Rao KC, Xu EM. Characteristics and outcome of impacted button batteries among young children less than 7 years of age in China: a retrospective analysis of 116 cases. *World J Pediatr* 2018;14:570-5.
238. Ng TT, Nasserallah M. The art of removing nasal foreign bodies. *Open Access Emerg Med* 2017;9:107-12.
239. Jackson CL, Behan L, Collins SA, Goggin PM, Adam EC, Coles JL, et al. Accuracy of diagnostic testing in primary ciliary dyskinesia. *Eur Respir J* 2016;47:837-48.
240. Lucas JS, Barbato A, Collins SA, Goutaki M, Behan L, Caudri D, et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. *Eur Respir J* 2017;49:1601090.
241. Shapiro AJ, Davis SD, Polineni D, Manion M, Rosenfeld M, Dell SD, et al. Diagnosis of primary ciliary dyskinesia: an official American Thoracic Society clinical practice guideline. *Am J Respir Crit Care Med* 2018;197:e24-39.
242. Laohasiriwong S, Johnston N, Woodson BT. Extra-esophageal reflux, NOSE score, and sleep quality in an adult clinic population. *Laryngoscope* 2013;123:3233-8.
243. Soylu A, Altintas A, Cakmak S, Poturoglu S, Kaya H, Sevindir I, et al. The coexistence of eosinophilic esophagitis with allergic rhinitis. *Eur Rev Med Pharmacol Sci* 2016;20:2315-23.
244. Loehrl TA. Sinonasal problems and reflux. *Facial Plast Surg Clin North Am* 2012;20:83-6.
245. Lupa M, DelGaudio JM. Evidence-based practice: reflux in sinusitis. *Otolaryngol Clin North Am* 2012;45:983-92.
246. Thompson LDR, Franchi A. New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: nasal cavity, paranasal sinuses and skull base. *Virchows Arch* 2018;472:315-30.
247. Tatekawa H, Shimono T, Ohsawa M, Doishita S, Sakamoto S, Miki Y. Imaging features of benign mass lesions in the nasal cavity and paranasal sinuses according to the 2017 WHO classification. *Jpn J Radiol* 2018;36:361-81.
248. Noon LB. Prophylactic inoculation against hay fever. *Lancet* 1911;177:1572-3.
249. Health Quality Ontario. Skin testing for allergic rhinitis: a health technology assessment. *Ont Health Technol Assess Ser* 2016;16:1-45.
250. Erel F, Sarioglu N, Kose M, Kaymakci M, Gokcen M, Kepekci AH, et al. Intradermal skin testing in allergic rhinitis and asthma with negative skin prick tests. *Iran J Allergy Asthma Immunol* 2017;16:193-7.
251. Nelson HS, Oppenheimer J, Buchmeier A, Kordash TR, Freshwater LL. An assessment of the role of intradermal skin testing in the diagnosis of clinically relevant allergy to timothy grass. *J Allergy Clin Immunol* 1996;97:1193-201.
252. Wood RA, Phipatanakul W, Hamilton RG, Eggleston PA. A comparison of skin prick tests, intradermal skin tests, and RASTs in the diagnosis of cat allergy. *J Allergy Clin Immunol* 1999;103:773-9.
253. Loureiro G, Machado D, Tavares B, Pereira C, Segorbe Luis A. Specific nasal provocation test as a diagnostic tool in local allergic rhinitis. *Allergy* 2011;66:352.
254. Demoly P, Bousquet PJ, Mesbah K, Bousquet J, Devillier P. Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary care: asthma and rhinitis. *Clin Exp Allergy* 2013;43:881-8.
255. Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Mechin H, Daures JP, et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. *Allergy* 2007;62:367-72.
256. Larenas-Linnemann DE, Dinger H, Shah-Hosseini K, Michels A, Mösges R, Mexican Study Group on Allergic Rhinitis and Sensitivity. Overdiagnosis of persistent allergic rhinitis in perennial allergic rhinitis patients: a nationwide study in Mexico. *Am J Rhinol Allergy* 2013;27:495-501.
257. Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, Jung K, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position paper of the German Society of Allergology (AeDA) and the German Society of Allergy and Clinical Immunology (DGAKI), ENT Section, in collaboration with the working group on Clinical Immunology, Allergology and Environmental Medicine of the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNOKHC). *Allergo J Int* 2017;26:16-24.
258. Kremer B. Quality of life scales in allergic rhinitis. *Curr Opin Allergy Clin Immunol* 2004;4:171-6.
259. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. *J Allergy Clin Immunol* 1994;94:182-8.
260. Bousquet J, Knani J, Dhivert H, Richard A, Chicoye A, Ware JE Jr, et al. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. *Am J Respir Crit Care Med* 1994;149:371-5.
261. Ciprandi G, Canonica WG, Grosclaude M, Ostinelli J, Brazzola GG, Bousquet J. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. *Allergy* 2002;57:586-91.
262. Caimmi D, Baiz N, Tanno LK, Demoly P, Arnavielhe S, Murray R, et al. Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. *Clin Exp Allergy* 2017;47:1526-33.
263. Bousquet J, Bewick M, Arnavielhe S, Mathieu-Dupas E, Murray R, Bedbrook A, et al. Work productivity in rhinitis using cell phones: the MASK pilot study. *Allergy* 2017;72:1475-84.
264. Demoly P, Calderon MA, Casale T, Scadding G, Annesi-Maesano I, Braun JJ, et al. Assessment of disease control in allergic rhinitis. *Clin Transl Allergy* 2013;3:7.
265. Meltzer EO, Schatz M, Nathan R, Garriss C, Stanford RH, Kosinski M. Reliability, validity, and responsiveness of the Rhinitis Control Assessment Test in patients with rhinitis. *J Allergy Clin Immunol* 2013;131:379-86.
266. Nathan RA, Dalal AA, Stanford RH, Meltzer EO, Schatz M, Derebery J, et al. Qualitative development of the Rhinitis Control Assessment Test (RCAT), an instrument for evaluating rhinitis symptom control. *Patient* 2010;3:91-9.
267. Schatz M, Meltzer EO, Nathan R, Derebery MJ, Mintz M, Stanford RH, et al. Psychometric validation of the rhinitis control assessment test: a brief patient-completed instrument for evaluating rhinitis symptom control. *Ann Allergy Asthma Immunol* 2010;104:118-24.
268. Nathan RA. The rhinitis control assessment test: implications for the present and future. *Curr Opin Allergy Clin Immunol* 2014;14:13-9.
269. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol* 2004;113:59-65.
270. Demoly P, Jankowski R, Chassany O, Bessah Y, Allaert FA. Validation of a self-questionnaire for assessing the control of allergic rhinitis. *Clin Exp Allergy* 2011;41:860-8.
271. Nogueira-Silva L, Martins SV, Cruz-Correia R, Azevedo LF, Morais-Almeida M, Bugalho-Almeida A, et al. Control of allergic rhinitis and asthma test—a formal approach to the development of a measuring tool. *Respir Res* 2009;10:52.

272. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, Sa-Sousa A, Azevedo LF, Ferreira J, et al. Control of Allergic Rhinitis and Asthma Test (CARAT) can be used to assess individual patients over time. *Clin Transl Allergy* 2012;2:16.
273. Fonseca JA, Nogueira-Silva L, Morais-Almeida M, Azevedo L, Sa-Sousa A, Branco-Ferreira M, et al. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. *Allergy* 2010;65:1042-8.
274. Vuurman EF, van Veggel LM, Uiterwijk MM, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. *Ann Allergy* 1993;71:121-6.
275. Simons FE, Reggin JD, Roberts JR, Simons KJ. Benefit/risk ratio of the antihistamines (H1-receptor antagonists) terfenadine and chlorpheniramine in children. *J Pediatr* 1994;124:979-83.
276. Bender BG, Berning S, Dudden R, Milgrom H, Tran ZV. Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. *J Allergy Clin Immunol* 2003;111:770-6.
277. O'Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. *Allergy* 1995;50:234-42.
278. Cimbura G, Lucas DM, Bennett RC, Warren RA, Simpson HM. Incidence and toxicological aspects of drugs detected in 484 fatally injured drivers and pedestrians in Ontario. *J Forensic Sci* 1982;27:855-67.
279. Ray WA, Thapa PB, Shorr RI. Medications and the older driver. *Clin Geriatr Med* 1993;9:413-38.
280. Ramaekers JG, Uiterwijk MM, O'Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. *Eur J Clin Pharmacol* 1992;42:363-9.
281. O'Hanlon JF. Alcohol, drugs and traffic safety. Institute for Drugs, Safety and Behavior 42. Maastricht (The Netherlands): Ryksuniversiteit Limburg; 1998:10-2.
282. Weiler JM, Bloomfield JR, Woodworth GG, Grant AR, Layton TA, Brown TL, et al. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa driving simulator. *Ann Intern Med* 2000;132:354-63.
283. Warren RSH, Hilchie J. Drugs detected in fatally injured drivers in the province of Ontario. In: Goldberg L, editor. Alcohol, drugs and safety. Stockholm (Sweden): Almqvist and Wiksell; 1981. pp. 203-17.
284. Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. *J Allergy Clin Immunol* 2003;111:S835-42.
285. Shamsi Z, Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. *Hum Psychopharmacol* 2000;15(suppl 1):S3-30.
286. Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R. A systematic review of amnesic and non-amnesic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. *Drugs Aging* 2012;29:639-58.
287. Wong L, Hendeles L, Weinberger M. Pharmacologic prophylaxis of allergic rhinitis: relative efficacy of hydroxyzine and chlorpheniramine. *J Allergy Clin Immunol* 1981;67:223-8.
288. Weiler JM, Donnelly A, Campbell BH, Connell JT, Diamond L, Hamilton LH, et al. Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis. *J Allergy Clin Immunol* 1988;82:801-11.
289. Harvey RP, Comer C, Sanders B, Westley R, Marsh W, Shapiro H, et al. Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. *J Allergy Clin Immunol* 1996;97:1233-41.
290. Safavi Naini A, Ghorbani J, Mazloom E. Comparative study of apo-cetirizine single therapy and intermittent sequential therapy with cetirizine, loratadine and chlorpheniramine in allergic rhinitis. *Indian J Otolaryngol Head Neck Surg* 2016;68:329-33.
291. Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. *Allergy* 2010;65:459-66.
292. Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. *J Allergy Clin Immunol* 2011;128:1139-50.e4.
293. Boyle J, Eriksson M, Stanley N, Fujita T, Kumagi Y. Allergy medication in Japanese volunteers: treatment effect of single doses on nocturnal sleep architecture and next day residual effects. *Curr Med Res Opin* 2006;22:1343-51.
294. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. *JAMA Intern Med* 2015;175:401-7.
295. Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. *JAMA Neurol* 2016;73:721-32.
296. Bernstein JA. Nonallergic rhinitis: therapeutic options. *Curr Opin Allergy Clin Immunol* 2013;13:410-6.
297. Bernstein JA. Characteristics of nonallergic vasomotor rhinitis. *World Allergy Organ J* 2009;2:102-5.
298. Halvorsen KH, Selbaek G, Ruths S. Trends in potentially inappropriate medication prescribing to nursing home patients: comparison of three cross-sectional studies. *Pharmacoepidemiol Drug Saf* 2017;26:192-200.
299. Ichimaru Y, Kanazawa H, Kamoi H, Kyoh S, Tochino Y, Kodama T, et al. Correlations of health-related quality of life questionnaire results in asthma and allergic rhinitis: effects of a leukotriene receptor antagonist. *J Int Med Res* 2008;36:559-66.
300. Santos CB, Hanks C, McCann J, Lehman EB, Pratt E, Craig TJ. The role of montelukast on perennial allergic rhinitis and associated sleep disturbances and daytime somnolence. *Allergy Asthma Proc* 2008;29:140-5.
301. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. *Drugs* 2007;67:887-901.
302. Weinstein SF, Philip G, Hampel FC Jr, Malice MP, Swern AS, Dass SB, et al. Onset of efficacy of montelukast in seasonal allergic rhinitis. *Allergy Asthma Proc* 2005;26:41-6.
303. Gonyeau MJ, Partisano AM. A clinical review of montelukast in the treatment of seasonal allergic rhinitis: Database of Abstracts of Reviews of Effects (DARE): quality-assessed reviews. York (UK): University of York: Centre for Reviews and Dissemination; 2003.
304. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. *Am J Med* 2004;116:338-44.
305. Rodrigo GJ, Yanez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. *Ann Allergy Asthma Immunol* 2006;96:779-86.
306. Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. *Clin Otolaryngol* 2006;31:360-7.
307. US Food and Drug Administration. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis 2020: risks may include suicidal thoughts or actions. March 13, 2020. Available from: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug>. Accessed May 23, 2020.
308. Meltzer EO, Malmstrom K, Lu S, Prenner BM, Wei LX, Weinstein SF, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. *J Allergy Clin Immunol* 2000;105:917-22.
309. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol* 2002;109:949-55.
310. Wilson AM, Orr LC, Sims EJ, Lipworth BJ. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. *Clin Exp Allergy* 2001;31:61-8.
311. Di Lorenzo G, Pacor ML, Pellitteri ME, Morici G, Di Gregoli A, Lo Bianco C, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. *Clin Exp Allergy* 2004;34:259-67.
312. Bisgaard H, Skoner D, Boza ML, Tozzi CA, Newcomb K, Reiss TF, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. *Pediatr Pulmonol* 2009;44:568-79.
313. Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. *Curr Med Res Opin* 2004;20:1549-58.
314. Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. *Pharmacology* 2014;94:60-70.
315. Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study. *J Allergy Clin Immunol* 2012;130:368-75.
316. Aldea Perona A, Garcia-Saiz M, Sanz Alvarez E. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase(R). *Drug Saf* 2016;39:69-78.
317. Law SWY, Wong AYS, Anand S, Wong ICK, Chan EW. Neuropsychiatric events associated with leukotriene-modifying agents: a systematic review. *Drug Saf* 2018;41:253-65.

318. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. *Arch Intern Med* 1998;158:1213-20.
319. Hedner P, Persson G. Suppression of the hypothalamic-pituitary-adrenal axis after a single intramuscular injection of methylprednisolone acetate. *Ann Allergy* 1981;47:176-9.
320. Ganderton MA, James VH. Clinical and endocrine side-effects of methylprednisolone acetate as used in hay-fever. *Br Med J* 1970;1:267-9.
321. Broersen LH, Pereira AM, Jorgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. *J Clin Endocrinol Metab* 2015;100:2171-80.
322. Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid therapy and adrenal insufficiency in adults: a systematic review. *Semin Arthritis Rheum* 2016;46:133-41.
323. Aasbjerg K, Torp-Pedersen C, Vaag A, Backer V. Treating allergic rhinitis with depot-steroid injections increase risk of osteoporosis and diabetes. *Respir Med* 2013;107:1852-8.
324. Jacobs MB. Local subcutaneous atrophy after corticosteroid injection. *Postgrad Med* 1986;80:159-60.
325. Dyment PG. Local atrophy following triamcinolone injection. *Pediatrics* 1970;46:136-7.
326. Horak F, Ziegelmayer UP, Ziegelmayer R, Kavina A, Marschall K, Munzel U, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. *Curr Med Res Opin* 2006;22:151-7.
327. Kaliner MA, Berger WE, Ratner PH, Siegel CJ. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. *Ann Allergy Asthma Immunol* 2011;106(2 suppl):S6-11.
328. LaForce CF, Corren J, Wheeler WJ, Berger WE, Rhinitis Study Group. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. *Ann Allergy Asthma Immunol* 2004;93:154-9.
329. Berger WE, White MV, Rhinitis Study Group. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. *Ann Allergy Asthma Immunol* 2003;91:205-11.
330. Ratner PH, Findlay SR, Hampel F Jr, van Bavel J, Widlitz MD, Freitag JJ. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. *J Allergy Clin Immunol* 1994;94:818-25.
331. LaForce C, Dockhorn RJ, Prenner BM, Chu TJ, Kraemer MJ, Widlitz MD, et al. Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. *Ann Allergy Asthma Immunol* 1996;76:181-8.
332. Patel P, Roland PS, Marple BF, Benninger PJ, Margalias H, Brubaker M, et al. An assessment of the onset and duration of action of olopatadine nasal spray. *Otolaryngol Head Neck Surg* 2007;137:918-24.
333. Ratner PH, Hampel F, Van Bavel J, Amar NJ, Daftary P, Wheeler W, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2008;100:74-81.
334. Kaliner MA. Azelastine and olopatadine in the treatment of allergic rhinitis. *Ann Allergy Asthma Immunol* 2009;103:373-80.
335. Carr WW, Ratner P, Munzel U, Murray R, Price D, Canonica GW, et al. Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. *Allergy Asthma Proc* 2012;33:450-8.
336. Stern MA, Wade AG, Ridout SM, Cambell LM. Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine. *Ann Allergy Asthma Immunol* 1998;81:354-8.
337. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. *Ann Allergy Asthma Immunol* 2002;89:479-84.
338. Bernstein JA. Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability. *Curr Med Res Opin* 2007;23:2441-52.
339. Casale TB. The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites. *J Allergy Clin Immunol* 1989;83:771-6.
340. Lieberman PL, Settipane RA. Azelastine nasal spray: a review of pharmacology and clinical efficacy in allergic and nonallergic rhinitis. *Allergy Asthma Proc* 2003;24:95-105.
341. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. *J Ocul Pharmacol Ther* 1996;12:389-400.
342. Storms WW, Pearlman DS, Chervinsky P, Grossman J, Halverson PC, Freitag JJ, et al. Effectiveness of azelastine nasal solution in seasonal allergic rhinitis. *Ear Nose Throat J* 1994;73:382-6, 90-4.
343. Banov CH, Lieberman P, Vasomotor Rhinitis Study Group. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. *Ann Allergy Asthma Immunol* 2001;86:28-35.
344. Smith PK, Collins J. Olopatadine 0.6% nasal spray protects from vasomotor challenge in patients with severe vasomotor rhinitis. *Am J Rhinol Allergy* 2011;25:e149-52.
345. Lumry W, Prenner B, Corren J, Wheeler W. Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily. *Ann Allergy Asthma Immunol* 2007;99:267-72.
346. Berger WE. Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis. *Expert Opin Drug Metab Toxicol* 2009;5:91-102.
347. Lieberman P. Management of allergic rhinitis with a combination antihistamine/anti-inflammatory agent. *J Allergy Clin Immunol* 1999;103(3 pt 2):S400-4.
348. Horak F. Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. *Ther Clin Risk Manag* 2008;4:1009-22.
349. Shah S, Berger W, Lumry W, La Force C, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. *Allergy Asthma Proc* 2009;30:628-33.
350. Corren J, Storms W, Bernstein J, Berger W, Nayak A, Sacks H, et al. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. *Clin Ther* 2005;27:543-53.
351. Berger W, Hampel F Jr, Bernstein J, Shah S, Sacks H, Meltzer EO. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2006;97:375-81.
352. Fairchild CJ, Meltzer EO, Roland PS, Wells D, Drake M, Wall GM. Comprehensive report of the efficacy, safety, quality of life, and work impact of olopatadine 0.6% and olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. *Allergy Asthma Proc* 2007;28:716-23.
353. Hampel FC Jr, Ratner PH, Amar NJ, van Bavel JH, Mohar D, Fairchild CJ, et al. Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. *Allergy Asthma Proc* 2006;27:202-7.
354. Meltzer EO, Hampel FC, Ratner PH, Bernstein DI, Larsen LV, Berger WE, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2005;95:600-6.
355. Ratner PH, Hampel FC, Amar NJ, van Bavel JH, Mohar D, Marple BF, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. *Ann Allergy Asthma Immunol* 2005;95:474-9.
356. Shah SR, Nayak A, Ratner P, Roland P, Michael Wall G. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. *Clin Ther* 2009;31:99-107.
357. Lieberman P, Meltzer EO, LaForce CF, Darter AL, Tort MJ. Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis. *Allergy Asthma Proc* 2011;32:151-8.
358. Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. *Ann Allergy Asthma Immunol* 1998;81:478-518.
359. Greiner AN, Meltzer EO. Overview of the treatment of allergic rhinitis and nonallergic rhinopathy. *Proceedings of the American Thoracic Society* 2011;8:121-31.
360. Kaszuba SM, Baroody FM, deTineo M, Haney L, Blair C, Naclerio RM. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. *Arch Intern Med* 2001;161:2581-7.
361. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. *J Allergy Clin Immunol* 2010;126:466-76.
362. Bielory L, Chun Y, Bielory BP, Canonica GW. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. *Allergy* 2011;66:686-93.
363. Rodrigo GJ, Neffen H. Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review. *Clin Exp Allergy* 2011;41:160-70.

364. Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. *Ann Allergy Asthma Immunol* 2007;98:12-21.
365. van Bavel JH, Ratner PH, Amar NJ, Hampel FC Jr, Melchior A, Dunbar SA, et al. Efficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with seasonal allergic rhinitis. *Allergy Asthma Proc* 2012;33:386-96.
366. Meltzer EO, Jacobs RL, LaForce CF, Kelley CL, Dunbar SA, Tantry SK. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. *Allergy Asthma Proc* 2012;33:249-57.
367. Ratner PH, Andrews C, Martin B, Howland W, Desai SY, Huang H, et al. A study of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol in patients with seasonal allergic rhinitis from mountain cedar pollen. *Allergy Asthma Proc* 2012;33:27-35.
368. Mener DJ, Shargorodsky J, Varadhan R, Lin SY. Topical intranasal corticosteroids and growth velocity in children: a meta-analysis. *Int Forum Allergy Rhinol* 2015;5:95-103.
369. Opatowsky I, Feldman RM, Gross R, Feldman ST. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. *Ophthalmology* 1995;102:177-9.
370. Valenzuela CV, Liu JC, Vila PM, Simon L, Doering M, Lieu JEC. Intranasal corticosteroids do not lead to ocular changes: a systematic review and metaanalysis. *Laryngoscope* 2019;129:6-12.
371. Valenzuela CV, Liu JC, Vila PM, Simon L, Doering M, Lieu JEC. Intranasal corticosteroids do not lead to ocular changes: a systematic review and meta-analysis. *Laryngoscope* 2019;129:6-12.
372. Biggs TC, Baruah P, Mainwaring J, Harries PG, Salib RJ. Treatment algorithm for oral anticoagulant and antiplatelet therapy in epistaxis patients. *J Laryngol Otol* 2013;127:483-8.
373. Smith J, Siddiq S, Dyer C, Rainsbury J, Kim D. Epistaxis in patients taking oral anticoagulant and antiplatelet medication: prospective cohort study. *J Laryngol Otol* 2011;125:38-42.
374. Abrisch V, Brozek A, Boyle TR, Chyou PH, Yale SH. Risk factors for recurrent spontaneous epistaxis. *Mayo Clin Proc* 2014;89:1636-43.
375. Menger H, Lin AE, Toriello HV, Bernert G, Spranger JW. Vitamin K deficiency embryopathy: a phenocopy of the warfarin embryopathy due to a disorder of embryonic vitamin K metabolism. *Am J Med Genet* 1997;72:129-34.
376. Baraniuk JN. Sensory, parasympathetic, and sympathetic neural influences in the nasal mucosa. *J Allergy Clin Immunol* 1992;90:1045-50.
377. Baraniuk JN. Neurogenic mechanisms in rhinosinusitis. *Curr Allergy Asthma Rep* 2001;1:252-61.
378. Devillier P, Dessanges JF, Rakotosihanaka F, Ghaem A, Boushey HA, Lockhart A, et al. Nasal response to substance P and methacholine in subjects with and without allergic rhinitis. *Eur Respir J* 1988;1:356-61.
379. Harlor EJ, Greene JS, Considine C. Traumatic unilateral vasomotor rhinitis. *Ear Nose Throat J* 2012;91:E4-6.
380. Kavut AB, Kalpaklioglu F, Atasoy P. Contribution of neurogenic and allergic ways to the pathophysiology of nonallergic rhinitis. *Int Arch Allergy Immunol* 2013;160:184-91.
381. Norlander T, Bolger WE, Stierna P, Uddman R, Carlsoo B. A comparison of morphological effects on the rabbit nasal and sinus mucosa after surgical denervation and topical capsaicin application. *Eur Arch Otorhinolaryngol* 1996;253:205-13.
382. Gerth Van Wijk R, Terreehorst IT, Mulder PG, Garrelts IM, Blom HM, Popering S. Intranasal capsaicin is lacking therapeutic effect in perennial allergic rhinitis to house dust mite: a placebo-controlled study. *Clin Exp Allergy* 2000;30:1792-8.
383. Cheng J, Yang XN, Liu X, Zhang SP. Capsaicin for allergic rhinitis in adults. *Cochrane Database Syst Rev* 2006;(2):CD004460.
384. Gevorgyan A, Segboer C, Gorissen R, van Drunen CM, Fokkens W. Capsaicin for non-allergic rhinitis. *Cochrane Database Syst Rev* 2015;(7):CD010591.
385. Bernstein JA, Davis BP, Picard JK, Cooper JP, Zheng S, Levin LS. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. *Ann Allergy Asthma Immunol* 2011;107:171-8.
386. Ciabatti PG, D'Ascanio L. Intranasal Capsicum spray in idiopathic rhinitis: a randomized prospective application regimen trial. *Acta Otolaryngol* 2009;129:367-71.
387. Filiaci F, Zambetti G, Ciofalo A, Luce M, Masieri S, Lovecchio A. Local treatment of aspecific nasal hyperreactivity with capsaicin. *Allergol Immunopathol (Madr)* 1994;22:264-8.
388. Marabini S, Ciabatti PG, Polli G, Fusco BM, Geppetti P. Beneficial effects of intranasal applications of capsaicin in patients with vasomotor rhinitis. *Eur Arch Otorhinolaryngol* 1991;248:191-4.
389. Rinder J. Sensory neuropeptides and nitric oxide in nasal vascular regulation. *Acta Physiol Scand Suppl* 1996;632:1-45.
390. Zheng C, Wang Z, Lacroix JS. Effect of intranasal treatment with capsaicin on the recurrence of polyps after polypectomy and ethmoidectomy. *Acta Otolaryngol* 2000;120:62-6.
391. Blom HM, Van Rijswijk JB, Garrelts IM, Mulder PG, Timmermans T, Gerth van Wijk R. Intranasal capsaicin is efficacious in non-allergic, non-infectious perennial rhinitis. A placebo-controlled study. *Clin Exp Allergy* 1997;27:796-801.
392. Van Rijswijk JB, Boeke EL, Keizer JM, Mulder PG, Blom HM, Fokkens WJ. Intranasal capsaicin reduces nasal hyperreactivity in idiopathic rhinitis: a double-blind randomized application regimen study. *Allergy* 2003;58:754-61.
393. Van Gerven L, Steelant B, Alpizar YA, Talavera K, Hellings PW. Therapeutic effect of capsaicin nasal treatment in patients with mixed rhinitis unresponsive to intranasal steroids. *Allergy* 2018;73:248-50.
394. Eccles R, Eriksson M, Garreffa S, Chen SC. The nasal decongestant effect of xylometazoline in the common cold. *Am J Rhinol* 2008;22:491-6.
395. Togias A, Naclerio RM, Proud D, Baumgarten C, Peters S, Creticos PS, et al. Mediator release during nasal provocation: a model to investigate the pathophysiology of rhinitis. *Am J Med* 1985;79:26-33.
396. Eskizmir G, Hircin Z, Ozyurt B, Unlu H. A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects. *Eur J Clin Pharmacol* 2011;67:19-23.
397. Reinecke S, Tschaikin M. [Investigation of the effect of oxymetazoline on the duration of rhinitis]. *MMW Fortschr Med* 2005;147:46.
398. Barnes ML, Bialosterski BT, Gray RD, Fardon TC, Lipworth BJ. Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis. *Rhinology* 2005;43:291-5.
399. Morris S, Eccles R, Martez SJ, Riker DK, Witek TJ. An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion. *Am J Rhinol* 1997;11:109-15.
400. Archontaki M, Symvoulakis EK, Hagiannou JK, Stamou AK, Kastrinakis S, Bizaki AJ, et al. Increased frequency of rhinitis medicamentosa due to media advertising for nasal topical decongestants. *B-ENT* 2009;5:159-62.
401. Yoo JK, Seikaly H, Calhoun KH. Extended use of topical nasal decongestants. *Laryngoscope* 1997;107:40-3.
402. Petruson B. Treatment with xylometazoline (Otrivin) nose drops over a six-week period. *Rhinology* 1981;19:167-72.
403. Watanabe H, Foo TH, Djazaeri B, Duncombe P, Mackay IS, Durham SR. Oxymetazoline nasal spray three times daily for four weeks in normal subjects is not associated with rebound congestion or tachyphylaxis. *Rhinology* 2003;41:167-74.
404. Mehuys E, Gevaert P, Brusselle G, Van Hees T, Adriaens E, Christiaens T, et al. Self-medication in persistent rhinitis: overuse of decongestants in half of the patients. *J Allergy Clin Immunol Pract* 2014;2:313-9.
405. Baroody FM, Brown D, Gavanescu L, DeTineo M, Naclerio RM. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. *J Allergy Clin Immunol* 2011;127:927-34.
406. Meltzer EO, Bernstein DI, Prenner BM, Berger WE, Shekar T, Teper AA. Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis. *Am J Rhinol Allergy* 2013;27:102-8.
407. Department of Health and Human Services. Final Monograph for OTC Nasal Decongestant Drug Products; Final Rule. *Fed Regist* 1994;59(162):[FR Doc No: 94-20456].
408. Nathan RA, Finn AF Jr, LaForce C, Ratner P, Chapman D, de Guia EC, et al. Comparison of cetirizine-pseudoephedrine and placebo in patients with seasonal allergic rhinitis and concomitant mild-to-moderate asthma: randomized, double-blind study. *Ann Allergy Asthma Immunol* 2006;97:389-96.
409. Eccles R. Substitution of phenylephrine for pseudoephedrine as a nasal decongestant: an illogical way to control methamphetamine abuse. *Br J Clin Pharmacol* 2007;63:10-4.
410. Meltzer EO, Ratner PH, McGraw T. Oral phenylephrine HCl for nasal congestion in seasonal allergic rhinitis: a randomized, open-label, placebo-controlled study. *J Allergy Clin Immunol Pract* 2015;3:702-8.
411. Meltzer EO, Ratner PH, McGraw T. Phenylephrine hydrochloride modified-release tablets for nasal congestion: a randomized, placebo-controlled trial in allergic rhinitis patients. *Ann Allergy Asthma Immunol* 2016;116:66-71.
412. Horak F, Ziegelmayer P, Ziegelmayer R, Lemell P, Yao R, Staudinger H, et al. A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber. *Ann Allergy Asthma Immunol* 2009;102:116-20.
413. Greiner AN, Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. *J Allergy Clin Immunol* 2006;118:985-98.

414. Salerno SM, Jackson JL, Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis. *Arch Intern Med* 2005;165:1686-94.
415. Department of Health and Human Services, Food and Drug Administration. Labeling of nasal decongestant drug products. Cold, cough, allergy, bronchodilator, and antihistaminic drug products for over-the-counter human use. 21CFR341.80.c. Available at: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=341&showFR=1>. Accessed September 4, 2020.
416. Roberge RJ, Hirani KH, Rowland PL 3rd, Berkeley R, Krenzlok EP. Dextromethorphan- and pseudoephedrine-induced agitated psychosis and ataxia: case report. *J Emerg Med* 1999;17:285-8.
417. Marinetti L, Lehman L, Casto B, Harshbarger K, Kubiczek P, Davis J. Over-the-counter cold medications-postmortem findings in infants and the relationship to cause of death. *J Anal Toxicol* 2005;29:738-43.
418. Sauder KL, Brady WJ Jr, Hennes H. Visual hallucinations in a toddler: accidental ingestion of a sympathomimetic over-the-counter nasal decongestant. *Am J Emerg Med* 1997;15:521-6.
419. Pentel P. Toxicity of over-the-counter stimulants. *JAMA* 1984;252:1898-903.
420. Kirkegaard J, Mygind N, Molgaard F, Grahne B, Holopainen E, Malmberg H, et al. Ordinary and high-dose ipratropium in perennial nonallergic rhinitis. *J Allergy Clin Immunol* 1987;79:585-90.
421. Georgitis JW, Banov C, Boggs PB, Dockhorn R, Grossman J, Tinkelman D, et al. Ipratropium bromide nasal spray in non-allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life. *Clin Exp Allergy* 1994;24:1049-55.
422. Becker B, Borum S, Nielsen K, Mygind N, Borum P. A time-dose study of the effect of topical ipratropium bromide on methacholine-induced rhinorrhea in patients with perennial non-allergic rhinitis. *Clin Otolaryngol Allied Sci* 1997;22:132-4.
423. Sheikh A, Singh Panesar S, Salvilla S, Dhami S. Hay fever in adolescents and adults. *BMJ Clin Evid* 2009;2009:0509.
424. Kirkegaard J, Mygind N, Molgaard F, Holopainen E, Malmberg H, Brondbo K, et al. Ipratropium treatment of rhinorrhea in perennial nonallergic rhinitis. A Nordic multicenter study. *Acta Otolaryngol Suppl* 1988;449:93-5.
425. Bonadonna P, Senna G, Zanon P, Cocco G, Dorizzi R, Gani F, et al. Cold-induced rhinitis in skiers—clinical aspects and treatment with ipratropium bromide nasal spray: a randomized controlled trial. *Am J Rhinol* 2001;15:297-301.
426. Kaiser HB, Findlay SR, Georgitis JW, Grossman J, Ratner PH, Tinkelman DG, et al. The anticholinergic agent, ipratropium bromide, is useful in the treatment of rhinorrhea associated with perennial allergic rhinitis. *Allergy Asthma Proc* 1998;19:23-9.
427. Kaiser HB, Findlay SR, Georgitis JW, Grossman J, Ratner PH, Tinkelman DG, et al. Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%. *J Allergy Clin Immunol* 1995;95:1128-32.
428. Bronsky EA, Druce H, Findlay SR, Hampel FC, Kaiser H, Ratner P, et al. A clinical trial of ipratropium bromide nasal spray in patients with perennial nonallergic rhinitis. *J Allergy Clin Immunol* 1995;95:1117-22.
429. Sanwkarja S, Schmitz PI, Dieges PH. The effect of locally applied ipratropium aerosol on the nasal methacholine challenge in patients with allergic and non-allergic rhinitis. *Ann Allergy* 1986;56:162-6.
430. Ostberg B, Winther B, Mygind N. Cold air-induced rhinorrhea and high-dose ipratropium. *Arch Otolaryngol Head Neck Surg* 1987;113:160-2.
431. Ratner PH, Ehrlich PM, Fineman SM, Meltzer EO, Skoner DP. Use of intranasal cromolyn sodium for allergic rhinitis. *Mayo Clin Proc* 2002;77:350-4.
432. Zhang T, Finn DF, Barlow JW, Walsh JJ. Mast cell stabilisers. *Eur J Pharmacol* 2016;778:158-68.
433. Handelman NI, Friday GA, Schwartz HJ, Kuhn FS, Lindsay DE, Koors PG, et al. Cromolyn sodium nasal solution in the prophylactic treatment of pollen-induced seasonal allergic rhinitis. *J Allergy Clin Immunol* 1977;59:237-42.
434. Knight A, Underdown BJ, Demanuele F, Hargreave FE. Disodium cromoglycate in ragweed-allergic rhinitis. *J Allergy Clin Immunol* 1976;58:278-83.
435. Meltzer EO, NasalCrom Study Group. Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study. *Clin Ther* 2002;24:942-52.
436. Cohan RH, Bloom FL, Rhoades RB, Wittig HJ, Haugh LD. Treatment of perennial allergic rhinitis with cromolyn sodium: double-blind study on 34 adult patients. *J Allergy Clin Immunol* 1976;58:121-8.
437. Warland A, Kapstad B. The effect of disodium cromoglycate in perennial allergic rhinitis: a controlled clinical study. *Acta Allergol* 1977;32:195-9.
438. Orgel HA, Meltzer EO, Kemp JP, Ostrom NK, Welch MJ. Comparison of intranasal cromolyn sodium, 4%, and oral terfenadine for allergic rhinitis: symptoms, nasal cytology, nasal ciliary clearance, and rhinomanometry. *Ann Allergy* 1991;66:237-44.
439. Taylor G, Shivalkar PR. Disodium cromoglycate: laboratory studies and clinical trial in allergic rhinitis. *Clin Allergy* 1971;1:189-98.
440. Pelikan Z. The diagnostic approach to immediate hypersensitivity in patients with allergic rhinitis; a comparison of nasal challenges and serum rast. *Ann Allergy* 1983;51:395-400.
441. Kolly M, Pecoud A. Comparison of levocabastine, a new selective H1-receptor antagonist, and disodium cromoglycate, in a nasal provocation test with allergen. *Br J Clin Pharmacol* 1986;22:389-94.
442. Davies HJ. Exposure of hay fever subjects to an indoor environmental grass pollen challenge system. *Clin Allergy* 1985;15:419-27.
443. Schatz M, Zeiger RS, Harden K, Hoffman CC, Chilingar L, Petitti D. The safety of asthma and allergy medications during pregnancy. *J Allergy Clin Immunol* 1997;100:301-6.
444. Ibanez MD, Laso MT, Martinez-San Irineo M, Alonso E. Anaphylaxis to disodium cromoglycate. *Ann Allergy Asthma Immunol* 1996;77:185-6.
445. Wass U, Plaschke P, Bjorkander J, Belin L. Assay of specific IgE antibodies to disodium cromoglycate in serum from a patient with an immediate hypersensitivity reaction. *J Allergy Clin Immunol* 1988;81:750-7.
446. Lofkvist T, Rundcrantz H, Svensson G. Treatment of vasomotor rhinitis with intranasal disodium cromoglycate (SCG): results from a double-blind cross-over study. *Acta Allergol* 1977;32:35-43.
447. Donovan R, Kapadia R. The effect of disodium cromoglycate on nasal polyp symptoms. *J Laryngol Otol* 1972;86:731-9.
448. Schata M, Jorde W, Richarz-Barthauer U. Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol* 1991;87:873-8.
449. Welsh PW, Stricker WE, Chu CP, Naessens JM, Reese ME, Reed CE, et al. Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. *Mayo Clin Proc* 1987;62:125-34.
450. Heatley DG, McConnell KE, Kille TL, Levenson GE. Nasal irrigation for the alleviation of sinonasal symptoms. *Otolaryngol Head Neck Surg* 2001;125:44-8.
451. Rabago D, Barrett B, Marchand L, Maberry R, Mundt M. Qualitative aspects of nasal irrigation use by patients with chronic sinus disease in a multimethod study. *Ann Fam Med* 2006;4:295-301.
452. Centers for Disease Control and Prevention. Sinus rinsing for health or religious practice 2017. Updated February 28, 2017. Available at: <https://www.cdc.gov/parasites/naegleria/sinus-rinsing.html>. Accessed August 16, 2020.
453. US Food and Drug Administration. Is rinsing your sinuses with neti pots safe? Updated January 24, 2017. Available at: <https://www.fda.gov/consumers/consumer-updates/rinsing-your-sinuses-neti-pots-safe>. Accessed January 28, 2020.
454. Hermelingmeier KE, Weber RK, Hellmich M, Heubach CP, Mosges R. Nasal irrigation as an adjunctive treatment in allergic rhinitis: a systematic review and meta-analysis. *Am J Rhinol Allergy* 2012;26:e119-25.
455. Head K, Snidvongs K, Glew S, Scadding G, Schilder AG, Philpott C, et al. Saline irrigation for allergic rhinitis. *Cochrane Database Syst Rev* 2018;6:CD012597.
456. Chen JR, Jin L, Li XY. The effectiveness of nasal saline irrigation (seawater) in treatment of allergic rhinitis in children. *Int J Pediatr Otorhinolaryngol* 2014;78:1115-8.
457. de Souza Campos Fernandes S, Ribeiro de Andrade C, da Cunha Ibiapina C. Application of peak nasal inspiratory flow reference values in the treatment of allergic rhinitis. *Rhinology* 2014;52:133-6.
458. Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. *Ann Allergy Asthma Immunol* 2010;105:168-73.
459. Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW, et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. *Int Arch Allergy Immunol* 2013;161:369-77.
460. Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. *J Allergy Clin Immunol* 2012;129:1282-9.e10.
461. Berger W, Bousquet J, Fox AT, Just J, Muraro A, Nieto A, et al. MP-AzeFlu is more effective than fluticasone propionate for the treatment of allergic rhinitis in children. *Allergy* 2016;71:1219-22.
462. Price D, Shah S, Bhatia S, Bachert C, Berger W, Bousquet J, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. *J Investig Allergol Clin Immunol* 2013;23:495-503.
463. Guo L, Sun X, Yang J, Liu J, Wang D. [Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis]. *Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2015;29:243-5, 251.
464. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. *Allergy* 2008;63:1292-300.
465. Berger WE, Shah S, Lieberman P, Hadley J, Price D, Munzel U, et al. Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of

- azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis. *J Allergy Clin Immunol Pract* 2014; 2:179-85.
466. Segall N, Prenner B, Lumry W, Caracta CF, Tantry SK. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. *Allergy Asthma Proc* 2019;40:301-10.
467. Gross GN, Berman G, Amar NJ, Caracta CF, Tantry SK. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2019;122:630-8.e3.
468. Hampel FC, Pedinoff AJ, Jacobs RL, Caracta CF, Tantry SK. Olopatadine-mometasone combination nasal spray: evaluation of efficacy and safety in patients with seasonal allergic rhinitis. *Allergy Asthma Proc* 2019;40:261-72.
469. Patel P, Salapatek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. *Ann Allergy Asthma Immunol* 2019;122:160-6.e1.
470. Andrews CP, Mohar D, Salhi Y, Tantry SK. Efficacy and safety of twice-daily and once-daily olopatadine-mometasone combination nasal spray for seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2020;124:171-8.e2.
471. LaForce CF, Carr W, Tilles SA, Chippis BE, Storms W, Meltzer EO, et al. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. *Allergy Asthma Proc* 2010;31:132-40.
472. Salapatek AM, Lee J, Patel D, D'Angelo P, Liu J, Zimmerer RO Jr, et al. Solubilized nasal steroid (CDX-947) when combined in the same solution nasal spray with an antihistamine (CDX-313) provides improved, fast-acting symptom relief in patients with allergic rhinitis. *Allergy Asthma Proc* 2011;32:221-9.
473. Dockhorn R, Aaronson D, Bronsky E, Chervinsky P, Cohen R, Ehtessabian R, et al. Ipratropium bromide nasal spray 0.03% and beclomethasone nasal spray alone and in combination for the treatment of rhinorrhea in perennial rhinitis. *Ann Allergy Asthma Immunol* 1999;82:349-59.
474. Vaidyanathan S, Williamson P, Clearie K, Khan F, Lipworth B. Fluticasone reverses oxymetazoline-induced tachyphylaxis of response and rebound congestion. *Am J Respir Crit Care Med* 2010;182:19-24.
475. Thongngarm T, Assanasen P, Pradubpongsa P, Tantilipikorn P. The effectiveness of oxymetazoline plus intranasal steroid in the treatment of chronic rhinitis: a randomised controlled trial. *Asian Pac J Allergy Immunol* 2016;34:30-7.
476. Chervinsky P, Nayak A, Rooklin A, Danzig M. Efficacy and safety of desloratadine/pseudoephedrine tablet, 2.5/120 mg two times a day, versus individual components in the treatment of patients with seasonal allergic rhinitis. *Allergy Asthma Proc* 2005;26:391-6.
477. Grubbe RE, Lumry WR, Anolik R. Efficacy and safety of desloratadine/pseudoephedrine combination vs its components in seasonal allergic rhinitis. *J Investig Allergol Clin Immunol* 2009;19:117-24.
478. Pleskow W, Grubbe R, Weiss S, Lutsky B. Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2005;94:348-54.
479. Eccles R, Martensson K, Chen SC. Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold. *Curr Med Res Opin* 2010;26:889-99.
480. Ciebiada M, Ciebiada MG, Kmiecik T, DuBuske LM, Gorski P. Quality of life in patients with persistent allergic rhinitis treated with montelukast alone or in combination with levocetirizine or desloratadine. *J Investig Allergol Clin Immunol* 2008;18:343-9.
481. Ciebiada M, Gorska-Ciebiada M, Barylski M, Kmiecik T, Gorski P. Use of montelukast alone or in combination with desloratadine or levocetirizine in patients with persistent allergic rhinitis. *Am J Rhinol Allergy* 2011;25:e1-6.
482. Cingi C, Gunhan K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. *Laryngoscope* 2010;120:1718-23.
483. Ho CY, Tan CT. Comparison of antileukotrienes and antihistamines in the treatment of allergic rhinitis. *Am J Rhinol* 2007;21:439-43.
484. Yamamoto H, Yamada T, Sakashita M, Kubo S, Susuki D, Tokunaga T, et al. Efficacy of prophylactic treatment with montelukast and montelukast plus add-on loratadine for seasonal allergic rhinitis. *Allergy Asthma Proc* 2012;33:e17-22.
485. Ciebiada M, Barylski M, Gorska-Ciebiada M. Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine. *Am J Rhinol Allergy* 2013;27:e58-62.
486. Lu S, Malice MP, Dass SB, Reiss TF. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis. *J Asthma* 2009;46: 878-83.
487. Kurowski M, Kuna P, Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. *Allergy* 2004;59:280-8.
488. Keskin O, Alyamac E, Tuncer A, Dogan C, Adalioglu G, Sekerel BE. Do the leukotriene receptor antagonists work in children with grass pollen-induced allergic rhinitis? *Pediatr Allergy Immunol* 2006;17:259-68.
489. Barnes ML, Menzies D, Fardon TC, Burns P, Wilson AM, Lipworth BJ. Combined mediator blockade or topical steroid for treating the unified allergic airway. *Allergy* 2007;62:73-80.
490. Esteite R, deTineo M, Naclerio RM, Baroody FM. Effect of the addition of montelukast to fluticasone propionate for the treatment of perennial allergic rhinitis. *Ann Allergy Asthma Immunol* 2010;105:155-61.
491. Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. *Methods Find Exp Clin Pharmacol* 2010;32:669-74.
492. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. *J Allergy Clin Immunol* 1996;97:617-26.
493. Day JH, Ellis AK, Rafeiro E, Ratz JD, Briscoe MP. Experimental models for the evaluation of treatment of allergic rhinitis. *Ann Allergy Asthma Immunol* 2006; 96:263-78.
494. Ellis AK, North ML, Walker T, Steacy LM. Environmental exposure unit: a sensitive, specific, and reproducible methodology for allergen challenge. *Ann Allergy Asthma Immunol* 2013;111:323-8.
495. Bousquet J, Meltzer EO, Couroux P, Koltun A, Kopietz F, Munzel U, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. *J Allergy Clin Immunol Pract* 2018;6:1726-32.e6.
496. Gomez-Hervás J, García-Valdecasas Bernal J, Fernandez-Prada M, Palomeque-Vera JM, Garcia-Ramos A, Fernandez-Castany BF. Effects of oxymetazoline on nasal flow and maximum aerobic exercise performance in patients with inferior turbinate hypertrophy. *Laryngoscope* 2015;125:1301-6.
497. Ellis AK, Zhu Y, Steacy LM, Walker T, Day JH. A four-way, double-blind, randomized, placebo controlled study to determine the efficacy and speed of azelastine nasal spray, versus loratadine, and cetirizine in adult subjects with allergen-induced seasonal allergic rhinitis. *Allergy Asthma Clin Immunol* 2013;9:16.
498. Patel P, D'Andrea C, Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. *Am J Rhinol* 2007;21:499-503.
499. Patel D, Garadi R, Brubaker M, Conroy JP, Kaji Y, Crenshaw K, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. *Allergy Asthma Proc* 2007;28:592-9.
500. Wagenmann M, Baroody FM, Jankowski R, Nadal JC, Roecker-Cooper M, Wood CC, et al. Onset and duration of inhibition of ipratropium bromide nasal spray on methacholine-induced nasal secretions. *Clin Exp Allergy* 1994;24:288-90.
501. Horak F, Stubner UP, Ziegelmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. *J Allergy Clin Immunol* 2002;109:956-61.
502. Stubner P, Ziegelmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit—the Vienna Challenge Chamber (VCC). *Curr Med Res Opin* 2004;20:891-902.
503. Lockett RF, Widlitz MD, Mitchell DQ, Lumry W, Dockhorn R, Woehler T, et al. Comparative study of cetirizine and terfenadine versus placebo in the symptomatic management of seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 1996;76:448-54.
504. Tenn MW, Steacy LM, Ng CC, Ellis AK. Onset of action for loratadine tablets for the symptomatic control of seasonal allergic rhinitis in adults challenged with ragweed pollen in the Environmental Exposure Unit: a post hoc analysis of total symptom score. *Allergy Asthma Clin Immunol* 2018;14:5.
505. Gutkowski A, Bedard P, Del Carpio J, Hebert J, Prevost M, Schulz J, et al. Comparison of the efficacy and safety of loratadine, terfenadine, and placebo in the treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol* 1988;81:902-7.
506. Georgitis JW, Meltzer EO, Kaliner M, Weiler J, Berkowitz R. Onset-of-action for antihistamine and decongestant combinations during an outdoor challenge. *Ann Allergy Asthma Immunol* 2000;84:451-9.
507. Patel P, Patel D, Kunjibettu S, Hall N, Wingertzahn MA. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. *Ear Nose Throat J* 2008;87:340-53.
508. Couroux P, Kunjibettu S, Hall N, Wingertzahn MA. Onset of action of ciclesonide once daily in the treatment of seasonal allergic rhinitis. *Ann Allergy Asthma Immunol* 2009;102:62-8.
509. Ratner PH, Wingertzahn MA, van Bavel JH, Hampel F, Darken PF, Shah T. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol* 2006;118:1142-8.

510. Meltzer EO, Berger WE, Berkowitz RB, Bronsky EA, Dvorin DJ, Finn AF, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. *J Allergy Clin Immunol* 1999;104:107-14.
511. Day JH, Briscoe MP, Rafeiro E, Ellis AK, Pettersson E, Akerlund A. Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. *J Allergy Clin Immunol* 2000;105:489-94.
512. Day J, Carrillo T. Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis. *J Allergy Clin Immunol* 1998;102:902-8.
513. Fokkens WJ, Cserhati E, dos Santos JM, Praca F, van Zanten M, Schade A, et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. *Ann Allergy Asthma Immunol* 2002;89:279-84.
514. Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. *J Allergy Clin Immunol* 2007;119:1430-7.
515. Meltzer EO, Rickard KA, Westlund RE, Cook CK. Onset of therapeutic effect of fluticasone propionate aqueous nasal spray. *Ann Allergy Asthma Immunol* 2001;86:286-91.
516. Day JH, Briscoe MP, Ratz JD. Efficacy of levocetirizine compared with montelukast in subjects with ragweed-induced seasonal allergic rhinitis in the Environmental Exposure Unit. *Allergy Asthma Proc* 2008;29:304-12.
517. Patel P, Patel D. Efficacy comparison of levocetirizine vs montelukast in ragweed sensitized patients. *Ann Allergy Asthma Immunol* 2008;101:287-94.
518. van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO, Ratner PH, Menten J, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. *Allergy* 2003;58:1268-76.
519. NasalCrom package insert. New York (NY): Upjohn, Pfizer; 1999.
520. Jacobs R, Lieberman P, Kent E, Silvey M, Locantore N, Philpot EE. Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment. *Allergy Asthma Proc* 2009;30:120-7.
521. Kirtsreesakul V, Hararuk K, Leelapong J, Ruttanaphol S. Clinical efficacy of nasal steroids on nonallergic rhinitis and the associated inflammatory cell phenotypes. *Am J Rhinol Allergy* 2015;29:343-9.
522. Webb DR, Meltzer EO, Finn AF Jr, Rickard KA, Pepsin PJ, Westlund R, et al. Intranasal fluticasone propionate is effective for perennial nonallergic rhinitis with or without eosinophilia. *Ann Allergy Asthma Immunol* 2002;88:385-90.
523. Segboer C, Gevorgyan A, Avdeeva K, Chusakul S, Kanjanaumporn J, Aumjaturapat S, et al. Intranasal corticosteroids for non-allergic rhinitis. *Cochrane Database Syst Rev* 2019;2019:CD010592.
524. Watts AM, Cripps AW, West NP, Cox AJ. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. *Front Pharmacol* 2019;10:294.
525. Kalpaklioglu AF, Kavut AB. Comparison of azelastine versus triamcinolone nasal spray in allergic and nonallergic rhinitis. *Am J Rhinol Allergy* 2010;24:29-33.
526. Abtahi SM, Hashemi SM, Abtahi SH, Bastani B. Septal injection in comparison with inferior turbinates injection of botulinum toxin A in patients with allergic rhinitis. *J Res Med Sci* 2013;18:400-4.
527. Sapci T, Yazici S, Evcimik MF, Bozkurt Z, Karavus A, Ugurlu B, et al. Investigation of the effects of intranasal botulinum toxin type a and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia. *Rhinology* 2008;46:45-51.
528. Braun T, Gurkov R, Kramer MF, Krause E. Septal injection of botulinum neurotoxin A for idiopathic rhinitis: a pilot study. *Am J Otolaryngol* 2012;33:64-7.
529. Rohrbach S, Junghans K, Kohler S, Laskawi R. Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis. *Head Face Med* 2009;5:18.
530. Ozcan C, Ismi O. Botulinum toxin for rhinitis. *Curr Allergy Asthma Rep* 2016;16:58.
531. Halderman A, Sindwani R. Surgical management of vasomotor rhinitis: a systematic review. *Am J Rhinol Allergy* 2015;29:128-34.
532. Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. *Allergy* 2017;72:1597-631.
533. Nurmatov U, Dhami S, Arasi S, Roberts G, Pfaar O, Muraro A, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. *Clin Transl Allergy* 2017;7:24.
534. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. *J Allergy Clin Immunol* 2011;127(1 suppl):S1-55.
535. Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. *Pediatr Allergy Immunol* 2017;28:18-29.
536. Lin SY, Erekosima N, Suarez-Cuervo C, Ramanathan M, Kim JM, Ward D, et al. Allergen-specific immunotherapy for the treatment of allergic rhinoconjunctivitis and/or asthma: comparative effectiveness review. AHRQ Comparative Effectiveness Reviews 13-EHC061-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2013.
537. Scadding GW, Calderon MA, Shamji MH, Eifan AO, Penagos M, Dumitru F, et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: the GRASS randomized clinical trial. *JAMA* 2017;317:615-25.
538. Greenhawt M, Oppenheimer J, Nelson M, Nelson H, Lockey R, Lieberman P, et al. Sublingual immunotherapy: a focused allergen immunotherapy practice parameter update. *Ann Allergy Asthma Immunol* 2017;118:276-82.e2.
539. Calderon MA, Bernstein DI, Blaiss M, Andersen JS, Nolte H. A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis. *Clin Exp Allergy* 2014;44:1228-39.
540. Radulovic S, Wilson D, Calderon M, Durham S. Systematic reviews of sublingual immunotherapy (SLIT). *Allergy* 2011;66:740-52.
541. Nelson H, Cartier S, Allen-Ramey F, Lawton S, Calderon MA. Network meta-analysis shows commercialized subcutaneous and sublingual grass products have comparable efficacy. *J Allergy Clin Immunol Pract* 2015;3:256-66.e3.
542. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. *J Allergy Clin Immunol* 2010;126:558-66.
543. Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. *Health Technol Assess* 2013;17:vi, xi-xiv, 1-322.
544. Hankin CS, Cox L, Bronstone A, Wang Z. Allergy immunotherapy: reduced health care costs in adults and children with allergic rhinitis. *J Allergy Clin Immunol* 2013;131:1084-91.
545. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. *J Allergy Clin Immunol Pract* 2014;2:161-7.
546. Larenas-Linnemann DE, Hauswirth DW, Calabria CW, Sher LD, Rank MA. American Academy of Allergy, Asthma and Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions. *Allergy Asthma Proc* 2016;37:112-22.
547. Moote W, Kim H, Ellis AK. Allergen-specific immunotherapy. *Allergy Asthma Clin Immunol* 2018;14(Suppl 2):53.
548. Cox L, Li JT, Nelson H, Lockey R. Allergen immunotherapy: a practice parameter second update. *J Allergy Clin Immunol* 2007;120(3 suppl):S25-85.
549. Larenas-Linnemann DE, Gupta P, Mithani S, Ponda P. Survey on immunotherapy practice patterns: dose, dose adjustments, and duration. *Ann Allergy Asthma Immunol* 2012;108:373-8.e3.
550. Lee MS, Pittler MH, Shin BC, Kim JI, Ernst E. Acupuncture for allergic rhinitis: a systematic review. *Ann Allergy Asthma Immunol* 2009;102:269-79; quiz 79-81, 307.
551. Feng S, Han M, Fan Y, Yang G, Liao Z, Liao W, et al. Acupuncture for the treatment of allergic rhinitis: a systematic review and meta-analysis. *Am J Rhinol Allergy* 2015;29:57-62.
552. Zhou F, Yan LJ, Yang GY, Liu JP. Acupoint herbal patching for allergic rhinitis: a systematic review and meta-analysis of randomised controlled trials. *Clin Otolaryngol* 2015;40:551-68.
553. Xue CC, Zhang AL, Zhang CS, DaCosta C, Story DF, Thien FC. Acupuncture for seasonal allergic rhinitis: a randomized controlled trial. *Ann Allergy Asthma Immunol* 2015;115:317-24.e1.
554. Tille KS, White KM. Acupuncture for seasonal allergic rhinitis: is it ready for prime time? *Ann Allergy Asthma Immunol* 2015;115:258-9.
555. Brinkhaus B, Ortiz M, Witt CM, Roll S, Linde K, Pfab F, et al. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. *Ann Intern Med* 2013;158:225-34.
556. Ng DK, Chow PY, Ming SP, Hong SH, Lau S, Tse D, et al. A double-blind, randomized, placebo-controlled trial of acupuncture for the treatment of childhood persistent allergic rhinitis. *Pediatrics* 2004;114:1242-7.
557. Luo Q, Zhang CS, Yang L, Zhang AL, Guo X, Xue CC, et al. Potential effectiveness of Chinese herbal medicine Yu ping feng san for adult allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials. *BMC Complement Altern Med* 2017;17:485.
558. Wang S, Tang Q, Qian W, Fan Y. Meta-analysis of clinical trials on traditional Chinese herbal medicine for treatment of persistent allergic rhinitis. *Allergy* 2012;67:583-92.

559. Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of allergic rhinitis: a systematic review. *Ann Allergy Asthma Immunol* 2007;99:483-95.
560. Zhang X, Lan F, Zhang Y, Zhang L. Chinese herbal medicine to treat allergic rhinitis: evidence from a meta-analysis. *Allergy Asthma Immunol Res* 2018;10:34-42.
561. Clarke TC, Black LI, Stussman BJ, Barnes PM, Nahin RL. Trends in the use of complementary health approaches among adults: United States, 2002-2012. *Natl Health Stat Report* 2015;79:1-16.
562. National Center for Complementary and Integrative Health. Butterbur. 2017. Available at: <https://nccih.nih.gov/health/butterbur>. Accessed August 16, 2020.
563. Jauregui I, Davila I, Sastre J, Bartra J, del Cuvillo A, Ferrer M, et al. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: the PEDRIAL study. *Pediatr Allergy Immunol* 2011;22:388-92.
564. Wong IY, Soh SE, Chng SY, Shek LP, Goh DY, Van Bever HP, et al. Compliance with topical nasal medication—an evaluation in children with rhinitis. *Pediatr Allergy Immunol* 2010;21:1146-50.
565. Roberts G, Xatzipsalti M, Borrego LM, Custovic A, Halken S, Hellings PW, et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. *Allergy* 2013;68:1102-16.
566. Shahar E, Nassar L, Kedem E, Hassoun G. Alpha-1 adrenergic antagonists induced severe rhinitis in patients with benign prostatic hyperplasia. *Curr Drug Saf* 2014;9:159-60.
567. Lurie A, Nadel JA, Roisman G, Siney H, Dusser DJ. Role of neutral endopeptidase and kininase II on substance P-induced increase in nasal obstruction in patients with allergic rhinitis. *Am J Respir Crit Care Med* 1994; 149:113-7.
568. Chatelain C, Pochon N, Lacroix JS. Functional effects of phosphoramidon and captopril on exogenous neuropeptides in human nasal mucosa. *Eur Arch Otorhinolaryngol* 1995;252:83-5.
569. Proud D, Naclerio RM, Meyers DA, Kagey-Sobotka A, Lichtenstein LM, Valentine MD. Effects of a single-dose pretreatment with captopril on the immediate response to nasal challenge with allergen. *Int Arch Allergy Appl Immunol* 1990;93:165-70.
570. Kaufman HS. Timolol-induced vasomotor rhinitis: a new iatrogenic syndrome. *Arch Ophthalmol* 1986;104:967-70.
571. Lee M. Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. *Clin Ther* 2011;33:1590-608.
572. Edelstein DR. Aging of the normal nose in adults. *Laryngoscope* 1996;106:1-25.
573. Rodriguez K, Rubinstein E, Ferguson BJ. Clear anterior rhinorrhea in the population. *Int Forum Allergy Rhinol* 2015;5:1063-7.
574. Parashar R, Amir M, Pakhare A, Rath P, Chaudhary L. Age related changes in autonomic functions. *J Clin Diagn Res* 2016;10:CC11-5.
575. Ciftci Z, Catli T, Hanci D, Cingi C, Erdogan G. Rhinorrhoea in the elderly. *Eur Arch Otorhinolaryngol* 2015;272:2587-92.
576. Bozek A. Pharmacological management of allergic rhinitis in the elderly. *Drugs Aging* 2017;34:21-8.
577. Ho JC, Chan KN, Hu WH, Lam WK, Zheng L, Tipoe GL, et al. The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia. *Am J Respir Crit Care Med* 2001;163:983-8.
578. Pinto JM, Jeswani S. Rhinitis in the geriatric population. *Allergy Asthma Clin Immunol* 2010;6:10.
579. Schrodter S, Biermann E, Halata Z. Histological evaluation of age-related changes in human respiratory mucosa of the middle turbinate. *Anat Embryol (Berl)* 2003;207:19-27.
580. Slavin RG. Treating rhinitis in the older population: special considerations. *Allergy Asthma Clin Immunol* 2009;5:9.
581. Sjogren I, Jonsson L, Koling A, Jansson C, Osterman K, Hakansson B. The effect of ipratropium bromide on nasal hypersecretion induced by methacholine in patients with vasomotor rhinitis: a double-blind, cross-over, placebo-controlled and randomized dose-response study. *Acta Otolaryngol* 1988;106:453-9.
582. Collamati A, Martone AM, Poscia A, Brandi V, Celi M, Marzetti E, et al. Anti-cholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. *Aging Clin Exp Res* 2016;28:25-35.
583. Berard A, Sheehy O, Kurzinger ML, Juhaeri J. Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes. *J Allergy Clin Immunol* 2016;138:97-104.e7.
584. Garavello W, Somigliana E, Acaia B, Gaini L, Pignataro L, Gaini RM. Nasal lavage in pregnant women with seasonal allergic rhinitis: a randomized study. *Int Arch Allergy Immunol* 2010;151:137-41.
585. Etwel F, Djokanovic N, Moretti ME, Boskovic R, Martinovic J, Koren G. The fetal safety of cetirizine: an observational cohort study and meta-analysis. *J Obstet Gynaecol* 2014;34:392-9.
586. Golembesky A, Cooney M, Boev R, Schlit AF, Bentz JWG. Safety of cetirizine in pregnancy. *J Obstet Gynaecol* 2018;38:940-5.
587. Li Q, Mitchell AA, Werler MM, Yau WP, Hernandez-Diaz S. Assessment of antihistamine use in early pregnancy and birth defects. *J Allergy Clin Immunol Pract* 2013;1:666-74.e1.
588. Kallen B, Olausson PO. No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy. *Int J Med Sci* 2006;3:106-7.
589. Gilboa SM, Ailes EC, Rai RP, Anderson JA, Honein MA. Antihistamines and birth defects: a systematic review of the literature. *Exp Opin Drug Saf* 2014; 13:1667-98.
590. Yau WP, Mitchell AA, Lin KJ, Werler MM, Hernandez-Diaz S. Use of decongestants during pregnancy and the risk of birth defects. *Am J Epidemiol* 2013;178: 198-208.
591. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. *Teratology* 1992;45:361-7.
592. Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJ. Maternal medications and environmental exposures as risk factors for gastroschisis. *Teratology* 1996;54: 84-92.
593. Kallen BA, Olausson PO. Use of oral decongestants during pregnancy and delivery outcome. *Am J Obstet Gynecol* 2006;194:480-5.
594. Caverro-Carbonell C, Vinkel-Hansen A, Rabanque-Hernandez MJ, Martos C, Garne E. Fetal exposure to montelukast and congenital anomalies: a population based study in Denmark. *Birth Defects Res* 2017;109:452-9.
595. Sarkar M, Koren G, Kalra S, Ying A, Smorlesi C, De Santis M, et al. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. *Eur J Clin Pharmacol* 2009;65:1259-64.
596. Bakhireva LN, Jones KL, Schatz M, Klonoff-Cohen HS, Johnson D, Slymen DJ, et al. Safety of leukotriene receptor antagonists in pregnancy. *J Allergy Clin Immunol* 2007;119:618-25.
597. Nelsen LM, Shields KE, Cunningham ML, Stoler JM, Bamshad MJ, Eng PM, et al. Congenital malformations among infants born to women receiving montelukast, inhaled corticosteroids, and other asthma medications. *J Allergy Clin Immunol* 2012;129:251-4.e1-6.
598. Shaikh WA, Shaikh SW. A prospective study on the safety of sublingual immunotherapy in pregnancy. *Allergy* 2012;67:741-3.